
<html lang="en"     class="pb-page"  data-request-id="2edafce0-404d-49dc-b6dc-e81d770a5bc5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00434;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma" /></meta><meta name="dc.Creator" content="Matthew W. D.  Perry" /></meta><meta name="dc.Creator" content="Karin  Björhall" /></meta><meta name="dc.Creator" content="Peter  Bold" /></meta><meta name="dc.Creator" content="Mikael  Brűlls" /></meta><meta name="dc.Creator" content="Ulf  Börjesson" /></meta><meta name="dc.Creator" content="Johan  Carlsson" /></meta><meta name="dc.Creator" content="Hui-Fang Amy  Chang" /></meta><meta name="dc.Creator" content="Yunhua  Chen" /></meta><meta name="dc.Creator" content="Anders  Eriksson" /></meta><meta name="dc.Creator" content="Britt-Marie  Fihn" /></meta><meta name="dc.Creator" content="Rebecca  Fransson" /></meta><meta name="dc.Creator" content="Linda  Fredlund" /></meta><meta name="dc.Creator" content="Hongbin  Ge" /></meta><meta name="dc.Creator" content="Haijuan  Huang" /></meta><meta name="dc.Creator" content="Kostas  Karabelas" /></meta><meta name="dc.Creator" content="Eva  Lamm Bergström" /></meta><meta name="dc.Creator" content="Sarah  Lever" /></meta><meta name="dc.Creator" content="Helena  Lindmark" /></meta><meta name="dc.Creator" content="Mickael  Mogemark" /></meta><meta name="dc.Creator" content="Antonios  Nikitidis" /></meta><meta name="dc.Creator" content="Anna-Pia  Palmgren" /></meta><meta name="dc.Creator" content="Nils  Pemberton" /></meta><meta name="dc.Creator" content="Jens  Petersen" /></meta><meta name="dc.Creator" content="Mio  Rodrigo Blomqvist" /></meta><meta name="dc.Creator" content="Reed W.  Smith" /></meta><meta name="dc.Creator" content="Matthew J.  Thomas" /></meta><meta name="dc.Creator" content="Victoria  Ullah" /></meta><meta name="dc.Creator" content="Christian  Tyrchan" /></meta><meta name="dc.Creator" content="Tiiu  Wennberg" /></meta><meta name="dc.Creator" content="Annika  Westin Eriksson" /></meta><meta name="dc.Creator" content="Wenzhen  Yang" /></meta><meta name="dc.Creator" content="Shuchun  Zhao" /></meta><meta name="dc.Creator" content="Linda  Öster" /></meta><meta name="dc.Description" content="Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We explor..." /></meta><meta name="Description" content="Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We explor..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 3, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00434" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00434" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00434" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00434" /></link>
        
    
    

<title>Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00434" /></meta><meta property="og:title" content="Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0019.jpeg" /></meta><meta property="og:description" content="Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ  inhibitors. We explored changes in two positions of the molecules, including macrocyclization, but ultimately identified a simpler series with the desired potency profile that had suitable physicochemical properties for inhalation. We were able to demonstrate efficacy in a rat ovalbumin challenge model of allergic asthma and in cells derived from asthmatic patients. The optimized compound, AZD8154, has a long duration of action in the lung and low systemic exposure coupled with high selectivity against off-targets." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00434"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00434">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00434&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00434&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00434&amp;href=/doi/10.1021/acs.jmedchem.1c00434" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8053-8075</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00482" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.1c00489" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Matthew W. D. Perry</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew W. D. Perry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#076a6673736f627029776275757e4766747375667d62696264662964686a"><span class="__cf_email__" data-cfemail="94f9f5e0e0fcf1e3bae4f1e6e6edd4f5e7e0e6f5eef1faf1f7f5baf7fbf9">[email protected]</span></a>. Phone: +46725827070.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+W.+D.++Perry">Matthew W. D. Perry</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9799-0746" title="Orcid link">https://orcid.org/0000-0002-9799-0746</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karin Björhall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karin Björhall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Bj%C3%B6rhall">Karin Björhall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Bold</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Bold</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Bold">Peter Bold</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mikael Brűlls</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mikael Brűlls</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Early Product Development & Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mikael++Br%C5%B1lls">Mikael Brűlls</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ulf Börjesson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ulf Börjesson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Computational Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ulf++B%C3%B6rjesson">Ulf Börjesson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Johan Carlsson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Johan Carlsson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Carlsson">Johan Carlsson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-Fang Amy Chang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-Fang Amy Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Fang+Amy++Chang">Hui-Fang Amy Chang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yunhua Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunhua Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunhua++Chen">Yunhua Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anders Eriksson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anders Eriksson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Eriksson">Anders Eriksson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Britt-Marie Fihn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Britt-Marie Fihn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Britt-Marie++Fihn">Britt-Marie Fihn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca Fransson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca Fransson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Advanced Drug Delivery, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca++Fransson">Rebecca Fransson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda Fredlund</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda Fredlund</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda++Fredlund">Linda Fredlund</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2104-5617" title="Orcid link">https://orcid.org/0000-0002-2104-5617</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongbin Ge</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongbin Ge</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongbin++Ge">Hongbin Ge</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haijuan Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haijuan Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haijuan++Huang">Haijuan Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kostas Karabelas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kostas Karabelas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kostas++Karabelas">Kostas Karabelas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eva Lamm Bergström</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eva Lamm Bergström</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eva++Lamm+Bergstr%C3%B6m">Eva Lamm Bergström</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Lever</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Lever</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Lever">Sarah Lever</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Helena Lindmark</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Helena Lindmark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Helena++Lindmark">Helena Lindmark</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mickael Mogemark</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mickael Mogemark</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mickael++Mogemark">Mickael Mogemark</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antonios Nikitidis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonios Nikitidis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonios++Nikitidis">Antonios Nikitidis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna-Pia Palmgren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna-Pia Palmgren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna-Pia++Palmgren">Anna-Pia Palmgren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nils Pemberton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nils Pemberton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nils++Pemberton">Nils Pemberton</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8875-7221" title="Orcid link">https://orcid.org/0000-0002-8875-7221</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jens Petersen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jens Petersen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Petersen">Jens Petersen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mio Rodrigo Blomqvist</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mio Rodrigo Blomqvist</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience Cough and In Vivo, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mio++Rodrigo+Blomqvist">Mio Rodrigo Blomqvist</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Reed W. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Reed W. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Reed+W.++Smith">Reed W. Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew J. Thomas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew J. Thomas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+J.++Thomas">Matthew J. Thomas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victoria Ullah</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victoria Ullah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victoria++Ullah">Victoria Ullah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Tyrchan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Tyrchan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Tyrchan">Christian Tyrchan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6470-984X" title="Orcid link">https://orcid.org/0000-0002-6470-984X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tiiu Wennberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tiiu Wennberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tiiu++Wennberg">Tiiu Wennberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annika Westin Eriksson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annika Westin Eriksson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annika++Westin+Eriksson">Annika Westin Eriksson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenzhen Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhen Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhen++Yang">Wenzhen Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2226-0869" title="Orcid link">https://orcid.org/0000-0003-2226-0869</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuchun Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuchun Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuchun++Zhao">Shuchun Zhao</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Linda Öster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda Öster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda++%C3%96ster">Linda Öster</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00434&amp;href=/doi/10.1021%2Facs.jmedchem.1c00434" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8053–8075</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 3, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 March 2021</li><li><span class="item_label"><b>Published</b> online</span>3 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00434" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00434</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8053%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthew%2BW.%2BD.%2BPerry%252C%2BKarin%2BBj%25C3%25B6rhall%252C%2BPeter%2BBold%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00434%26title%3DDiscovery%2Bof%2BAZD8154%252C%2Ba%2BDual%2BPI3K%25CE%25B3%25CE%25B4%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAsthma%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8075%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00434"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1851</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00434" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;W. D. Perry&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Björhall&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Bold&quot;},{&quot;first_name&quot;:&quot;Mikael&quot;,&quot;last_name&quot;:&quot;Brűlls&quot;},{&quot;first_name&quot;:&quot;Ulf&quot;,&quot;last_name&quot;:&quot;Börjesson&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Carlsson&quot;},{&quot;first_name&quot;:&quot;Hui-Fang&quot;,&quot;last_name&quot;:&quot;Amy Chang&quot;},{&quot;first_name&quot;:&quot;Yunhua&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Eriksson&quot;},{&quot;first_name&quot;:&quot;Britt-Marie&quot;,&quot;last_name&quot;:&quot;Fihn&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;Fransson&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Fredlund&quot;},{&quot;first_name&quot;:&quot;Hongbin&quot;,&quot;last_name&quot;:&quot;Ge&quot;},{&quot;first_name&quot;:&quot;Haijuan&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Kostas&quot;,&quot;last_name&quot;:&quot;Karabelas&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Lamm Bergström&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Lever&quot;},{&quot;first_name&quot;:&quot;Helena&quot;,&quot;last_name&quot;:&quot;Lindmark&quot;},{&quot;first_name&quot;:&quot;Mickael&quot;,&quot;last_name&quot;:&quot;Mogemark&quot;},{&quot;first_name&quot;:&quot;Antonios&quot;,&quot;last_name&quot;:&quot;Nikitidis&quot;},{&quot;first_name&quot;:&quot;Anna-Pia&quot;,&quot;last_name&quot;:&quot;Palmgren&quot;},{&quot;first_name&quot;:&quot;Nils&quot;,&quot;last_name&quot;:&quot;Pemberton&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Petersen&quot;},{&quot;first_name&quot;:&quot;Mio&quot;,&quot;last_name&quot;:&quot;Rodrigo Blomqvist&quot;},{&quot;first_name&quot;:&quot;Reed&quot;,&quot;last_name&quot;:&quot;W. Smith&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;J. Thomas&quot;},{&quot;first_name&quot;:&quot;Victoria&quot;,&quot;last_name&quot;:&quot;Ullah&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Tyrchan&quot;},{&quot;first_name&quot;:&quot;Tiiu&quot;,&quot;last_name&quot;:&quot;Wennberg&quot;},{&quot;first_name&quot;:&quot;Annika&quot;,&quot;last_name&quot;:&quot;Westin Eriksson&quot;},{&quot;first_name&quot;:&quot;Wenzhen&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Shuchun&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Öster&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8053-8075&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00434&quot;},&quot;abstract&quot;:&quot;Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We explored changes in two positions of the molecules, including macrocyclization, but ultimately identified a simpler series with the desired potency profile that had suitable physicochemical properties for inhalation. We were able to demonstrate efficacy in a rat ovalbumin challenge model of allergic asthma and in cells derived from asthmatic patients. The optimized compound, AZD8154, has a long duration of action in the lung and low systemic exposure coupled with high selectivity against off-targets.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00434&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00434" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00434&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00434" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00434&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00434" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00434&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00434&amp;href=/doi/10.1021/acs.jmedchem.1c00434" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00434" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00434" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00434%26sid%3Dliteratum%253Aachs%26pmid%3D34080862%26genre%3Darticle%26aulast%3DPerry%26date%3D2021%26atitle%3DDiscovery%2Bof%2BAZD8154%252C%2Ba%2BDual%2BPI3K%25CE%25B3%25CE%25B4%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BAsthma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8053%26epage%3D8075%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=290716" title="Sulfones">Sulfones</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure–activity relationships that led to the discovery of highly potent dual PI3Kγδ  inhibitors. We explored changes in two positions of the molecules, including macrocyclization, but ultimately identified a simpler series with the desired potency profile that had suitable physicochemical properties for inhalation. We were able to demonstrate efficacy in a rat ovalbumin challenge model of allergic asthma and in cells derived from asthmatic patients. The optimized compound, AZD8154, has a long duration of action in the lung and low systemic exposure coupled with high selectivity against off-targets.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18362" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18362" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositol 3-kinases (PI3Ks) are a group of lipid kinases that phosphorylate the 3′-hydroxyl of the inositol ring of phosphatidyl inositol lipids. They have been divided into three classes, I, II, and III, based on their preferred substrates. The most intensively studied of these classes are the four class I enzymes, known as PI3Kα, β, γ, and δ. These enzymes exist as heterodimers consisting of a catalytic p110 subunit and a regulatory subunit. PI3Kα, β, and δ, which share p85 regulatory subunits and principally act downstream of tyrosine kinase receptors, are known as class IA. PI3Kγ, in contrast, has its own regulatory subunits (p101 and p84) and is found downstream of GPCRs through the agency of GTPases; it is the only member of class IB PI3Ks. The class I PI3Ks principally convert the membrane lipid phosphoinositol-4,5-bis phosphate (PIP<sub>2</sub>) to phosphoinositol-3,4,5-tris phosphate (PIP<sub>3</sub>). PIP<sub>3</sub> is recognized by proteins containing a pleckstrin homology domain which are recruited to and activated by PIP<sub>3</sub>. Pleckstrin homology domains are found in a variety of proteins that activate multiple pathways leading to cell proliferation, differentiation, and other effects. PI3Ks have been widely studied, and extensive reviews cover the biology in detail.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a></div><div class="NLM_p">Unlike PI3Kα and β, which are ubiquitously or widely distributed throughout the body,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> PI3Kγ and δ have a much more restricted distribution and are principally found in leukocytes.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Inhibitors of PI3Ks have been investigated for the treatment of cancers, with four agents now on the market, but the roles of PI3Kγ and δ in leukocytes have also resulted in investigation of inhibitors of these isoforms for the treatment of inflammatory diseases.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> PI3Kδ has been shown to be responsible for cytokine release from Th2 and Th17 cells,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> while PI3Kγ has been shown to be involved in the activation of both eosinophils and neutrophils.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These mechanisms are believed to be important in asthma, both for allergic (Type 2) asthma but also to less defined non-Th2 asthmatics with mixed T cell subsets driving the inflammatory responses.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">The oral dual PI3Kδγ inhibitor Duvelisib has been investigated in clinical trials for asthma<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and rheumatoid arthritis,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> where it has shown positive effects, but further development for these indications has not been pursued, possibly because of side effects. The inhaled selective PI3Kδ inhibitor Nemiralisib has been evaluated in clinical trials with asthmatics,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> COPD patients,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and patients with activated PI3Kδ syndrome,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> though development of this compound appears to have stopped, potentially based on a lack of clinical efficacy (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed and investigational PI3Kδ and PI3Kδγ inhibitors referred to in the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oral PI3Kδ inhibitors, such as Idelalisib (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and Duvelisib, have been effective in the treatment of B cell lymphomas, but dose-limiting toxicity has been a problem,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and it is notable that Duvelisib was not further investigated for inflammatory diseases beyond two small studies. Inhaled administration has been used to target drugs to the lung where systemic side effects might otherwise result in unacceptable toxicity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We were thus interested to discover a dual PI3Kγδ inhibitor with properties suitable for inhaled administration which we hoped would be able to display profound immune modulation while minimizing undesired systemic effects.</div><div class="NLM_p">We have previously described our earlier series of PI3Kδ inhibitors<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> and the optimization of one of them for inhalation. We have also described the discovery of a series of PI3Kγ inhibitors<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with an unprecedented mode of action and selectivity<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> that led to the identification of <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as a potential development candidate. Given the roles of both PI3Kγ and PI3Kδ in hematopoetic cells, it was of great interest to us to try to identify compounds that combined these activities in a single molecule. In this work, we describe our exploration of the chemistry around our PI3Kγ selective series that led to the identification of features that gave inhibition of PI3Kδ while retaining activity against PI3Kγ and the optimization of the compounds for inhaled delivery.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PI3Kγ selective inhibitor <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the compounds reported began with preparation of the sulfonyl chloride <b>4</b>, via displacement of chlorine from chloride <b>2</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> by benzyl thiolate followed by oxidative chlorination of thioether <b>3</b> with sulfuryl chloride. Condensation of <b>4</b> with amines gave sulfonamides <b>5</b>–<b>15</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Sulfonamides <b>5</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, PhCH<sub>2</sub>SH, NaO<i>t</i>-Am, DMF, 110 °C; ii, SO<sub>2</sub>Cl<sub>2</sub>, MeCN, AcOH, H<sub>2</sub>O, 0–5 °C; iii, R1R2NH, pyridine, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><div class="NLM_p">In order to explore substitution on the aminothiazole, we began by hydrolyzing the acetamide of <b>1</b> and <b>5</b> to give the amines <b>16</b> and <b>17</b>. These could then be used to displace a halogen from a heterocycle under palladium-catalyzed conditions to give compounds <b>18</b>–<b>22</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Heterocyclic Derivatives <b>18</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, HCl, EtOH; ii, R4X, Pd(OAc)<sub>2</sub>, Xantphos, dioxane, 120 °C.</p></p></figure><div class="NLM_p">Synthesis of the macrocycles <b>32</b>−<b>37</b> used the sulfonyl chloride <b>4</b> and readily assembled pyridine amide moieties (<b>25</b>, <b>27</b>–<b>31</b>) that were joined together through formation of a sulfonamide. Deprotection of the aminothiazole enabled macrocyclization via an intramolecular Buchwald-Hartwig coupling to give the target compounds (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Macrocycle Synthesis <i>via</i> Buchwald–Hartwig Amination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, diamine, CH<sub>2</sub>Cl<sub>2</sub>; ii, 4-acetamidobenzaldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH then aq CH<sub>2</sub>O; iii, HCl (3 M aq), EtOH; iv, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>N(Me)(CH<sub>2</sub>)<sub>2</sub>NHBOC, T3P, Et<sub>3</sub>N, EtOAc; v, HCl, dioxane, CH<sub>2</sub>Cl<sub>2</sub>; vi, <b>30</b>, BOCNHCH<sub>2</sub>CHO, NaBH<sub>3</sub>CN, AcOH, MeOH; vii, TFA, CH<sub>2</sub>Cl<sub>2</sub>; viii amine (<b>28</b>, <b>29</b>, <b>25</b>, <b>30</b>, <b>31</b>, <b>27</b>), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; ix, HCl (3 M aq), EtOH; x, second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C.</p></p></figure><div class="NLM_p">The substituted pyridine derivatives <b>52</b>–<b>72</b> were synthesized by palladium-catalyzed amination of <b>16</b>, <b>17</b>, or analogues thereof. The required bromopyridine derivatives were either commercial or synthesized simply. Heterocycles <b>38</b>, <b>39</b>, and <b>40</b> were built up from the available acid or acid chloride. Most of the reversed amides were made by amination of 2,6-dibromopyridine with the appropriate lactam, though in some cases acylation of 2-amino-6-bromopyridine followed by cyclization was used. Alcohols were protected as TBS ethers and free amines with carbobenzyloxy groups (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Amide Isosteres and Reversed Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, acetamidine hydrochloride, HATU, DIPEA, DMF; ii, MeNHNH<sub>2</sub>, AcOH, DMF, 80 °C; iii, ethyl 2-isocyanoacetate, Et<sub>3</sub>N, DMAP, THF; iv, NaBH<sub>4</sub>, EtOH, 0 °C; v, Ac<sub>2</sub>O, py, 120 °C; vi, second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C; vii, deprotection, if required; viii, ClCH<sub>2</sub>CH<sub>2</sub>NCO, toluene; ix, NaH, DMF, THF; x, Cl(CH<sub>2</sub>)<sub><i>n</i></sub>ZCOCl, pyridine; xi, Cs<sub>2</sub>CO<sub>2</sub>, DMF; xii second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the very high selectivity displayed by (<b>2</b>) and the close analogue (<b>5</b>), it is noticeable that there is more activity against PI3Kδ than against either PI3Kα or β; thus, we wondered if we could discover modifications that gave a dual PI3Kγδ inhibitory profile while retaining selectivity against PI3Kα and β.</div><div class="NLM_p">As part of the SAR exploration of this series of molecules and, having access to the sulfonyl chloride (<b>4</b>), we made a series of sulfonamides through reaction with a variety of amines. Small aliphatic amines had been explored previously<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and did not show any significant changes in potency, but heterocyclic sulfonamides and, particularly, sulfonanilides exhibited a marked jump in inhibition of PI3Kδ, though with considerable variation, depending on substitution. The most interesting analogues are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. It should be noted that the ceiling for activity in our enzyme assays was approximately pIC<sub>50</sub> 9.1, and any activity greater than about pIC<sub>50</sub> 8.9 may be an underestimate. This was particularly an issue for the PI3Kγ activity, and we regarded the potency figure from the cell assays as indicative of the true inhibition achieved.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Data for Sulfonanilides</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All values are <i>n</i> ≥ 3 unless otherwise shown.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Inhibition of the production of ADP by recombinant human PI3K detected by ADP-Glo (Promega).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in RAW264 cells stimulated by C5a.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in JeKo-1 cells stimulated anti-IgM.</p></div></div><div></div></div><div class="NLM_p">The gain in activity at PI3Kδ was modest for the parent sulfonanilide (<b>6</b>); however, two different sulfonamide substitution patterns were found to be favored for increasing potency at PI3Kδ, <i>meta</i>-electron withdrawing groups (sulfone <b>7</b>, cyano <b>8</b>); however, this could not be enhanced by 3,5-disubstitution (<b>10</b>). Alternatively, para-amino methyl substitution gave an improvement in PI3Kδ potency but at a slight cost to that at PI3Kγ (<b>12</b>). The specificity of these substitutions was shown by the <i>meta</i>-dimethylaminomethyl analogue (<b>11</b>) and the <i>para</i>-cyano and sulfone analogues (<b>14</b>, <b>15</b>). <i>N</i>-Methylation of the sulfonamide was not beneficial (<b>9</b>, <b>13</b>). For all these compounds, an appreciable drop in potency in the cell assay of about 10-fold was unsurprising but left us needing to find additional potency to be useful.</div><div class="NLM_p">We were able to obtain X-ray crystal structures of <b>7</b> and <b>12</b> in a PI3Kδ construct. The protein structure observed matched closely to that seen previously for <b>1</b>, with the anilide moiety fitting nicely into the space available. For the sulfone of <b>7</b>, we were unable to identify any specific interactions made that could account for the improved potency of this group relative to others. The <i>para</i>-dimethylaminomethyl substituent of <b>12</b>, however, was close to, though probably beyond direct contact with, the side chain carboxylate group of Asp897 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structures of compounds <b>7</b> and <b>12</b> bound in PI3Kδ. (Top) <b>7</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4">7oi4</a>, 1.8 Å). (Bottom) <b>12</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois">7ois</a>, 2.3 Å) Note that for each compound hydrogen bonds can be seen from the acetylaminothiazole to the hinge Val828 and from the carbonyl of the isoindolinone to the terminal amino of Lys779.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Among the changes that we made to the parent compounds (<b>1</b> and analogues) during SAR exploration was to replace the acetamide group with a heterocycle (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Of the various heterocyclic rings that we attached, it was noticeable that pyridyl (<b>18</b>) particularly with an amide substituent (<b>19</b>) gave significantly increased activity against PI3Kδ. Changing the position of the amide (<b>21</b>) appeared to have little effect, while disubstitution on the amide (<b>22</b>) appeared not to be favorable for activity at PI3Kδ.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Heterocyclic Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">R4</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">pIC<sub>50</sub> PI3K<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R3</th><th class="colsep0 rowsep0" align="center">Het</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">γ</th><th class="colsep0 rowsep0" align="center" char=".">δ</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" colspan="2" align="center">Ac</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" colspan="2" align="center">Ac</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">X1</td><td class="colsep0 rowsep0" align="char" char=".">9.1<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">8.3<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">X2</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left">X2</td><td class="colsep0 rowsep0" align="char" char=".">8.9<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">8.2<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">X3</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">6.8<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">all values are <i>n</i> ≥ 3 unless otherwise shown.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of the production of ADP by recombinant human PI3K detected by ADP-Glo (Promega).</p></div></div></div><div class="NLM_p">Crystallization of <b>20</b> in PI3Kδ showed that the pyridine ring was coplanar with the thiazole and with the nitrogen of the pyridine pointing inward; we interpreted this as a lone pair-sulfur interaction<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> stabilizing this conformation. The amide side chain continued along the same axis, leaving the terminal dimethylamino group in proximity to Asp897, which in turn rotates slightly to optimize the interaction, though the observed distance is slightly too long (∼5.4 Å) for a direct interaction (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Inspection of the crystal structure of <b>20</b> in comparison to that of <b>12</b> showed that the two amino functions both pointed toward the same Asp897 carboxylate. This raised the prospect that a macrocycle might be an effective way forward.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>20</b> in PI3Kδ. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> X-ray structure of compound <b>20</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij">7oij</a>, 1.7 Å). Note how the amine at the terminus of the side chain ends up close to the sulfonamide on the isoindolinone suggesting the possibility for macrocyclization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our initial design of macrocycle hybridized between the amines <b>12</b> and <b>20</b>. These compounds (<b>32</b>, <b>33</b>) showed very good potency at PI3Kδ but lost activity against PI3Kγ (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). We continued to investigate macrocyclic analogues, and after a preliminary study using ring closing metathesis established that the optimal linker length was five atoms between the amide and sulfonamide (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">Supplementary Table 1</a>), we made a series with purely aliphatic linkers (<b>34</b>–<b>37</b>). These compounds had excellent activity at both PI3Kγ and PI3Kδ, with good cellular activity at both isoforms as well, though activity against PI3Kα also increased, resulting in lower selectivity against this isoform than we desired. Activity against PI3Kβ (not shown) was weaker.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activities of Macrocyclic Dual PI3Kγδ Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0016.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">PI3K enzyme IC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">PI3K cell IC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">core</th><th class="colsep0 rowsep0" align="center">linker</th><th class="colsep0 rowsep0" align="center" char=".">γ</th><th class="colsep0 rowsep0" align="center" char=".">δ</th><th class="colsep0 rowsep0" align="center" char=".">α</th><th class="colsep0 rowsep0" align="center" char=".">γ<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">δ<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">L1</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">8.8<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">L2</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">9.0<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="left">L3</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="left">L4</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="left">L5</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">G</td><td class="colsep0 rowsep0" align="left">L6</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Al values are <i>n</i> ≥ 3 unless otherwise shown.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Inhibition of the production of ADP by recombinant human PI3K detected by ADP-Glo (Promega).</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in RAW264 cells stimulated by C5a</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in JeKo-1 cells stimulated anti-IgM.</p></div></div></div><div class="NLM_p">In parallel with our exploration of macrocycles, we continued to explore SAR of compounds related to the pyridyl amides. We synthesized isosteres to amides as a possible way to further improve δ cell potency (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Heterocycles (<b>52</b>–<b>54</b>) were similar to or poorer than earlier compounds, and likewise reversing the amide (<b>55</b>) had little effect until we <i>N</i>-alkylated (<b>56</b>, <b>57</b>), which gave a significant improvement in potency against PI3Kδ, in contrast to the effect seen previously with the alternate orientation (<b>22</b>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Amide Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">pIC50<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R3</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kγ</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kγ cell</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ cell</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">J</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">K</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">L</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All values are <i>n</i> ≥ 3.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Inhibition of the production of ADP by recombinant human PI3K detected by ADP-Glo (Promega).</p></div></div></div><div class="NLM_p">In following up on the results for the reversed amides, we made a series of lactams, cyclic carbamates, and ureas. In this exploration, we also investigated the combination of the sulfone or sulfonamide substituent on the isoindolinone with the pyridine substituent. Many of the resulting compounds exhibited the levels of PI3Kδ cell activity that we had been hoping to see without any loss of PI3Kγ activity (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Lactams, Carbamates, and Ureas</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0018.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">PI3K enzyme IC<sub>50</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">PI3K cell IC<sub>50</sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R3</th><th class="colsep0 rowsep0" align="center" char=".">δ</th><th class="colsep0 rowsep0" align="center" char=".">α</th><th class="colsep0 rowsep0" align="center" char=".">γ<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">δ<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="left">NHOx</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">NHOx</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">P</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">Q</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">R</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">T</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">T</td><td class="colsep0 rowsep0" align="left">NHOx</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">T</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">8.9<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">8.9<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">8.4<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left">U</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">U</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">V</td><td class="colsep0 rowsep0" align="left">NHMe</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All compounds reached the maximum inhibition in the PI3Kγ enzyme inhibition assay.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">All values are <i>n</i> ≥ 3 unless otherwise shown.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Inhibition of the production of ADP by recombinant human PI3K detected by ADP-Glo (Promega).</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in RAW264 cells stimulated by C5a.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Inhibition of phosphorylation of AKT (at Ser473) in JeKo-1 cells stimulated anti-IgM.</p></div></div></div><div class="NLM_p">We were able to crystallize <b>58</b> in PI3Kδ (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>; <a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">Supplementary Figure S2</a>); the molecule binds in the same general orientation as <b>20</b>. The lactam moiety is almost coplanar with the pyridine ring and is not within contact distance of any residues of the protein. The carbonyl group is oriented antiparallel to the C═N of the pyridine, as expected from electrostatic effects, and it appears that the carbonyl group can make a water-mediated hydrogen bond to the terminal amino group of the nonconserved asparagine 836 (PI3Kα Gln859, PI3Kβ Asp856, PI3Kγ Lys890). This hydrogen bond is not possible for the earlier amide compounds and may account for the improved potency observed at PI3Kδ with this motif. Consistent with the crystal structures, the SAR for PI3Kδ activity was flat, with only subtle changes apparent upon varying this group. Inhibition of PI3Kα, however, showed larger variations, and some compounds had quite high activity against that isoform. Inhibition of PI3Kβ was always low (data not shown).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of <b>58</b> bound to PI3Kδ. X-ray view of <b>58</b> bound in PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil">7oil</a>, 2.0 Å). The binding mode is essentially identical to earlier compounds. The lactam can be seen to make a water-mediated hydrogen bond to the terminal NH<sub>2</sub> of Asp836, which itself is in a network of hydrogen bonds with Thr833. Other residues shown are Trp760 and Met752 that form the other side of the pocket around the lactam and Lys779 that forms H-bonds with the carbonyl of the isoindolinone and the sulfone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the broad range of compounds with good primary potency against PI3Kγ and PI3Kδ, we focused attention on the margin of selectivity against PI3Kα, for which we hoped to achieve two log units (based on the enzyme inhibition values) and the PI3Kδ cell potency, which we wanted to be as potent as possible, giving as a good dual PI3Kγδ profile as we could attain. On the basis of these criteria, compounds <b>58</b> and <b>68</b> were selected for further profiling, with compound <b>59</b>, synthesized slightly later in our program, as a back-up.</div><div class="NLM_p">From the outset of this program, we had intended to administer our molecule by inhalation, and thus we had not concerned ourselves with metabolic stability, being hopeful instead of achieving low systemic exposure. As our program developed, we found ourselves with a set of compounds with high lipophilicity and often high crystallinity as well. Indeed, some compounds we made, principally those with amide NH groups in the X substituent (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), were extremely problematic to work with as they precipitated from DMSO stock solution.</div><div class="NLM_p">Several approaches have been described by which extended duration of action for inhaled molecules can be achieved.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Given the physicochemical properties that we had, we decided that we would focus our attention on a low-solubility approach, whereby slow dissolution of the drug substance in the lung is used to maintain an efficacious concentration over a prolonged period, thus providing a long duration of action. To this end, we were determined to carry out our pharmacokinetic studies by nebulization of suspensions of crystalline material in order that the effect of the dissolution rate could be observed. In order to achieve timely availability of suitable material for PK experiments, we initiated a procedure whereby, as soon as synthesis was complete and primary assays requested, all compounds were investigated for crystallinity by X-ray powder diffraction. Unless the material was already crystalline, we then slurried it in multiple solvent systems to identify a crystalline form that could be used for inhalation dosing, though at the initial stage we did not explicitly seek a preferred polymorph. With crystalline material available, we were able to determine crystalline solubility and melting onset to give an indication of the likely behavior of the material in the lung. Our hypothesis was that solubility of 1 μM or less would give an extended duration upon dosing of a nebulized suspension. Compounds were selected for further study based on their <i>in vitro</i> profile and dosed by nebulization to rats to study the pharmacokinetics. We also ran conventional iv and po pharmacokinetic studies in order to understand the behavior of compound once it was absorbed into the systemic circulation and the fate of any fraction of the dose that was swallowed (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). We were interested to understand the permeabilities of these molecules and tested them in CaCO-2 permeability assays; however, low recovery of the compounds meant that we were unable to define precise values with confidence (data not shown). The results we did get suggested that the macrocycles (<b>35</b>, <b>37</b>) had low permeability and moderate efflux, while the nonmacrocycles (<b>58</b>, <b>68</b>) had moderate permeability and little efflux.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Properties and PK Data for Advanced Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">rat PK<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" align="center" char=".">inhaled</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">iv</th><th class="rowsep1 colsep0" align="center">po</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">crystalline solubility (phosphate buffer pH 7.4)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> μM</th><th class="colsep0 rowsep0" align="center" char=".">melting onset °C</th><th class="colsep0 rowsep0" align="center" char=".">LogD pH 7.4</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> h</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL mL/min/kg</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> h</th><th class="colsep0 rowsep0" align="center"><i>F</i> %</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">1.09</td><td class="colsep0 rowsep0" align="char" char=".">349</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">0.084</td><td class="colsep0 rowsep0" align="char" char=".">377</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">NT</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">0.054</td><td class="colsep0 rowsep0" align="char" char=".">285</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="left"><4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="char" char=".">0.337</td><td class="colsep0 rowsep0" align="char" char=".">187</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">136</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">ND = not detected; NT = not tested.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">PK experiments are the mean of values obtained for at least two animals. Compound was dosed at 0.5 mg/kg iv and 1.0 mg/kg po.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Material of known crystallinity was suspended in pH 7.4 phosphate buffer at 1 mg/mL and stirred at 1100 rpm for 24 h. Solid material was removed by centrifugation and the concentration of substrate was determined by HPLC MS.</p></div></div></div><div class="NLM_p">We were pleased to find that our design hypothesis was borne out in reality for the compounds that we tested and that we could obtain an extensive residence in the lung through very low solubility. Of note, this apparent terminal <i>t</i><sub>1/2</sub> (inhaled <i>t</i><sub>1/2</sub>) was longer in every case than the plasma half-life measured from iv dosing, which implies that a depot effect was accounting for the prolonged half-life, in accordance with our hypothesis. Compounds <b>35</b>, <b>37</b>, and <b>68</b> had very high <i>in vivo</i> clearance, being measured at or above liver blood flow, probably as a result of biliary clearance (observed for other compounds in this series, data not shown) and, for <b>35</b> and <b>68</b>, undetectable oral bioavailability. In contrast, <b>58</b> had a more modest, though still quite high, clearance; despite this clearance, bioavailability of <b>58</b> was very low. For <b>58</b> biliary clearance was only a minor factor (about 2% total clearance); however, Caco-2 permeability (<i>P</i><sub>app</sub> ≈ 0.4 but poor recovery of the lipophilic compound makes the precise value uncertain) was low, which, coupled with the very low solubility, places it into BCS category 4.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In combination with the moderately high clearance, the low bioavailability is thus unsurprising.</div><div class="NLM_p">With compounds available that gave extended lung exposure through inhaled dosing, we were in a position to explore pharmacodynamic effects. Disease models for asthma, particularly severe asthma, are in their infancy, so we opted to use a mechanistic model of allergic lung inflammation driven by an allergic response to ovalbumin,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> even though we realized that this simplistic model did not recapitulate the full complexity of asthma. Rats were sensitized by ip administration of ovalbumin, then primed by inhalation of ovalbumin, expected to result in recruitment of antigen specific T cells and granulocytes to the lung. On the day of challenge test, compound was administered to the lung 1 h prior to administration of ovalbumin to the lung. Following drug treatment and ovalbumin challenge we waited for 48 h until the animals were terminated and the recruitment of eosinophils to the lung was measured by bronchioalveolar lavage (BAL) to give an indication of the anti-inflammatory effect of the compound. (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>)</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A–D) Inhibition of eosinophil migration in response to an inhaled ovalbumin challenge. Rats (BN, male, 10 per group) were sensitized to ovalbumin by ip administration on two separate occasions, then challenged with aerosolized administration of ovalbumin and, after a week dosed with compound by nebulization before subsequent challenge with aerosolized ovalbumin. After 48 h the animals were terminated, the lungs lavaged, and the numbers of eosinophils in the BAL fluid were measured by flow cytometry. Budesonide (300 μg, dosed i.t.) was used as positive control. Individual animals are represented by points with the average effect shown in bars. Compound amounts represent the administered dose of compound.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further analyze the effects of the compounds, we could track the progress of target engagement by measurement of the degree of phosphorylation of the downstream target S6 ribosomal protein in the lymphocyte population at 2 h post dosing. We were further able to measure the levels of inflammatory cytokines in lung lavage fluid. In both cases, the data were consistent with the picture obtained from the eosinophil level (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">Supplementary Figures S3 and S4</a>).</div><div class="NLM_p">In order to probe the pharmacodynamic duration of the compounds, we ran an experiment where the compound was dosed at various time points prior to the ovalbumin challenge (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Experiment showing duration of effect of nebulized <b>58</b> in rats. Compound <b>58</b> was dosed by nebulization (240 μg/kg administered dose) to male rats (BN, 8–10 per group) that had been sensitized to ovalbumin at varying intervals prior to ovalbumin challenge. 48 h after challenge, the animals were terminated, the lungs lavaged, and the numbers of eosinophils in the lung lavage fluid were measured by flow cytometry, and the results were compared to time-matched controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this experiment, we saw that we obtained statistically significant inhibition with dosing 7 h prior to challenge and a weaker effect with 12 h predosing. Dosing 24 h before challenge had no effect. These data suggested that twice-daily dosing of compound <b>58</b> might be required to achieve a durable effect in man.</div><div class="NLM_p">Comparison of the four compounds that we had evaluated <i>in vivo</i> was based on a balance of factors. The weakly basic compound <b>35</b> (p<i>K</i><sub>a</sub> 6.4) had the least attractive profile when tested in a panel of 150 diverse targets, showing activity at 1 μM at 16 of these, consistent with the common experience that lipophilic amines are more likely to exhibit off-target effects. In contrast, the neutral compounds <b>37</b> (8 targets inhibited at 1 μM), <b>58</b> (7), and <b>68</b> (5) were less promiscuous (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">Supplementary Table S2</a>).</div><div class="NLM_p">Kinase selectivity for the compounds was evaluated in a panel of 348 protein kinases at 1 μM; however, none of the compounds showed >50% activity against any of the tested kinases (full details in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">Supplementary Data Table S3 and Figure S5</a>). Compounds <b>37</b>, <b>58</b>, and <b>68</b> were also evaluated in a panel of lipid kinases; beyond the activity at class I PI3Ks, we also observed some inhibition of class 2 PI3Ks (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). The activity against class 2 PI3Ks, PIK3C2B, and PIK3C2G was significant; however, we decided to take a compound forward with these activities as a potential risk.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inhibition of Lipid Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">pIC<sub>50</sub><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center" char=".">PIK3C2A</th><th class="colsep0 rowsep0" align="center" char=".">PIK3C2B</th><th class="colsep0 rowsep0" align="center">PIK3C2G</th><th class="colsep0 rowsep0" align="center" char=".">PIK3C3</th><th class="colsep0 rowsep0" align="center" char=".">PI4KA</th><th class="colsep0 rowsep0" align="center" char=".">PI4KB</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">6.5<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">9.1<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">7.6<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="."><5.0<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">7.7<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char="."><5.0<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">5.5<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="char" char=".">5.5<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">9.0<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="char" char=".">7.5<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="."><5.0<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">6.3<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">NT = not tested.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 3 unless otherwise shown.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">FRET Adapta assays measuring inhibition of phosphorylation of a synthetic substrate run by Thermo Fisher Scientific.</p></div></div></div><div class="NLM_p">The synthetic complexity of the macrocycles was an additional factor in our prioritization since this was anticipated to result in delays and costs during the development process. Compound <b>58</b> was selected as having the best overall profile and was advanced to preclinical studies.</div><div class="NLM_p">In order to build confidence in our inhibitor for the treatment of human disease, we carried out studies using blood obtained from GINA 3 or 4 asthmatic patients. In peripheral blood mononuclear cells (PBMCs), a PI3Kδ response was obtained through stimulation of T cell antigen receptor with a mixture of antibodies to CD2, 3, and 28 for 24 h. Inhibition of this response was measured by detection of the impact of δ, γ and dual γ δ inhibitors on the release of IL-5 and IL-17. In contrast, eosinophils from the same patients’ blood was treated with eotaxin-3 (CCL26) to produce a PI3Kγ-driven effect, observable by the appearance of CD11b expression, that can be measured by flow cytometry. Both these effects could be inhibited by the dual PI3Kγδ inhibitor <b>58</b>, in contrast to a pure PI3Kδ inhibitor (PI3Kδ p<i>K</i><sub>i</sub> 9.9; PI3Kγ pIC<sub>50</sub> 5.2)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or a pure PI3Kγ inhibitor (PI3Kδ pIC<sub>50</sub> < 6.1; PI3Kγ pIC<sub>50</sub> 9.1) (<b>1</b>), each of which could only effectively inhibit one of the responses (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PI3K isoform specific inhibition of T cell cytokine release and eosinophil surface CD11b expression, using PBMC and purified granulocytes from severe asthma patients (GINA 3 and 4). Effects of PI3Kγ (Cpd <b>1</b>), PI3Kδ (Nemiralisib), or PI3Kγδ dual (Cpd <b>58</b>) selective inhibitors on (A) IL-5, (B) IL-17 release after anti-CD2/3/28 stimulation of PBMCs, and (C) CD11b surface expression on blood-derived eosinophils stimulated with eotaxin-3 measured by flow cytometry. The impact of treatment is visualized as %-inhibition. Error bars depicts SEM, asthmatic donors <i>N</i> = 6–10.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described how, through SAR exploration and paying particular attention to cellular activity, we went from a highly selective PI3Kγ inhibitor to a series of dual PI3Kγδ inhibitors. On the basis of the physicochemical properties of the series and our desire for inhaled administration, we focused on making crystalline material and understanding solid state properties. Administration of compounds to rats by nebulization showed prolonged retention of compounds in the lungs and extended pharmacodynamic effects in a mechanistic model, building confidence in the suitability of the identified compounds for investigation as inhaled agents. Studies using human patient derived blood cells demonstrated a potential benefit of dual PI3Kγδ inhibition. On the basis of excellent potency and good in vivo PK with long duration of action coupled with an acceptable off-target profile, compound <b>58</b> (AZD8154) was selected for development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reagents obtained from commercial sources were used without further purification; anhydrous solvents were used without further drying. All compounds were purified to ≥95% purity as judged by HPLC with UV and MS analysis. When Cl or Br was present, expected isotopic distribution patterns were observed. Proton (<sup>1</sup>H) and carbon (<sup>13</sup>C) NMR spectra were recorded at ambient temperature. Solutions were typically prepared in deuterated dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>), deuteromethanol (CD<sub>3</sub>OD), or deuterochloroform (CDCl<sub>3</sub>) with chemical shifts referenced to solvent as an internal standard. <sup>1</sup>H NMR data are reported indicating the chemical shift (δ), the multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets; etc.), the coupling constant (J) in Hz, and the integration (e.g., 1H). <sup>13</sup>C NMR spectra are reported with proton decoupling.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure A – Synthesis of Sulfonamides from Sulfonyl Chloride <b>4</b></h3><div class="NLM_p">(<i>S</i>)-6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonyl chloride<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (4, 80 mg) was dissolved in a mixture of dichloromethane (3 mL) and pyridine (42 μL, 2 equiv). The appropriate aniline (1 equiv) was added, and the mixture was stirred overnight. Solvent was evaporated, and the residue was purified by preparative reverse phase HPLC. Typically a 5 μM Xbridge C-18 19 × 150 mm column was used running a gradient of acetonitrile in 0.05% TFA in water at 20 mL/min.</div><div class="NLM_p">The following compounds were prepared according to general procedure A and the appropriate aniline:</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-(5-{2-[(1<i>S</i>)-1-Cyclopropylethyl]-1-oxo-7-(phenylsulfamoyl)-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>6</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H; exchangeable NH and reduced to ∼60%), 10.14 (s, 1H; exchangeable NH and reduced to ∼72%), 7.96 (d, <i>J</i> = 1.5 Hz, 1H), 7.81 (d, <i>J</i> = 1.5 Hz, 1H), 7.23 (dd, <i>J</i> = 8.5, 7.3 Hz, 2H), 7.12–7.07 (m, 2H), 7.07–7.01 (m, 1H), 4.80–4.67 (m, 2H), 3.70 (dq, <i>J</i> = 9.3, 6.8 Hz, 1H), 2.36 (s, 3H), 2.16 (s, 3H), 1.36 (d, <i>J</i> = 6.8 Hz, 3H), 1.24–1.13 (m, 1H), 0.67–0.58 (m, 1H), 0.50–0.40 (m, 2H), 0.39–0.30 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 164.6, 156.4, 146.1, 144.9, 137.1, 136.1, 135.8, 129.4, 127.4, 126.9, 125.8, 125.0, 121.5, 120.5, 52.8, 46.5, 22.5, 18.1, 16.3, 15.7, 4.0, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 511.1487 expected 511.1474.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-[5-(2-[(1<i>S</i>)-1-Cyclopropylethyl]-7-{[3-(methylsulfonyl)phenyl]sulfamoyl}-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl)-4-methyl-1,3-thiazol-2-yl]acetamide (<b>7</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.29 (s, 1H), 10.55 (s, 1H), 7.97 (d, <i>J</i> = 1.7 Hz, 1H), 7.90 (d, <i>J</i> = 1.7 Hz, 1H), 7.63 (t, <i>J</i> = 2.0 Hz, 1H), 7.59 (d, <i>J</i> = 7.8 Hz, 1H), 7.53 (t, <i>J</i> = 8.0 Hz, 1H), 7.48–7.43 (m, 1H), 4.80–4.65 (m, 2H), 3.69 (dq, <i>J</i> = 9.3, 6.8 Hz, 1H), 3.12 (s, 3H), 2.37 (s, 3H), 2.16 (s, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.22–1.12 (m, 1H), 0.65–0.55 (m, 1H), 0.52–0.38 (m, 2H), 0.38–0.29 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.74, 164.31, 156.44, 146.21, 144.93, 141.86, 138.14, 135.81, 135.59, 130.74, 127.71, 127.08, 125.82, 124.41, 122.90, 121.44, 117.69, 52.75, 46.47, 43.37, 22.45, 17.96, 16.33, 15.57, 3.95, 3.37.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 589.1263 expected 589.1249.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(5-{7-[(3-Cyanophenyl)sulfamoyl]-2-[(1<i>S</i>)-1-cyclopropylethyl]-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>8</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H), 10.48 (s, 1H), 7.98 (d, <i>J</i> = 1.5 Hz, 1H), 7.89 (d, <i>J</i> = 1.6 Hz, 1H), 7.52–7.40 (m, 4H), 4.78–4.68 (m, 2H), 3.72–3.64 (m, 1H), 2.38 (s, 3H), 2.16 (s, 3H), 1.36 (d, <i>J</i> = 6.8 Hz, 3H), 1.22–1.14 (m, 1H), 0.65–0.58 (m, 1H), 0.49–0.40 (m, 2H), 0.40–0.32 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO<i>-d</i><sub>6</sub>) δ 168.8, 164.3, 156.5, 146.2, 144.9, 138.2, 135.8, 135.4, 130.9, 128.22, 127.8, 127.2, 125.9, 124.5, 122.8, 121.4, 118.0, 112.1, 52.7, 46.5, 22. 5, 18.0, 16.3, 15.7, 3.9, 3.3.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 536.1440 expected 536.1426.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-(5-{7-[(3-Cyanophenyl)(methyl)sulfamoyl]-2-[(1<i>S</i>)-1-cyclopropylethyl]-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>9</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.27 (s, 1H), 7.99 (d, <i>J</i> = 1.5 Hz, 1H), 7.78 (d, <i>J</i> = 1.5 Hz, 1H), 7.73 (t, <i>J</i> = 1.9 Hz, 1H), 7.66 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.63 (ddd, <i>J</i> = 8.3, 2.4, 1.1 Hz, 1H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 4.67–4.59 (m, 2H), 3.58 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.41 (s, 3H), 2.29 (s, 3H), 2.16 (s, 3H), 1.28 (d, <i>J</i> = 6.8 Hz, 3H), 1.15–1.08 (m, 1H), 0.62–0.55 (m, 1H), 0.47–0.36 (m, 2H), 0.28–0.21 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7, 162.7, 156.3, 146.4, 144.5, 142.0, 135.1, 134.3, 130.3, 130.2, 129.9, 129.4, 128.3, 128.0, 127.8, 121.6, 118.1, 111.8, 51.9, 45.5, 37.9, 22.4, 18.0, 16.1, 15.6, 3.9, 3.3.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 550.1573 expected 550.1583.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-[5-(7-{[3-Cyano-5-(methylsulfonyl)phenyl]sulfamoyl}-2-[(1<i>S</i>)-1-cyclopropylethyl]-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl)-4-methyl-1,3-thiazol-2-yl]acetamide (<b>10</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H), 10.90 (s, 1H), 7.67–8.13 (m, 5H), 4.70 (s, 2H), 3.66 (p, <i>J</i> = 6.8 Hz, 1H), 3.22 (s, 3H), 2.38 (s, 3H), 2.17 (s, 3H), 1.34 (d, <i>J</i> = 6.7 Hz, 3H), 1.17 (dd, <i>J</i> = 8.2, 4.4 Hz, 1H), 0.61 (dt, <i>J</i> = 8.6, 4.1 Hz, 1H), 0.38–0.48 (m, 2H), 0.3–0.37 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.2, 164.5, 156.9, 146.7, 145.1, 144.1, 143.5, 134.8, 127.9, 127.0, 126.0, 123.4, 121.9, 119.3, 115.4, 52.7, 43.4, 22.9, 18.4, 16.8, 16.1, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 614.1219 expected 614.1202.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(5-{2-[(1<i>S</i>)-1-Cyclopropylethyl]-7-({3-[(dimethylamino)methyl]phenyl}sulfamoyl)-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>11</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.28 (s, 1H), 10.01 (s, 1H), 7.95 (d, <i>J</i> = 1.2 Hz, 1H), 7.78 (d, <i>J</i> = 1.4 Hz, 1H), 7.17 (t, <i>J</i> = 7.8 Hz, 1H), 7.03–7.01 (m, 1H), 6.99 (d, <i>J</i> = 8.0 Hz, 1H), 6.92 (d, <i>J</i> = 7.6 Hz, 1H), 4.73 (s, 2H), 3.75–3. 67 (m, 1H), 3.23 (q, <i>J</i> = 13.2 Hz, 2H), 2.35 (s, 3H), 2.16 (s, 3H), 1.96 (s, 6H), 1.37 (d, <i>J</i> = 6.8 Hz, 3H), 1.23–1.15 (m,1H), 0.66–0.60 (m, 1H), 0.50–0.43 (m, 2H), 0.37–0.31 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.2, 165.1, 156.9, 146.5, 145.2, 140.7, 137.5, 136.3, 136.2, 129.5, 127.8, 127.6, 126.3, 125.8, 121.9, 121.1, 119.9, 63.4, 53.2, 46.9, 45.2, 22.9, 18.5, 16.7, 16.1, 4.5, 3.9.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 568.2058 expected 568.2052.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(5-{2-[(1<i>S</i>)-1-Cyclopropylethyl]-7-({4-[(dimethylamino)methyl]phenyl}sulfamoyl)-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>12</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.28 (s, 1H), 10.10 (s, 1H), 7.96 (d, <i>J</i> = 1.6 Hz, 1H), 7.79 (d, <i>J</i> = 1.6 Hz, 1H), 7.15–7.11 (m, 2H), 7.05–7.01 (m, 2H), 4.80–4.70 (m, 2H), 3.71 (dq, <i>J</i> = 9.4, 6.8 Hz, 1H), 3.21 (s, 2H), 2.35 (s, 3H), 2.16 (s, 3H), 2.03 (s, 6H), 1.37 (d, <i>J</i> = 6.8 Hz, 3H), 1.24–1.15 (m, 1H), 0.64–0.59 (m, 1H), 0.51–0.41 (m, 2H), 0.38–0.31 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7, 164.7, 156.4, 146.1, 144.8, 136.1, 135.8, 135.7, 135.7, 129.6, 127.4, 126.8, 125.8, 121.5, 120.5, 62.6, 52.7, 46.5, 44.9, 22. 5, 18.0, 16.3, 15.7, 4.0, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 568.2070 expected 568.2052.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(5-{2-[(1<i>S</i>)-1-cyclopropylethyl]-7-[{4-[(dimethylamino)methyl]phenyl}(methyl)sulfamoyl]-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>13</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.24 (s, 1H), 7.93 (d, <i>J</i> = 1.6 Hz, 1H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.21–7.16 (m, 2H), 7.16–7.11 (m, 2H), 4.67–4.58 (m, 2H), 3.63 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.43 (s, 3H), 3.35 (s, 2H), 2.22 (s, 3H), 2.15 (s, 3H), 2.08 (s, 6H), 1.30 (d, <i>J</i> = 6.8 Hz, 3H), 1.18–1.09 (m, 1H), 0.63–0.56 (m, 1H), 0.47–0.37 (m, 2H), 0.32–0.24 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7, 163.7, 162.9, 156.2, 146.2, 144.3, 139.9, 136.8, 135.2, 134.8, 129.4, 127.7, 127.4, 125.5, 121.7, 62.3, 51.9, 45.4, 44.6, 38.7, 22.4, 19.0, 16.1, 15.6, 4.0, 3.3.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 582.2244 expected 582.2209.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(5-{7-[(4-cyanophenyl)sulfamoyl]-2-[(1<i>S</i>)-1-cyclopropylethyl]-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl}-4-methyl-1,3-thiazol-2-yl)acetamide (<b>14</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.32 (s, 1H), 10.63 (br. s, 1H), 7.99 (d, <i>J</i> = 1.5 Hz, 1H), 7.93 (d, <i>J</i> = 1.6 Hz, 1H), 7.74–7.67 (m, 2H), 7.31–7.25 (m, 2H), 4.78–4.65 (m, 2H), 3.66 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 2.38 (s, 3H), 2.17 (br. s, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.11 (m, 1H), 0.65–0.56 (m, 1H), 0.48–0.36 (m, 2H), 0.36–0.27 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 164.1, 156.5, 146.3, 145.0, 141.8, 135.7, 135.6, 133.8, 127.8, 127.2, 126.0, 121.5, 119.2, 118.6, 106.2, 52.7, 46.4, 22.5, 18.0, 16.4, 15.7, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 536.1389 expected 536.1426.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-[5-(2-[(1<i>S</i>)-1-Cyclopropylethyl]-7-{[4-(methylsulfonyl)phenyl]sulfamoyl}-1-oxo-2,3-dihydro-1<i>H</i>-isoindol-5-yl)-4-methyl-1,3-thiazol-2-yl]acetamide (<b>15</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.31 (s, 1H), 10.69 (s, 1H), 8.00 (s, 1H), 7.95 (d, <i>J</i> = 1.2 Hz, 1H), 7.80 (d, <i>J</i> = 8.7 Hz, 2H), 7.35 (d, <i>J</i> = 8.7 Hz, 2H), 4.73 (s, 2H), 3.73–3. 65 (m, 1H), 3.12 (s, 3H), 2.40 (s, 3H), 2.18 (s, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.18–1.14 (m,1H), 0.65–0.59 (m, 1H), 0.48–0.40 (m, 2H), 0.37–0.31 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.2, 164.7, 156.9, 151.8, 146.8, 145.4, 142.4, 136.4, 136.2, 129.2, 128.2, 127.6, 126.4, 122.0, 119.5, 53.1, 46.9, 44.0, 22.9, 18.4, 16.8, 16.1, 4.4, 3.9.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 589.1236 expected 589.1249.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>S</i>)-5-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>)</h4><div class="NLM_p"><b>1</b> (2.28 g, 5.26 mmol) was suspended in EtOH (11.5 mL). Hydrochloric acid (3.8 M, 13.8 mL, 52.6 mmol) was added to the slurry. The reaction mixture was stirred at reflux for 20 h. The reaction mixture was allowed to come to RT and was then cooled to 0 °C. The mixture was neutralized with 2 M NaOH and was then extracted with DCM (100 mL; 2 × 50 mL), and the combined organic layers were dried through a phase separator and concentrated to dryness to give the title compound (1.76 g, 86%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.9–7.86 (m, 2H), 7.31 (s, 2H), 4.66 (s, 2H), 3.61 (m, 4H), 2.30 (s, 3H), 1.29 (d, <i>J</i> = 6.8 Hz, 3H), 1.17–1.09 (m, 1H), 0.62–0.56 (m, 1H), 0.46–0.36 (m, 2H), 0.29–0.23 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.9, 163.7, 146.8, 145.8, 137.5, 136.3, 126.3, 125.8, 125.7, 115.4, 51.9, 45.8, 43.0, 17.9, 16.8, 15.5, 3.8, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 392.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>S</i>)-6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>)</h4><div class="NLM_p">Prepared from <b>5</b> analogously to <b>16</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (s, 1H), 7.98 (d, <i>J</i> = 1.4 Hz, 1H), 7.80 (d, <i>J</i> = 1.5 Hz, 1H), 7.56 (q, <i>J</i> = 5.1 Hz, 1H), 4.75 (s, 2H), 3.69–3.61 (m, 1H), 2.51 (s, 3H), 2.34 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.13 (m, 1H), 0.65–0.57 (m, 1H), 0.48–0.38 (m, 2H), 0.31–0.24 (m, 1H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 407.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure B, Arylations of Amines <b>16</b> and <b>17</b></h3><div class="NLM_p">(<i>S</i>)-6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (150 mg, 0.37 mmol), haloheterocycle (0.44 mmol, 1.2 equiv), potassium phosphate (157 mg, 0.74 mmol, 2 equiv), PdOAc<sub>2</sub> (41 mg, 0.18 mmol, 0.5 equiv), and Xantphos (214 mg, 0.37 mmol. 1 equiv) were mixed in dioxane (10 mL) and sealed into a microwave tube. The reaction was heated to 120 °C for 60 min in a microwave reactor. The solvent was removed under reduced pressure, and the crude product was purified by preparative HPLC.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-methylpyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>18</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.46 (s, 1H), 7.98 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (d, <i>J</i> = 1.6 Hz, 1H), 7.65–7.58 (m, 2H), 6.87 (d, <i>J</i> = 8.2 Hz, 1H), 6.82 (d, <i>J</i> = 7.3 Hz, 1H), 4.76 (s, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 2.52 (d, <i>J</i> = 5.2 Hz, 3H), 2.48 (s, 3H), 2.44 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.12 (m, 1H), 0.64–0.57 (m, 1H), 0.48–0.38 (m, 2H), 0.31–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.7, 158.08, 155.3, 150.5, 145.9, 144.9, 138.3, 136.7, 136.0, 126.7, 126.3, 125.1, 119.7, 115.3, 107.8, 52.3, 46.3, 29.2, 23.4, 17.9, 16.7, 15.5, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 498.1617 expected 498.1633.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-6-((5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)-<i>N</i>-(2-methoxyethyl)picolinamide (<b>19</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H; exchangeable NH and reduced to ∼57%), 8.15 (br. t, <i>J</i> = 5.6 Hz, 1H), 8.08 (s, 2H), 7.92 (t, <i>J</i> = 7.9 Hz, 1H), 7.61 (d, <i>J</i> = 7.4 Hz, 1H), 7.26 (d, <i>J</i> = 8.3 Hz, 1H), 4.83–4.57 (m, 2H), 3.67–3.59 (m, 4H), 3.59–3.54 (m, 2H), 3.54–3.48 (m, 2H), 3.04 (s, 3H), 2.47 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.24–1.09 (m, 1H), 0.67–0.52 (m, 1H), 0.51–0.35 (m, 2H), 0.34–0.20 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.7, 163.5, 157.2, 150.4, 147.1, 145.8, 145.2, 139.5, 137.7, 135.8, 127.4, 126.9, 126.6, 119.5, 114.7, 114.5, 70.4, 57.6, 52.1, 45.9, 43.1, 38.5, 18.0, 16.6, 15.6, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 570.1837 expected 570.1844.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-6-((5-(2-(1-Cyclopropylethyl)-7-(<i>N</i>-methylsulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)-<i>N</i>-(3-(dimethylamino)propyl)picolinamide (<b>20</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (bs, 1H), 9.47 (bs, 1H), 8.24 (t, <i>J</i> = 6.3 Hz, 1H), 8.08 (d, <i>J</i> = 1.3 Hz, 1H), 7.96 (d, <i>J</i> = 1.5 Hz, 1H), 7.96–7.92 (m, 1H), 7.63 (q, <i>J</i> = 5.2 Hz, 1H), 7.62–7.59 (m, 1H), 7.30–7.27 (m, 1H), 4.76 (s, 2H), 3.69–3.63 (m, 1H), 3.51 (q, <i>J</i> = 6.7 Hz, 2H), 3.16–3.08 (m, 2H), 2.74 (s, 3H), 2.73 (s, 3H), 2.53 (d, <i>J</i> = 5.2 Hz, 3H), 2.51 (s, 3H), 2.00–1.92 (m, 2H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.14 (m, 1H), 0.65–0. 59 (m, 1H), 0.48–0.4 (m, 2H), 0.31–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO<i>-d</i><sub>6</sub>) δ 165.1, 164.8, 157.7, 150.8, 147.8, 146.4, 145.9, 140.0, 136.6, 136.6, 127.3, 126.6, 125.8, 119.9, 115.4, 114.9, 55.2, 52.9, 46.9, 42.7, 36.7, 29.7, 25.2, 18.4, 17.2, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 612.2409 expected 612.2427.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-6-((5-(2-(1-Cyclopropylethyl)-7-(<i>N</i>-methylsulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)-<i>N</i>-(3-(dimethylamino)propyl)nicotinamide (<b>21</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 8.84 (d, <i>J</i> = 2.3 Hz, 1H), 8.44 (t, <i>J</i> = 5.6 Hz, 1H), 8.12 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 8.01 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (d, <i>J</i> = 1.6 Hz, 1H), 7.61 (s, 1H), 7.09 (d, <i>J</i> = 8.6 Hz, 1H), 4.75 (s, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.27 (td, <i>J</i> = 7.2, 5.6 Hz, 2H), 2.52 (s, 3H), 2.47 (s, 3H), 2.25 (t, <i>J</i> = 7.1 Hz, 2H), 2.13 (s, 6H), 1.65 (p, <i>J</i> = 7.1 Hz, 2H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.11 (m, 1H), 0.64–0.57 (m, 1H), 0.47–0.37 (m, 2H), 0.32–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.7, 164.3, 157.6, 152.7, 146.2, 145.9, 145.1, 137.0, 136.3, 136.0, 126.7, 126.3, 125.3, 122.7, 120.4, 110.3, 56.8, 52.4, 46.4, 45.2, 37.6, 29.2, 27.1, 18.0, 16.6, 15.5, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 612.2415 expected 612.2427.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-6-((5-(2-(1-Cyclopropylethyl)-7-(<i>N</i>-methylsulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)-<i>N</i>,<i>N</i>-diethylpicolinamide (<b>22</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.75 (s, 1H), 7.98 (d, <i>J</i> = 1.5 Hz, 1H), 7.86 (d, <i>J</i> = 1.5 Hz, 1H), 7.84 (t, <i>J</i> = 7.8 Hz, 1H), 7.59 (q, <i>J</i> = 5.2 Hz, 1H), 7.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.02 (d, <i>J</i> = 7.4 Hz, 1H), 4.75 (s, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.49 (q, <i>J</i> = 7.0 Hz, 2H), 3.35–3.30 (m, 2H), 2.51 (s, 3H), 2.47 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.22–1.12 (m, 4H), 1.03 (t, <i>J</i> = 7.1 Hz, 3H), 0.65–0.56 (m, 1H), 0.50–0.37 (m, 2H), 0.34–0.23 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.3, 164.7, 157.8, 152.3, 150.1, 145.9, 145.1, 139.1, 136.4, 136.1, 126.8, 126.0, 125.2, 120.1, 114.1, 111.1, 52.4, 46.3, 42.3, 38.5, 29.1, 17.9, 16.6, 15.5, 14.3, 12.8, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 583.2151 expected 583.2161.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-Aminopropyl)-6-chloropicolinamide (<b>23</b>)</h4><div class="NLM_p">Propane-1,3-diamine (1.6 g, 21.5 mmol) was added to ethyl 6-chloropicolinate (1.0 g, 5.4 mmol) in DCM (10 mL). The resulting mixture was stirred at RT overnight, and then the solvent was evaporated. The residue was purified by reverse phase C18-flash chromatography, elution gradient 0 to 100% MeCN in water to give the title compound (1.1 g, 96%) as a brown oil.</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 214/216.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(4-Aminobutyl)-6-bromopicolinamide hydrochloride (<b>24</b>)</h4><div class="NLM_p">Step 1: <i>tert</i>-Butyl (4-(6-bromopicolinamido)butyl)carbamate</div><div class="NLM_p">6-Bromopicolinic acid (2.0 g, 9.90 mmol) was dissolved in ethyl acetate (20 mL). Triethylamine (3.0 mL, 21.8 mmol) was added followed by <i>tert</i>-butyl (4-aminobutyl)carbamate (2.05 g, 10.9 mmol) and then 1-propanephosphonic acid cyclic anhydride (50% in EtOAc) (8.8 mL, 14.8 mmol). The resultant hazy solution was stirred overnight at RT. The reaction was quenched with water, and the layers were separated. The organic layer was washed with water and then with a sat. solution of sodium bicarbonate and then finally with dilute hydrochloric acid (<1 N). The organic layer was dried over sodium sulfate, filtered, and concentrated to obtain the subtitle compound (3.50 g, 95%) as a light yellow colored gum which slowly crystallized into a solid.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.14 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H), 7.86 (d, <i>J</i> = 6.8 Hz, 1H), 7.70 (t, <i>J</i> = 7.7 Hz, 1H), 7.60 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 4.60 (s, 0H), 4.11 (q, <i>J</i> = 7.1 Hz, 1H), 3.47 (q, <i>J</i> = 6.8 Hz, 2H), 3.15 (d, <i>J</i> = 7.1 Hz, 2H), 2.03 (s, 1H), 1.52–1.71 (m, 4H), 1.25 (t, <i>J</i> = 7.1 Hz, 2H).</div><div class="NLM_p">ES+ [M + H]<sup>+</sup> 372/374.</div><div class="NLM_p">Step 2: <i>N</i>-(4-Aminobutyl)-6-bromopicolinamide hydrochloride</div><div class="NLM_p"><i>tert</i>-Butyl (4-(6-bromopicolinamido)butyl)carbamate (3.5 g, 9.40 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL). Dioxane-HCl 4 M (5 mL, 20 mmol) was added and the solution was stirred overnight at RT. The resulting precipitate was collected and was washed with CH<sub>2</sub>Cl<sub>2</sub> to give the title compound (2.80 g, 97%) as a white colored solid.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d6</i>) δ 8.72 (t, <i>J</i> = 6.2 Hz, 1H), 8.03 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H), 7.94 (t, <i>J</i> = 7.7 Hz, 1H), 7.83–7.9 (m, 3H), 5.76 (s, 1H), 3.31 (d, <i>J</i> = 6.1 Hz, 2H), 2.79 (q, <i>J</i> = 6.2 Hz, 2H), 1.52–1.61 (m, 4H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 272/274.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(5-Aminopentyl)-6-bromopicolinamide (<b>25</b>)</h4><div class="NLM_p">Prepared analogously to <b>23</b> using pentane-1,5-diamine and methyl 6-bromopicolinate.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ 8.66 (t, <i>J</i> = 5.7 Hz, 1H), 8.03 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H), 7.94 (t, <i>J</i> = 7.7 Hz, 1H), 7.85 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H),3.32–3.23 (m, 2H), 2.55–2.51 (m, 1H), 1.53 (p, <i>J</i> = 7.4 Hz, 3H), 1.42–1.22 (m, 6H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 286/288.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-Chloro-<i>N</i>-(3-(methylamino)propyl)picolinamide (<b>26</b>)</h4><div class="NLM_p">Prepared analogously to <b>23</b> using <i>N</i>-1-methylpropane-1,3-diamine.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub> δ 8.46 (s, 1H), 8.14 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.83 (td, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.47 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 3.57 (q, <i>J</i> = 6.0 Hz, 2H), 2.74 (td, <i>J</i> = 6.7, 1.2 Hz, 2H), 2.49 (s, 3H), 1.92–1.83 (m, 2H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 228/230.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(2-(2-Aminoethoxy)ethyl)-6-bromopicolinamide (<b>27</b>)</h4><div class="NLM_p">2-(2-Aminoethoxy)ethanamine (4.82 g, 46.3 mmol) was added to a solution of methyl 6-bromopicolinate (5.0 g, 23.1 mmol) in THF (100 mL) at 25 °C over a period of 15 min. The resulting solution was heated to 50 °C for 45 h. The solvent was evaporated, and the residue was purified by flash silica chromatography, elution gradient 10 to 10% MeOH in DCM to give the title compound (5.0 g, 75%) as a brown oil.</div><div class="NLM_p">1H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.22 (s, 1H), 8.15 (dd, J = 7.6, 1.0 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 7.61 (dd, J = 8.0, 1.0 Hz, 1H), 3.73–3.62 (m, 4H), 3.55 (t, J = 5.1 Hz, 2H), 2.91 (t, J = 5.1 Hz, 2H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 288/290.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-((4-Aminobenzyl)(methyl)amino)propyl)-6-chloropicolinamide (<b>28</b>)</h4><div class="NLM_p">Step 1 <i>N</i>-(3-aminopropyl)-6-chloropicolinamide (1.1 g, 5.15 mmol), <i>N</i>-(4-formylphenyl)acetamide (0.924 g, 5.66 mmol), acetic acid (0.309 mL, 5.41 mmol) and sodium cyanotrihydroborate (0.971 g, 15.44 mmol) were dissolved in MeOH (20 mL) to give a brown solution. The resulting mixture was stirred at RT for 1 h. Aqueous formaldehyde (4.73 mL, 51.48 mmol) was added. The resulting mixture was stirred at RT for a further 30 min. The crude product was added to a silica gel column and was eluted with DCM:EA:MeOH 5:5:1 to give <i>N</i>-(3-((4-acetamidobenzyl)(methyl)amino)propyl)-6-chloropicolinamide (0.550 g, 28%) as a pale tan oil.</div><div class="NLM_p">ES+ [M + H]<sup>+</sup> 375/377.</div><div class="NLM_p">Step 2 <i>N</i>-(3-((4-acetamidobenzyl)(methyl)amino)propyl)-6-chloropicolinamide (500 mg, 1.33 mmol) was dissolved in a mixture of hydrochloric acid (3 M aq, 4.45 mL, 13.34 mmol) and ethanol (4.45 mL) to give a colorless solution. The resulting mixture was stirred at 85 °C for 3 h. The solvent was removed under reduced pressure. The crude product was neutralized with saturated aqueous NaHCO<sub>3</sub>, and evaporated to dryness. The residue was purified by C18-flash chromatography, elution gradient 0 to 100% MeCN in water to give the title compound (460 mg, 100%) as a pale yellow oil.</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 333/335.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(4-((4-Aminobenzyl)(methyl)amino)butyl)-6-chloropicolinamide (<b>29</b>)</h4><div class="NLM_p">Prepared analogously to <b>28</b>.</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 347/349.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(2-((2-Aminoethyl)(methyl)amino)ethyl)-6-bromopicolinamide (<b>30</b>)</h4><div class="NLM_p">Methyl 6-bromopicolinate (2.0 g, 9.26 mmol) was dissolved in THF (20 mL). <i>N</i>-1-(2-Aminoethyl)-<i>N</i>-1-methylethane-1,2-diamine (2.17 g, 18.52 mmol) was added, and the mixture was heated to 50 °C for 16 h. The mixture was allowed to cool, and the volatiles were evaporated. The residue was purified using a Biotage KP-SIL 100 g column eluting with a gradient of 0–8% methanolic ammonia (2 M) in DCM to give the title compound (2.40 g, 86%) as a light yellow colored viscous oil.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.33 (br. s, 1H), 8.12 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H), 7.68 (t, <i>J</i> = 7.7 Hz, 1H), 7.57 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 3.52 (q, <i>J</i> = 5.82 Hz, 2H), 2.78 (dd, <i>J</i> = 6.4, 5.1 Hz, 2H), 2.61 (t, <i>J</i> = 6.1 Hz, 2H), 2.49 (dd, <i>J</i> = 6.4, 5.0 Hz, 2H), 2.28 (s, 3H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 301/303.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(3-((2-Aminoethyl)(methyl)amino)propyl)-6-chloropicolinamide (<b>31</b>)</h4><div class="NLM_p">Step 1: 6-Chloro-<i>N</i>-(3-(methylamino)propyl)picolinamide (<b>26</b>, 1.0 g, 4.39 mmol), <i>tert</i>-butyl (2-oxoethyl)carbamate (1.05 g, 6.59 mmol), and acetic acid (0.025 mL, 0.44 mmol) were dissolved in MeOH (50 mL) to give a yellow solution which was stirred at 25 °C for 30 min, and then sodium cyanoborohydride (0.828 g, 13.18 mmol) was added, and the resulting mixture was stirred at 25 °C for 12 h. The solvent was evaporated, and the residue was purified by flash silica chromatography, elution gradient 0 to 5% MeOH in DCM to give <i>tert</i>-butyl (2-((3-(6-chloropicolinamido)propyl)(mmethyl)amino)ethyl)carbamate (1.00 g, 61%) as a yellow liquid. ES+ [M + H]<sup>+</sup> 371/373.</div><div class="NLM_p">Step 2: <i>tert</i>-Butyl (2-((3-(6-chloropicolinamido)propyl)(methyl)amino)ethyl)carbamate (600 mg, 1.62 mmol) was dissolved in DCM (10 mL) to give a colorless solution. TFA (5 mL, 64.9 mmol) was added, and the resulting mixture was stirred at 25 °C for 1 h. The volatiles were evaporated, and the residue was dissolved in DCM (150 mL) and washed with 2 M NaOH (50 mL) and saturated brine (100 mL × 2). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give the title compound (400 mg, 91%) as a yellow liquid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.03 (bs, 1H), 8.12 (d, <i>J</i> = 7.6 Hz, 1H), 7.80 (t, <i>J</i> = 7.8 Hz, 1H), 7.43 (d, <i>J</i> = 7.9 Hz, 1H), 3.56 (q, <i>J</i> = 6.0 Hz, 2H), 2.86 (t, <i>J</i> = 5.9 Hz, 2H), 2.56–2.42 (m, 4H), 2.26 (d, <i>J</i> = 4.9 Hz, 3H), 1.90–1.77 (m, 4H).</div><div class="NLM_p last">ES+ [M + H]<sup>+</sup> 271/273.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>S</i>)-1<sup>2</sup>-(1-Cyclopropylethyl)-2<sup>4</sup>,12-dimethyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-16-thia-3,6,12,15-tetraaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridina-14(1,4)-benzenacyclohexadecaphane-1<sup>3</sup>,5-dione 16,16-dioxide (<b>32</b>)</h4><div class="NLM_p">Step 1: (<i>S</i>)-6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonyl chloride (<b>4</b>, 558 mg, 1.23 mmol), <i>N</i>-(3-((4-aminobenzyl)(methyl)amino)propyl)-6-chloropicolinamide (<b>28</b>, 450 mg, 1.35 mmol), and triethylamine (373 mg, 3.69 mmol) were dissolved in DCM (10 mL) to give a yellow solution. The resulting mixture was stirred at RT for 3 h, and then the solvent was evaporated. The residue was purified by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water to give (<i>S</i>)-<i>N</i>-(3-((4-(6-(2-acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)benzyl)(methyl)amino)propyl)-6-chloropicolinamide (400 mg, 43%) as a yellow solid.</div><div class="NLM_p">ES+ [M + H]<sup>+</sup> 750/752.</div><div class="NLM_p">Step 2: (<i>S</i>)-<i>N</i>-(3-((4-(6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)benzyl)(methyl)amino)propyl)-6-chloropicolinamide.</div><div class="NLM_p">(<i>S</i>)-<i>N</i>-(3-((4-(6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)benzyl)(methyl)amino)propyl)-6-chloropicolinamide (390 mg, 0.52 mmol) was dissolved in ethanol (8.7 mL) to give a colorless solution. Hydrogen chloride (3 M aq, 8.66 mL, 26 mmol) was added, and the reaction was heated under reflux for 3 h. The solvent was evaporated, and the residue was diluted with MeOH (5 mL), basified with saturated NaHCO<sub>3</sub>, and purified by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water to give the subtitle compound (320 mg, 87%) as a yellow solid.</div><div class="NLM_p">ES+ [M + H]<sup>+</sup> 708/710.</div><div class="NLM_p">Step 3: (<i>S</i>)-<i>N</i>-(3-((4-(6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)benzyl)(methyl)amino)propyl)-6-chloropicolinamide (320 mg, 0.45 mmol), PdOAc<sub>2</sub> (51 mg, 0.23 mmol), 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-triisopropylbiphenyl (211 mg, 0.50 mmol) and DIPEA (0.473 mL, 2.71 mmol) were dissolved in DMF (40 mL) to give a brown solution. The resulting mixture was stirred at 130 °C overnight. The solvent was evaporated, and the residue was purified by preparative HPLC (X Bridge RP18, 19 × 150 mm, 5 μm; mobile phase A: water/10 nmol NH<sub>4</sub>HCO<sub>3</sub>, mobile phase B: MeCN; flow rate: 30 mL/min; gradient: 48% B to 55% B over 8 min) to give the title compound (30 mg, 10%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 10.08 (s, 1H), 8.00 (s, 1H), 7.91–7.85 (m, 2H), 7.59–7.56 (m, 1H), 7.51 (d, <i>J</i> = 7.4 Hz, 1H), 7.20 (t, <i>J</i> = 8.7 Hz, 3H), 7.04 (d, <i>J</i> = 8.4 Hz, 2H), 4.81 (s, 2H), 3.78–3.72 (m, 1H), 3.32 (s, 6H), 2.36 (s, 3H), 2.30 (s, 3H), 2.01–1.92 (m, 2H), 1.40 (d, <i>J</i> = 6.8 Hz, 3H), 1.26–1.19 (m,1H), 0.67–0.61 (m, 1H), 0.54–0.45 (m, 2H), 0.42–0.35 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.4, 163.8, 157.7, 150.6, 147.9, 146.4, 140.0, 137.7, 136.5, 136.3, 135.9, 130.6, 129.0, 128.3, 126.7, 122.1, 119.5, 114.8, 114.6, 61.6, 53.4, 53.3, 47.1, 44.0, 39.3, 27.5, 18.5, 16.1, 156.0, 4.5, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 672.2441 expected 672.2427.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-1<sup>2</sup>-(1-Cyclopropylethyl)-2<sup>4</sup>,10-dimethyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-14-thia-3,6,10,13-tetraaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridina-12(1,4)-benzenacyclotetradecaphane-1<sup>3</sup>,5-dione 14,14-dioxide (<b>33</b>)</h4><div class="NLM_p">Prepared analogously to compound <b>32</b> using <b>4</b> and <b>29</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 9.96 (s, 1H), 7.98 (s, 1H), 7.93–7. 87 (m, 1H), 7.84 (t, <i>J</i> = 5.8 Hz, 1H), 7.73–7.69 (m, 1H), 7.55 (d, <i>J</i> = 7.2 Hz, 1H), 7.21 (d, <i>J</i> = 8.2 Hz, 1H), 7.12 (d, <i>J</i> = 8.4 Hz, 2H), 6.98 (d, <i>J</i> = 8.4 Hz, 2H), 4.73 (s, 2H), 3.76–3.73 (m, 1H), 3.21 (d, <i>J</i> = 5.6 Hz, 2H), 2.36 (s, 3H), 2.17 (s, 3H), 1.79 (t, <i>J</i> = 6.6 Hz, 2H), 1.40 (d, <i>J</i> = 6.8 Hz, 3H), 1.33–1.26 (m, 2H), 1.25–1.17 (m, 3H), 0.67–0.61 (m, 1H), 0.53–0.44 (m, 2H), 0.39–0.33 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.3, 164.1, 157.7, 150.8, 148.1, 146.1, 145.6, 139.9, 136.5, 136.5, 136.1, 136.0, 130.1, 128.6, 128.4, 126.4, 121.9, 119.4, 115.0, 114.7, 62.0, 54.0, 53.3, 46.9, 43.2, 39.3, 26.9, 24.1, 18.6, 16.3, 16.1, 4.5, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 686.257 expected 686.2583.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-1<sup>2</sup>-(1-Cyclopropylethyl)-2<sup>4</sup>-methyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-13-thia-3,6,12-triaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotridecaphane-1<sup>3</sup>,5-dione 13,13-dioxide (<b>34</b>)</h4><div class="NLM_p">Prepared analogously to compound <b>32</b> using <b>4</b> and <b>25</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 8.06 (s, 1H), 7.92 (t, <i>J</i> = 7.8 Hz, 1H), 7.90–7.85 (m, 2H), 7.57 (d, <i>J</i> = 7.3 Hz, 1H), 7.23 (d, <i>J</i> = 8.3 Hz, 1H), 7.15–7.11 (m, 1H), 4.75 (s, 2H), 3.67–3.60 (m, 1H), 3.26 (dt, <i>J</i> = 11.4, 5.8 Hz, 2H), 2.80–2.73 (m, 2H), 2.48 (s, 3H), 1.61–1.52 (m, 2H), 1.51–1.43 (m, 2H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.27–1.20 (m, 2H), 1.20–1.12 (m, 1H), 0.64–0.58 (m, 1H), 0.47–0.38 (m, 2H), 0.30–0.25 (m, 1H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 581.2052 expected 581.2004.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>S</i>)-1<sup>2</sup>-(1-cyclopropylethyl)-2<sup>4</sup>,9-dimethyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-13-thia-3,6,9,12-tetraaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotridecaphane-1<sup>3</sup>,5-dione 13,13-dioxide (<b>35</b>)</h4><div class="NLM_p">Prepared analogously to compound <b>32</b> using <b>4</b> and <b>30</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.07 (s, 1H), 7.94–7. 89 (m, 3H), 7.58 (d, <i>J</i> = 7.4 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 7.10 (t, <i>J</i> = 4.8 Hz, 1H), 4.75 (s, 2H), 3.68–3.61 (m, 1H), 3.45–3.37 (m, 2H), 2.93–2. 82 (m, 2H), 2.62 (t, <i>J</i> = 7.9 Hz, 2H), 2.50 (s, 3H), 2.49–2.44 (m, 2H), 2.21 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.13 (m, 1H), 0.63–0.58 (m, 1H), 0.47–0.38 (m, 2H), 0.30–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.6, 163.9, 157.6, 150.7, 147.7, 146.6, 144.5, 139.9, 136.3, 136.0, 129.2, 127.4, 126.8, 120.3, 115.2, 114.8, 56.9, 55.1, 52.6, 46.8, 43.5, 37.7, 18.4, 16.4, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 596.2120 expected 596.2114.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>S</i>)-1<sup>2</sup>-(1-cyclopropylethyl)-2<sup>4</sup>,10-dimethyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-14-thia-3,6,10,13-tetraaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotetradecaphane-1<sup>3</sup>,5-dione 14,14-dioxide (<b>36</b>)</h4><div class="NLM_p">Prepared analogously to compound <b>32</b> using <b>4</b> and <b>31</b>.</div><div class="NLM_p">Step 1: (<i>S</i>)-<i>N</i>-(3-((2-(6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)ethyl)(methyl)amino)propyl)-6-chloropicolinamide.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.57 (bs, 1H), 8.62 (bs, 1H), 8.11 (s, 1H), 8.08 (d, <i>J</i> = 7.6 Hz, 1H), 7.77 (t, <i>J</i> = 7.8 Hz, 2H), 7.65 (s, 1H), 7.38 (d, <i>J</i> = 7.9 Hz, 1H), 4.70–4. 45 (m, 2H), 3.87–3.70 (m, 1H), 3.47 (q, <i>J</i> = 6.1 Hz, 2H), 3.17 (bs, 2H), 2.66–2.44 (m, 3H), 2.42 (s, 3H), 2.30 (s, 3H), 2.18 (bs, 3H), 1.67 (bs, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.11–0.94 (m, 1H), 0.73–0.59 (m, 1H), 0.52–0.29 (m, 3H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 688/690.</div><div class="NLM_p">Step 2: (<i>S</i>)-<i>N</i>-(3-((2-(6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonamido)ethyl)(methyl)amino)propyl)-6-chloropicolinamide.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 8.07 (d, <i>J</i> = 7.6 Hz, 1H), 7.98 (s, 1H), 7.80–7.70 (m, 2H), 7.55 (s, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 5.21–5.06 (m, 2H), 4.45–4.68 (m, 2H), 3.81–3.71 (m, 1H), 3.50–3.41 (m, 2H), 3.21–3.10 (m, 2H), 2.57 (bs, 2H), 2.45 (bs, 2H), 2.35 (d, <i>J</i> = 1.4 Hz, 3H), 2.17 (s, 3H), 1.34 (d, <i>J</i> = 6.8 Hz, 3H), 1.25 (s, 1H), 1.06–0.96 (m, 1H), 0.90–0.79 (m, 1H), 0.69–0.60 (m, 1H), 0.49–0.30 (m, 3H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 646/648.</div><div class="NLM_p">Step 3: (<i>S</i>)-1<sup>2</sup>-(1-cyclopropylethyl)-2<sup>4</sup>,10-dimethyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-14-thia-3,6,10,13-tetraaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotetradecaphane-1<sup>3</sup>,5-dione 14,14-dioxide.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 7.98 (s, 1H), 7.95–7. 89 (m, 2H), 7.79 (d, <i>J</i> = 1.2 Hz, 1H), 7.68 (t, <i>J</i> = 5.9 Hz, 1H), 7.56 (d, <i>J</i> = 7.3 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.76 (s, 2H), 3.71–3. 64 (m, 1H), 3.29–3.23 (m, 2H), 3.22–3.13 (m, 2H), 2.45 (s, 3H), 2.38–2.29 (m, 2H), 2.26–2.18 (m, 2H), 1.75 (s, 3H), 1.59 (p, <i>J</i> = 7.8 Hz, 2H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.14 (m, 1H), 0.65–0.58 (m, 1H), 0.46–0.40 (m, 2H), 0.32–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.4, 163.9, 157.4, 150.7, 147.8, 146.0, 144.6, 140.4, 140.0, 136.1, 126.7, 126.3, 125.7, 120.1, 114.9, 114.7, 54.9, 52.79, 52.77, 46.7, 43.4, 41.8, 38.4, 26.1, 18.5, 16.2, 16.1, 4.5, 3.7.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 610.2282 expected 610.2270.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>S</i>)-1<sup>2</sup>-(1-Cyclopropylethyl)-2<sup>4</sup>-methyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-9-oxa-13-thia-3,6,12-triaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotridecaphane-1<sup>3</sup>,5-dione 13,13-dioxide (<b>37</b>)</h4><div class="NLM_p">Prepared analogously to compound <b>32</b> using <b>4</b> and <b>27</b>.</div><div class="NLM_p">Step 1: (<i>S</i>)-<i>N</i>-(2-(2-((6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline)-4-sulfonamido)ethoxy)ethyl)-6-bromopicolinamide.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.69 (s, 1H), 8.26–8.17 (m, 1H), 8.14 (d, <i>J</i> = 1.4 Hz, 1H), 8.12 (dd, <i>J</i> = 7.5, 1.0 Hz, 1H), 8.05–7.97 (m, 1H), 7.95 (t, <i>J</i> = 5.9 Hz, 1H), 7.74–7.65 (m, 2H), 7.58 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 4.72–4.49 (m, 2H), 3.87–3.73 (m, 1H), 3.60–3.41 (m, 6H), 3.22 (q, <i>J</i> = 5.6 Hz, 2H), 2.43 (s, 3H), 2.30 (s, 3H), 1.35 (d, <i>J</i> = 6.8 Hz, 3H), 1.11–0.95 (m, 1H), 0.70–0.60 (m, 1H), 0.51–0.40 (m, 1H), 0.4–0.31 (m, 2H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 705/707.</div><div class="NLM_p">Step 2: (S)-<i>N</i>-(2-(2-((6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline)-4-sulfonamido)ethoxy)ethyl)-6-bromopicolinamide.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.49 (s, 1H), 7.99 (dd, <i>J</i> = 7.4, 1.1 Hz, 1H), 7.91 (t, <i>J</i> = 7.6 Hz, 2H), 7.83 (dd, <i>J</i> = 7.8, 1.1 Hz, 1H), 7.78 (d, <i>J</i> = 1.4 Hz, 1H), 7.71 (d, <i>J</i> = 1.5 Hz, 1H), 4.70 (s, 2H), 3.67–3. 53 (m, 1H), 3.37 (t, <i>J</i> = 5.1 Hz, 2H), 3.26 (m, 4H), 3.03 (s, 2H), 2.28 (s, 3H), 1.33–1.20 (m, 4H), 1.13–1. 06 (m, 1H), 0.89–0.81 (m, 1H), 0.59–0.47 (m, 1H), 0.46–0.29 (m, 2H), 0.28–0.17 (m, 1H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 663/665.</div><div class="NLM_p">Step 3: (<i>S</i>)-1<sup>2</sup>-(1-Cyclopropylethyl)-2<sup>4</sup>-methyl-1<sup>2</sup>,1<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>-9-oxa-13-thia-3,6,12-triaza-2(5,2)-thiazola-1(6,4)-isoindolina-4(2,6)-pyridinacyclotridecaphane-1<sup>3</sup>,5-dione 13,13-dioxide.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 8.07–8.03 (m, 2H), 7.94–7.90 (m, 2H), 7.59–7.62 (m, 1H), 7.43–7.39 (m, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.72 (s, 2H), 3.66–3.60 (m, 1H), 3.60–3. 51 (m, 6H), 3.17–3. 08 (m, 2H), 1.31 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.12 (m, 1H), 0.63–0.58 (m, 1H), 0.47–0.38 (m, 2H), 0.31–0.25 (m, 1H). 3H obscured.</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.1, 163.9, 157.7, 150.9, 147.8, 146.4, 145.3, 139.9, 137.5, 136.0, 127.7, 127.0, 126.8, 120.5, 115.3, 114.9, 68.8, 68.6, 52.4, 46.4, 42.0, 39.0, 18.4, 16.9, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 583.1800 expected 583.1797.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-Bromo-6-(1,3-dimethyl-1<i>H</i>-1,2,4-triazol-5-yl)pyridine (<b>38</b>)</h4></div><div id="sec5_2_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-Bromo-6-(1,5-dimethyl-1<i>H</i>-1,2,4-triazol-3-yl)pyridine (<b>39</b>)</h4><div class="NLM_p">Step 1: 6-Bromopicolinic acid (200 mg, 0.99 mmol), acetimidamide hydrochloride (140 mg, 1.49 mmol) and DIPEA (0.692 mL, 3.96 mmol) were dissolved in DMF (5 mL) at 25 °C under nitrogen. HATU (565 mg, 1.49 mmol) was added, and the resulting mixture was stirred for 12 h. The reaction mixture was poured onto water and was then extracted with ethyl acetate (3 × 10 mL), and the organic phases were combined, dried, filtered, and evaporated to give a product that was used without purification (240 mg).</div><div class="NLM_p">Step 2: Methylhydrazine sulfate (0.536 g, 3.72 mmol) was added to (<i>Z</i>)-<i>N</i>-(1-aminoethylidene)-6-bromopicolinamide (previous step, 0.60 g, 2.48 mmol) and acetic acid (1.49 g, 24.8 mmol) in DMF (20 mL) at 25 °C over a period of 15 min. The resulting mixture was heated to 80 °C for 12 h. The reaction mixture was quenched with water (25 mL) and extracted with DCM (3 × 20 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, eluting with 30% EtOAc in petroleum ether, to give the title compounds (0.060 g, 9.6%) and (0.180 g, 29%) as yellow solids.</div><div class="NLM_p"><b>38</b><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.12 (d, <i>J</i> = 7.7 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.49 (d, <i>J</i> = 7.9 Hz, 1H), 4.27 (s, 3H), 2.40 (s, 3H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 253/255.</div><div class="NLM_p"><b>39</b><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.77 (d, <i>J</i> = 7.6 Hz, 1H), 7.60 (t, <i>J</i> = 7.8 Hz, 1H), 7.41 (d, <i>J</i> = 7.8 Hz, 1H), 3.63 (s, 3H), 2.23 (s, 3H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 253/255.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (5-(6-Bromopyridin-2-yl)oxazol-4-yl)methanol (<b>40</b>)</h4><div class="NLM_p">Step 1: Ethyl 5-(6-bromopyridin-2-yl)oxazole-4-carboxylate</div><div class="NLM_p">Oxalyl chloride (0.942 g, 7.43 mmol) was added to 6-bromopicolinic acid (1 g, 4.95 mmol) and <i>N</i>,<i>N</i>-dimethylformamide (0.036 g, 0.50 mmol) in DCM (15 mL) at 0 °C. The resulting mixture was stirred at r.t. for 5 h. The volatiles were evaporated to leave a brown solid (1.10 g, 100%) that was used without purification.</div><div class="NLM_p">6-Bromopicolinoyl chloride (500 mg, 2.27 mmol), ethyl 2-isocyanoacetate (308 mg, 2.72 mmol), DMAP (14 mg, 0.11 mmol), and TEA (1.31 g, 12.9 mmol) were dissolved in THF (20 mL), and the mixture was heated to 60 °C for 12 h. The reaction mixture was allowed to cool and was filtered. The filtrate was diluted with EtOAc, and the resultant solution was washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in petroleum ether to give the title compound (270 mg, 40%) as a brown solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (s, 1H), 8.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.94 (t, <i>J</i> = 7.8 Hz, 1H), 7.78 (d, <i>J</i> = 7.9 Hz, 1H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 297/299.</div><div class="NLM_p">Step 2 (5-(6-Bromopyridin-2-yl)oxazol-4-yl)methanol</div><div class="NLM_p">Ethyl 5-(6-bromopyridin-2-yl)oxazole-4-carboxylate (200 mg, 0.67 mmol) was dissolved in EtOH (20 mL), and the solution was cooled to 0 °C. NaBH<sub>4</sub> (153 mg, 4.04 mmol) was added, and the resulting mixture was heated to 70 °C for 2 h. Water (15 mL) was added to the cooled reaction mixture which was then extracted with EtOAc (3 × 15 mL), and the organic phases were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash alumina chromatography, elution gradient 0 to 80% EtOAc in petroleum ether to give the title compound (110 mg, 64%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.50 (s, 1H), 7.89 (t, <i>J</i> = 7.8 Hz, 1H), 7.82–7.75 (m, 1H), 7.63 (dd, <i>J</i> = 7.9, 0.7 Hz, 1H), 5.21 (t, <i>J</i> = 5.9 Hz, 1H), 4.76 (d, <i>J</i> = 5.8 Hz, 2H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 255/257.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(6-Bromopyridin-2-yl)-<i>N</i>-methylacetamide (<b>41</b>)</h4><div class="NLM_p">6-Bromo-<i>N</i>-methylpyridin-2-amine (200 mg, 1.07 mmol) was dissolved in acetic anhydride (303 μL, 3.2 mmol) and pyridine (259 μL, 3.2 mmol). The resulting solution was heated to 120 °C for 2 h. The reaction mixture was concentrated, and then EtOAc (100 mL) was added. The solution was washed with saturated NaHCO<sub>3</sub> (75 mL × 2), 0.1 M HCl (75 mL × 2) and saturated brine (75 mL × 2). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give the title compound (180 mg, 73%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.45–7.31 (m, 2H), 3.40 (s, 3H), 2.19 (s, 3H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 229/231.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(6-Bromopyridin-2-yl)pyrrolidin-2-one (<b>42</b>)</h4><div class="NLM_p">Pyrrolidin-2-one (1.61 mL, 21.1 mmol) was added to a solution of 2,6-dibromopyridine (5.0 g, 21.1 mmol) in dioxane (5 mL). Xantphos (3.66 g, 6.3 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (20.63 g, 63.3 mmol), second Generation XantPhos precatalyst (3.75 g, 4.2 mmol) were added. The resulting mixture was stirred at 105 °C for 5 h. The crude product was purified by flash silica chromatography, elution gradient 0 to 1:20 EtOAc in petroleum ether to give the title compound (4.00 g, 79%) as a white solid.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.33–8.26 (m, 1H), 7.79–7.71 (m, 1H), 7.4–7.33 (m, 1H), 3.97–3.89 (m, 2H), 2.58 (t, <i>J</i> = 8.1 Hz, 2H), 2.09–1.97 (m, 2H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 241/243.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-(6-Bromopyridin-2-yl)imidazolidin-2-one (<b>43</b>)</h4><div class="NLM_p">Step 1: 1-(6-Bromopyridin-2-yl)-3-(2-chloroethyl)urea 6-bromopyridin-2-amine (3.0 g, 17.3 mmol) was added to a solution of 1-chloro-2-isocyanatoethane (2.20 g, 20.8 mmol) in toluene (20 mL. The resulting mixture was heated to 70 °C for 2 h. The reaction mixture was filtered through a Celite pad, and the crude product was purified by crystallization from EtOAc/petroleum ether = 1/10 to give the subtitle compound (3.10 g, 64%) as a white solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.59 (s, 1H), 7.70–7.57 (m, 2H), 7.30 (t, <i>J</i> = 5.9 Hz, 1H), 7.16 (dd, <i>J</i> = 6.7, 1.7 Hz, 1H), 3.68 (t, <i>J</i> = 5.9 Hz, 2H), 3.48 (q, <i>J</i> = 5.9 Hz, 2H).</div><div class="NLM_p">ES+ (M + H])<sup>+</sup> = 278/280/282.</div><div class="NLM_p">Step 2:1-(6-Bromopyridin-2-yl)imidazolidin-2-one</div><div class="NLM_p">A solution of 1-(6-bromopyridin-2-yl)-3-(2-chloroethyl)urea (3.0 g, 10.8 mmol) in DMF (25 mL) was added to a stirred suspension of 60% sodium hydride (0.775 g, 19.39 mmol) in THF (25 mL) at 0 °C under nitrogen. The resulting mixture was stirred at 25 °C for 1 h. The reaction mixture was quenched by the addition of water (10 mL), filtered, and evaporated to give the title compound (2.10 g, 81%) white solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16 (d, <i>J</i> = 8.3 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.33–7.39 (m, 1H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 3.93 (dd, <i>J</i> = 8.9, 7.1 Hz, 2H), 3.40 (t, <i>J</i> = 8.0 Hz, 2H).</div><div class="NLM_p last">ES+ (M + H])<sup>+</sup> = 242/244.</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(6-Bromopyridin-2-yl)-3-methylimidazolidin-2-one (<b>44</b>)</h4><div class="NLM_p">Prepared following the method of example <b>42</b> using 1-methylimidazolidin-2-one.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.27–8.17 (m, 1H), 7.48–7. 37 (m, 1H), 7.08–6.98 (m, 1H), 4.06–3.96 (m, 2H), 3.51–3.40 (m, 2H), 2.92–2.85 (m, 3H).</div><div class="NLM_p last">ES+ (M + H])<sup>+</sup> = 256/258.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>R</i>)-1-(6-bromopyridin-2-yl)-3-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one (<b>45</b>)</h4><div class="NLM_p">Step 1: (<i>R</i>)-3-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one</div><div class="NLM_p"><i>tert</i>-Butylchlorodimethylsilane (2.24 g, 14.8 mmol) was added to a solution of (<i>R</i>)-3-hydroxypyrrolidin-2-one (1.0 g, 9.89 mmol) and imidazole (1.35 g, 19.8 mmol) in DMF (15 mL). The resulting mixture was stirred at RT for 2 h. The reaction mixture was diluted with EtOAc (50 mL) and washed sequentially with water (20 mL × 3), saturated brine (20 mL × 2). The aqueous layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified by flash silica chromatography, elution gradient 0 to 2% DCM in MeOH to give the subtitle compound (1.90 g, 89%) as a pale yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.72 (s, 1H), 4.19 (t, <i>J</i> = 8.0 Hz, 1H), 3–3.22 (m, 2H), 2.21–2.37 (m, 1H), 1.77 (dq, <i>J</i> = 12.4, 8.4 Hz, 1H), 0.86 (s, 9H), 0.08 (d, <i>J</i> = 1.4 Hz, 6H).</div><div class="NLM_p">ES+ (M-<i>t</i>-Bu)<sup>+</sup> = 158.</div><div class="NLM_p">Step 2: (<i>R</i>)-1-(6-bromopyridin-2-yl)-3-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one</div><div class="NLM_p">Prepared following the method of example <b>42</b> using (R)-3-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (dd, <i>J</i> = 8.2, 0.7 Hz, 1H), 7.81–7. 73 (m, 1H), 7.40 (dd, <i>J</i> = 7.6, 0.7 Hz, 1H), 4.62 (dd, <i>J</i> = 9.7, 8.0 Hz, 1H), 4.02–3.89 (m, 1H), 3.73–3.58 (m, 1H), 2.48–2.37 (m, 1H), 1.95–1.77 (m, 1H), 0.90 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> = 371/373.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>R</i>)-1-(6-Bromopyridin-2-yl)-4-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one (<b>46</b>)</h4><div class="NLM_p">Step 1: (<i>R</i>)-4-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one.</div><div class="NLM_p">Prepared from (<i>R</i>)-4-hydroxypyrrolidin-2-one following the method of example <b>45</b> Step 1.</div><div class="NLM_p">ES+ (M + H])<sup>+</sup> = 216.</div><div class="NLM_p">Step 2: (<i>R</i>)-1-(6-bromopyridin-2-yl)-4-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one.</div><div class="NLM_p">Prepared from (<i>R</i>)-4-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one following the method of example <b>45</b> Step 2.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (d, <i>J</i> = 8.3 Hz, 1H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.38 (d, <i>J</i> = 7.7 Hz, 1H), 4.65–4.52 (m, 1H), 4.11 (dd, <i>J</i> = 11.6, 5.1 Hz, 1H), 3.80 (d, <i>J</i> = 11.6 Hz, 1H), 3.00 (dd, <i>J</i> = 17.1, 6.0 Hz, 1H), 2.39 (d, <i>J</i> = 17.1 Hz, 1H), 0.85 (s, 9H), 0.09 (s, 6H).</div><div class="NLM_p last">ES+ (M + H])<sup>+</sup> = 371/373.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(6-Bromopyridin-2-yl)piperidin-2-one (<b>47</b>)</h4><div class="NLM_p">Step 1: <i>N</i>-(6-Bromopyridin-2-yl)-5-chloropentanamide</div><div class="NLM_p">5-Chloropentanoyl chloride (1.08 g, 6.94 mmol) was added to a solution of 6-bromopyridin-2-amine (1.0 g, 5.78 mmol) and pyridine (1,37 g, 17.3 mmol) in MeCN (10 mL). The resulting mixture was stirred at RT for 5 h. The solvent was removed under reduced pressure to give the subtitle compound (1.68 g, 100%) as a colorless oil which crystallized on standing. Used without further purification.</div><div class="NLM_p">ES+ (M + H])<sup>+</sup> = 291/293/295.</div><div class="NLM_p">Step 2:1-(6-Bromopyridin-2-yl)piperidin-2-one.</div><div class="NLM_p">Cs<sub>2</sub>CO<sub>3</sub> (11.26 g, 34.6 mmol) was added to a solution of <i>N</i>-(6-bromopyridin-2-yl)-5-chloropentanamide (1.68 g, 5.76 mmol) in DMF (20 mL). The resulting suspension was stirred at 80 °C for 2 h. The reaction mixture was allowed to cool and was then diluted with DCM (75 mL) and washed sequentially with water (50 mL × 2) and saturated brine (75 mL × 2). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give the title compound (1.48 g, 100%) as a colorless oil.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.79 (dd, <i>J</i> = 8.1, 1.1 Hz, 1H), 7.72 (dd, <i>J</i> = 8.1, 7.3 Hz, 1H), 7.42 (dd, <i>J</i> = 7.4, 1.0 Hz, 1H), 3.80 (t, <i>J</i> = 5.7 Hz, 2H), 2.53–2.46 (m, 2H), 1.91–1.75 (m, 4H).</div><div class="NLM_p last">ES+ (M + H])<sup>+</sup> = 255/257.</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-(6-Bromopyridin-2-yl)morpholin-3-one (<b>48</b>)</h4><div class="NLM_p">Prepared following the method of example <b>42</b> using morpholin-3-one.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (d, <i>J</i> = 8.1 Hz, 1H), 7.78 (t, <i>J</i> = 8.0 Hz, 1H), 7.46 (d, <i>J</i> = 7.7 Hz, 1H), 4.27 (s, 2H), 3.98 (dd, <i>J</i> = 6.0, 3.6 Hz, 2H), 3.91 (dd, <i>J</i> = 6.0, 3.6 Hz, 2H).</div><div class="NLM_p last">ES+ (M + H])<sup>+</sup> = 257/259.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3-(6-Bromopyridin-2-yl)-1,3-oxazinan-2-one (<b>49</b>)</h4><div class="NLM_p">Step 1: 3-Chloropropyl (6-bromopyridin-2-yl)carbamate</div><div class="NLM_p">Pyridine (3.51 mL, 43.4 mmol) was added dropwise to a solution of 6-bromopyridin-2-amine (5.0 g, 28.9 mmol) and 3-chloropropyl carbonochloridate (5.44 g, 34.7 mmol) in acetonitrile (50 mL) cooled in ice over a period of 15 min. The resulting solution was stirred at RT for 4 h. The reaction mixture was diluted with EtOAc(150 mL) and was then washed with 0.1 M HCl (3 × 100 mL) and brine (2 × 100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give the subtitle compound (8.20 g, 97%) as a pale yellow oil which solidified on standing.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 7.83 (dd, <i>J</i> = 8.3, 0.7 Hz, 1H), 7.71 (t, <i>J</i> = 7.9 Hz, 1H), 7.25–7.3 (m, 1H), 4.20 (t, <i>J</i> = 6.2 Hz, 2H), 3.66–3.77 (m, 2H), 2.06 (p, <i>J</i> = 6.3 Hz, 2H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> = 293/295/297.</div><div class="NLM_p">Step 2:3-(6-Bromopyridin-2-yl)-1,3-oxazinan-2-one</div><div class="NLM_p">Cs<sub>2</sub>CO<sub>3</sub> (1.89 g, 5.79 mmol) was added to a solution of 3-chloropropyl (6-bromopyridin-2-yl)carbamate (1.70 g, 5.79 mmol) and KI (0.96 g, 5.79 mmol) in DMF (20 mL). The resulting suspension was stirred at 60 °C for 1 h. The reaction mixture was filtered through Celite and then diluted with EtOAc (100 mL). The resulting suspension was washed sequentially with water (100 mL × 3) and saturated brine (100 mL × 2). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in petroleum ether to give the title compound (1.20 g, 81%) as a white solid.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.87 (dd, <i>J</i> = 8.2, 0.7 Hz, 1H), 7.74 (dd, <i>J</i> = 8.2, 7.6 Hz, 1H), 7.42 (dd, <i>J</i> = 7.6, 0.7 Hz, 1H), 4.35 (t, <i>J</i> = 5.4 Hz, 2H), 3.87 (t, <i>J</i> = 6.2 Hz, 2H), 2.11 (qd, <i>J</i> = 6.1, 4.7 Hz, 2H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> = 257/259.</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Benzyl 4-(6-bromopyridin-2-yl)-3-oxopiperazine-1-carboxylate (<b>50</b>)</h4><div class="NLM_p">Prepared from benzyl 3-oxopiperazine-1-carboxylate following the method of example <b>42</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.04 (s, 1H), 7.53–7.6 (m, 1H), 7.31–7.42 (m, 5H), 7.29 (d, <i>J</i> = 7.6 Hz, 1H), 5.18 (s, 2H), 4.35 (s, 2H), 4.08–4.18 (m, 2H), 3.79–3.85 (m, 2H), 1.23–1.34 (m, 1H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> = 390/392.</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-(6-Bromopyridin-2-yl)-4-methylpiperazin-2-one (<b>51</b>)</h4><div class="NLM_p">Prepared from 4-methylpiperazine-2-one following the method of Example <b>42</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.95 (d, <i>J</i> = 8.2 Hz, 1H), 7.77 (t, <i>J</i> = 7.9 Hz, 1H), 7.47 (d, <i>J</i> = 7.7 Hz, 1H), 3.83 (t, <i>J</i> = 5.6 Hz, 2H), 3.19 (s, 2H), 2.73 (t, <i>J</i> = 5.5 Hz, 2H), 2.27 (s, 3H).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> = 270/272.</div></div><div id="sec5_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(2-((6-(1,3-dimethyl-1<i>H</i>-1,2,4-triazol-5-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>52</b>)</h4><div class="NLM_p">(<i>S</i>)-5-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>, 100 mg, 0.26 mmol), 2-bromo-6-(1,3-dimethyl-1<i>H</i>-1,2,4-triazol-5-yl)pyridine (<b>38</b>, 64 mg, 0.26 mmol), Xantphos (44 mg, 0.08 mmol), second Generation Xantphos precatalyst (45 mg, 0.05 mmol), and Na<sub>2</sub>CO<sub>3</sub> (81 mg, 0.77 mmol) were dissolved in DMF (5 mL) and sealed into a microwave tube. The reaction was heated to 120 °C for 1 h in a microwave reactor and cooled to RT. The reaction mixture was poured into water (10 mL) and extracted with DCM (3 × 10 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by preparative HPLC (XBridge Prep Phenyl OBD column, 5 μ silica, 19 mm diameter, 150 mm length) using decreasingly polar mixtures of water (containing 0.5% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents to give the title compound (44 mg, 30%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.75 (s, 1H), 8.03 (d, <i>J</i> = 1.6 Hz, 1H), 8.01 (d, <i>J</i> = 1.7 Hz, 1H), 7.90 (dd, <i>J</i> = 8.4, 7.4 Hz, 1H), 7.51 (dd, <i>J</i> = 7.3, 0.8 Hz, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 4.75–4.65 (m, 2H), 4.19 (s, 3H), 3.68–3.58 (m, 4H), 2.47 (s, 3H), 2.30 (s, 3H), 1.30 (d, <i>J</i> = 6.9 Hz, 3H), 1.18–1.11 (m, 1H), 0.64–0.56 (m, 1H), 0.48–0.37 (m, 2H), 0.31–0.23 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.65, 158.72, 157.46, 152.31, 151.15, 145.98, 145.31, 144.68, 139.12, 137.65, 135.75, 126.89, 126.68, 126.21, 119.83, 117.25, 112.48, 52.00, 45.95, 43.05, 37.57, 17.95, 16.61, 15.55, 13.45, 3.86, 3.40.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 564.1871 expected 564.1851.</div></div><div id="sec5_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(2-((6-(1,5-dimethyl-1<i>H</i>-1,2,4-triazol-3-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>53</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and 2-bromo-6-(1,5-dimethyl-1<i>H</i>-1,2,4-triazol-3-yl)pyridine (<b>39</b>) following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.62 (s, 1H), 8.15 (d, <i>J</i> = 1.6 Hz, 1H), 8.06 (d, <i>J</i> = 1.6 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.57 (d, <i>J</i> = 7.4 Hz, 1H), 7.07 (d, <i>J</i> = 8.2 Hz, 1H), 4.76–4.66 (m, 2H), 3.90 (s, 3H), 3.69–3.60 (m, 4H), 2.50 (s, 3H), 2.48 (s, 3H), 1.31 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.12 (m, 1H), 0.64–0.56 (m, 1H), 0.48–0.38 (m, 2H), 0.31–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.77, 158.70, 158.40, 153.31, 150.83, 147.26, 145.90, 145.04, 138.69, 137.75, 136.74, 126.24, 126.19, 125.93, 120.58, 113.47, 110.61, 52.00, 45.93, 43.11, 35.33, 17.96, 17.02, 15.55, 11.49, 3.85, 3.42.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 564.1898 expected 564.1851.</div></div><div id="sec5_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(2-((6-(4-(hydroxymethyl)oxazol-5-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>54</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and (5-(6-bromopyridin-2-yl)oxazol-4-yl)methanol (<b>40</b>) following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.67 (s, 1H), 8.46 (s, 1H), 8.11 (d, <i>J</i> = 1.6 Hz, 1H), 8.08 (d, <i>J</i> = 1.6 Hz, 1H), 7.86 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (d, <i>J</i> = 7.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.2 Hz, 1H), 5.25 (t, <i>J</i> = 5.9 Hz, 1H), 4.84 (d, <i>J</i> = 5.3 Hz, 2H), 4.75–4.65 (m, 2H), 3.67–3.60 (m, 4H), 2.49 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.11 (m, 1H), 0.65–0.55 (m, 1H), 0.49–0.36 (m, 2H), 0.30–0.22 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.70, 157.94, 151.35, 151.32, 145.92, 145.13, 144.42, 139.00, 138.05, 137.65, 136.14, 126.79, 126.44, 125.86, 120.11, 114.08, 110.89, 55.13, 51.99, 45.88, 43.07, 18.00, 16.82, 15.58, 3.89, 3.41. (one signal obscured).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 566.1558 expected 566.1532.</div></div><div id="sec5_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>S</i>)-<i>N</i>-(6-((5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)acetamide (<b>55</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and <i>N</i>-(6-bromopyridin-2-yl)acetamide following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.42 (s, 1H), 10.06 (s, 1H), 8.08 (d, <i>J</i> = 1.6 Hz, 1H), 8.03 (d, <i>J</i> = 1.7 Hz, 1H), 7.68–7.62 (m, 2H), 6.75 (dd, <i>J</i> = 7.4, 1.4 Hz, 1H), 4.76–4.66 (m, 2H), 3.69–3.59 (m, 4H), 2.42 (s, 3H), 2.17 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.13 (m, 1H), 0.63–0.57 (m, 1H), 0.47–0.38 (m, 2H), 0.3–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.38, 163.73, 158.56, 150.42, 149.71, 145.70, 145.07, 139.66, 137.55, 136.39, 127.47, 126.60, 126.52, 119.82, 106.08, 105.11, 52.07, 45.89, 43.17, 24.26, 17.95, 16.52, 15.53, 3.85, 3.44.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 526.1610 expected 526.1583.</div></div><div id="sec5_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>S</i>)-<i>N</i>-(6-((5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)-<i>N</i>-methylacetamide (<b>56</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>), and <i>N</i>-(6-bromopyridin-2-yl)-<i>N</i>-methylacetamide (<b>41</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.68 (br. s, 1H), 8.03 (d, <i>J</i> = 1.6 Hz, 1H), 8.00 (d, <i>J</i> = 1.6 Hz, 1H), 7.78 (t, <i>J</i> = 7.9 Hz, 1H), 7.04 (d, <i>J</i> = 7.6 Hz, 1H), 6.95 (d, <i>J</i> = 8.1 Hz, 1H), 4.75–4.67 (m, 2H), 3.67–3.57 (m, 4H), 3.36 (s, 3H), 2.44 (s, 3H), 2.09 (s, 3H), 1.31 (d, <i>J</i> = 6.9 Hz, 3H), 1.18–1.10 (m, 1H), 0.63–0.56 (m, 1H), 0.48–0.37 (m, 2H), 0.31–0.24 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO<i>-d</i><sub>6</sub>) δ 169.71, 163.68, 157.68, 153.27, 150.67, 145.95, 145.04, 139.89, 137.66, 136.00, 127.09, 126.69, 126.24, 119.83, 112.00, 108.55, 52.01, 45.95, 43.08, 34.98, 22.98, 17.96, 16.58, 15.56, 3.87, 3.40.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 540.1755 expected 540.1739.</div></div><div id="sec5_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>S</i>)-<i>N</i>-(6-((5-(2-(1-Cyclopropylethyl)-7-(<i>N</i>-methylsulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)-<i>N</i>-methylacetamide (<b>57</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>), and <i>N</i>-(6-bromopyridin-2-yl)-<i>N</i>-methylacetamide (<b>41</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69 (s, 1H), 7.96 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (d, <i>J</i> = 1.6 Hz, 1H), 7.79 (t, <i>J</i> = 7.9 Hz, 1H), 7.61 (q, <i>J</i> = 5.2 Hz, 1H), 7.05 (d, <i>J</i> = 7.6 Hz, 1H), 6.96 (d, <i>J</i> = 8.1 Hz, 1H),), 4.85–4.69 (m, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.37 (s, 3H), 2.51 (d, <i>J</i> = 5.3 Hz, 3H), 2.44 (s, 3H), 2.09 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.11 (m, 1H), 0.64–0.57 (m, 1H), 0.48–0.38 (m, 2H), 0.31–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.70, 164.65, 157.60, 153.26, 150.51, 145.89, 145.09, 139.91, 136.25, 136.03, 126.74, 126.37, 125.30, 119.87, 112.07, 108.41, 52.33, 46.35, 34.97, 29.16, 22.99, 17.91, 16.56, 15.53, 3.89, 3.34.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 564.1866 expected 564.1848.</div></div><div id="sec5_2_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>58</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and 1-(6-bromopyridin-2-yl)pyrrolidin-2-one (<b>42</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.54 (s, 1H), 8.06 (d, <i>J</i> = 1.6 Hz, 1H), 8.01 (d, <i>J</i> = 1.6 Hz, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.71 (t, <i>J</i> = 8.0 Hz, 1H), 6.76 (d, <i>J</i> = 8.0 Hz, 1H), 4.70 (s, 2H), 4.23 (t, <i>J</i> = 7.1 Hz, 2H), 3.64 (s, 4H), 2.59 (t, <i>J</i> = 8.0 Hz, 2H), 2.45 (s, 3H), 2.10 (p, <i>J</i> = 7.7 Hz, 2H), 1.31 (d, <i>J</i> = 6.8 Hz, 3H), 1.15 (tt, <i>J</i> = 8.1, 3.9 Hz, 1H), 0.56–0.64 (m, 1H), 0.37–0.48 (m, 2H), 0.24–0.31 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.6 (s), 163.7 (s), 157.5 (s), 149.9 (d, <i>J</i> = 11.4 Hz), 146.0 (s), 145.3 (s), 139.6 (s), 137.7 (s), 136.1 (s), 126.5 (d, <i>J</i> = 11.2 Hz), 126.1 (s), 119.6 (s), 105.7 (s), 105.3 (s), 52.0 (s), 48.5 (s), 46.0 (s), 43.1 (s), 33.0 (s), 18.0 (s), 17.3 (s), 16.8 (s), 15.6 (s), 3.9 (s), 3.4 (s).</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 552.1739 expected 552.1739.</div></div><div id="sec5_2_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>S</i>)-2-(1-Cyclopropylethyl)-6-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide (<b>59</b>)</h4><div class="NLM_p">Step 1: (S)-<i>N</i>-(5-(2-(1-Cyclopropylethyl)-7-(N-(oxetan-3-yl)sulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)acetamide</div><div class="NLM_p">(<i>S</i>)-6-(2-Acetamido-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-3-oxoisoindoline-4-sulfonyl chloride (1.80 g, 4.0 mmol) was dissolved in DCM (30 mL). DMAP (1.45 g, 11.9 mmol) and MgSO<sub>4</sub> (0.48 g, 4.0 mmol) were added followed by oxetan-3-amine (0.435 g, 6.0 mmol). The resulting mixture was stirred at r.t. for 2 h. The reaction mixture was filtered through Celite. The solvent was evaporated, and the residue was purified by flash silica chromatography, elution gradient 0 to 20% MeOH in DCM to give the subtitle compound (1.80 g, 93%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.33 (s, 1H), 8.57 (d, J = 7.0 Hz, 1H), 8.02 (d, J = 1.6 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 4.75 (s, 2H), 4.53 (q, J = 6.4 Hz, 2H), 4.44 (dt, J = 13.7, 6.8 Hz, 1H), 4.35 (q, J = 6.0 Hz, 2H), 3.72–3.61 (m, 1H), 2.44 (s, 3H), 2.17 (s, 3H), 1.33 (d, J = 6.8 Hz, 3H), 1.22–1.12 (m, 1H), 0.65–0.56 (m, 1H), 0.48–0.38 (m, 2H), 0.32–0.25 (m, 1H).ES+ (M + H)<sup>+</sup> 491.</div><div class="NLM_p">Step 2: (<i>S</i>)-6-(2-Amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide</div><div class="NLM_p">(<i>S</i>)-<i>N</i>-(5-(2-(1-Cyclopropylethyl)-7-(<i>N</i>-(oxetan-3-yl)sulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)acetamide (1.80 g, 3.67 mmol) was dissolved in MeOH (20 mL). A solution of LiOH (0.879 g, 36.7 mmol) in water (0.2 mL) was added, and the resulting solution was heated to 80 °C for 10 h. The reaction mixture was allowed to cool, and then the solvent was evaporated. The residue was dissolved in DCM (100 mL) and washed sequentially with water (50 mL × 2) and saturated brine (50 mL × 2). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give the subtitle compound (1.50 g, 91%) as a yellow solid.</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59 (s, 1H), 7.83 (d, <i>J</i> = 1.6 Hz, 1H), 7.70 (d, <i>J</i> = 1.6 Hz, 1H), 7.37 (s, 2H), 4.71 (s, 2H), 4.52 (q, <i>J</i> = 6.8 Hz, 2H), 4.49–4.37 (m, 1H), 4.37–4.30 (m, 2H), 3.71–3.59 (m, 1H), 2.30 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.10 (m, 1H), 0.66–0.55 (m, 1H), 0.48–0.36 (m, 2H), 0.32–0.22 (m, 1H).</div><div class="NLM_p">ES+ (M + H)<sup>+</sup> 449.</div><div class="NLM_p">Step 3: (<i>S</i>)-2-(1-Cyclopropylethyl)-6-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-N-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide Prepared from (S)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-N-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide, and 1-(6-bromopyridin-2-yl)pyrrolidin-2-one (<b>42</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (s, 1H), 8.56 (d, <i>J</i> = 7.1 Hz, 1H), 7.98 (d, <i>J</i> = 1.4 Hz, 1H), 7.90 (d, <i>J</i> = 1.5 Hz, 1H), 7.88–7.84 (m, 1H), 7.72 (t, <i>J</i> = 8.0 Hz, 1H), 6.79–6.76 (m, 1H), 4.75 (s, 2H), 4.57–4.50 (m, 2H), 4.48–4.39 (m, 1H), 4.40–4. 34 (m, 2H), 4.25 (t, <i>J</i> = 7.1 Hz, 2H), 3.72–3. 63 (m, 1H), 2.60 (t, <i>J</i> = 8.1 Hz, 2H), 2.45 (s, 3H), 2.10 (p, <i>J</i> = 7.9 Hz, 2H), 1.34 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.12 (m, 1H), 0.65–0.56 (m, 1H), 0.49–0.39 (m, 2H), 0.33–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.6, 164.7, 157.6, 149.9, 149.8, 146.1, 145.4, 139.6, 137.4, 136.4, 126.1, 125.9, 124.8, 119.5, 105.7, 105.4, 76.9, 76.8, 52.5, 48.5, 47.2, 46.5, 33.0, 18.0, 17.3, 16.7, 15.6, 3.9, 3.3.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 609.1938 expected 609.1954.</div></div><div id="sec5_2_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (S)-2-(1-Cyclopropylethyl)-6-(4-methyl-2-((6-(2-oxoimidazolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide (<b>60</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide (<b>59</b>, step 2), and 1-(6-bromopyridin-2-yl)imidazolidin-2-one (<b>43</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.45 (s, 1H), 8.54 (d, <i>J</i> = 7.2 Hz, 1H), 7.97 (s, 1H), 7.89 (d, <i>J</i> = 1.3 Hz, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.22 (s, 1H), 6.62 (d, <i>J</i> = 7.8 Hz, 1H), 4.74 (s, 2H), 4.57–4.50 (m, 2H), 4.44 (h, <i>J</i> = 6.6 Hz, 1H), 4.39–4. 32 (m, 2H), 4.31–4.23 (m, 2H), 3.72–3. 62 (m, 1H), 3.46 (t, <i>J</i> = 8.1 Hz, 2H), 2.44 (s, 3H), 1.34 (d, <i>J</i> = 6.8 Hz, 3H), 1.22–1. Thirteen (m, 1H), 0.66–0.57 (m, 1H), 0.47–0.39 (m, 2H), 0.33–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.7, 158.1, 157.8, 151.1, 149.9, 146.1, 145.3, 139.1, 137.4, 136.4, 126.2, 125.9, 124.8, 119.3, 103.5, 103.2, 76.9, 76.8, 52.4, 47.2, 46.4, 45.0, 36.6, 18.0, 16.7, 15.6, 3.9, 3.3.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 610.1912 expected 610.1906.</div></div><div id="sec5_2_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(4-methyl-2-((6-(3-methyl-2-oxoimidazolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>61</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>), and 1-(6-bromopyridin-2-yl)-3-methylimidazolidin-2-one (<b>44</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>)) δ 11.44 (s, 1H), 8.07 (d, <i>J</i> = 1.6 Hz, 1H), 8.01 (d, <i>J</i> = 1.4 Hz, 1H), 7.74–7.71 (m, 1H), 7.63 (t, <i>J</i> = 8.0 Hz, 1H), 6.61 (d, <i>J</i> = 7.9 Hz, 1H), 4.70 (s, 2H), 4.20 (dd, <i>J</i> = 8.9, 7.2 Hz, 2H), 3.64 (s, 4H), 3.48–3.52 (m, 2H), 2.81 (s, 3H), 2.45 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.12 (m, 1H), 0.64–0.58 (m, 1H), 0.47–0.39 (m, 2H), 0.31–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.2, 158.1, 157.1, 151.5, 150.4, 146.4, 145.7, 139.7, 138.1, 136.6, 127.0, 126.9, 126.6, 119.9, 103.7, 103.7, 52.5, 46.4, 43.9, 43.5, 42.9, 31.1, 18.5, 17.2, 16.1, 4.4, 3.9.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 567.1859 expected 567.1848.</div></div><div id="sec5_2_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-((<i>S</i>)-1-Cyclopropylethyl)-6-(2-((6-((<i>R</i>)-3-hydroxy-2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>62</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>) and (<i>R</i>)-1-(6-bromopyridin-2-yl)-3-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one (<b>45</b>), following the method used for <b>52</b>, followed by deprotection of the alcohol: (triethylamine trihydrofluoride (2 mL, 12.28 mmol) was added dropwise to 6-(2-((6-((<i>S</i>)-3-((<i>tert</i>-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-2-((<i>S</i>)-1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (95 mg, 0.14 mmol) in THF (6 mL) at 25 °C over 15 min. The resulting solution was stirred at 25 °C for 3 h. The solvent was evaporated, and the residue was purified by preparative HPLC.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.58 (s, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.75 (t, <i>J</i> = 8.0 Hz, 1H), 7.61–7.56 (m, 1H), 6.80 (d, <i>J</i> = 8.0 Hz, 1H), 4.76 (s, 2H), 4.44–4.39 (m, 1H), 4.31–4.25 (m, 1H), 4.02–3.94 (m, 1H), 3.69–3.62 (m, 1H), 2.53 (d, <i>J</i> = 5.2 Hz, 3H), 2.48–2.41 (m, 4H), 1.94–1.85 (m, 1H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.23 (bs, 1H), 1.21–1.13 (m, 1H), 0.65–0.58 (m, 1H), 0.49–0.39 (m, 2H), 0.32–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.2, 165.1, 158.0, 150.6, 150.2, 146.4, 145.7, 140.2, 136.8, 136.5, 127.2, 126.5, 125.7, 120.1, 106.5, 105.7, 70.8, 52.8, 46.9, 44.4, 29.6, 28.2, 18.4, 17.1, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 583.1816 expected 583.1797.</div></div><div id="sec5_2_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-((<i>S</i>)-1-Cyclopropylethyl)-6-(2-((6-((<i>R</i>)-4-hydroxy-2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)-4-methylthiazol-5-yl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>63</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>), and (<i>R</i>)-4-((<i>tert</i>-butyldimethylsilyl)oxy)pyrrolidin-2-one (<b>46</b>), following the method used for <b>62</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97 (s, 1H), 7.92 (d, <i>J</i> = 1.5 Hz, 1H), 7.87 (d, <i>J</i> = 8.1 Hz, 1H), 7.73 (t, <i>J</i> = 8.0 Hz, 1H), 7.57 (s, 1H), 6.78 (d, <i>J</i> = 8.0 Hz, 1H), 5.30 (d, <i>J</i> = 3.1 Hz, 1H), 4.75 (s, 2H), 4.41 (bs, 1H), 4.34–4.27 (m, 1H), 4.17 (d, <i>J</i> = 11.6 Hz, 1H), 3.69–3.60 (m, 1H), 3.00–2.61 (m, 1H), 2.52 (s, H), 2.44 (s, 3H), 2.36 (d, <i>J</i> = 17.1 Hz, 1H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.19 (m, 1H), 0.66–0. 57 (m, 1H), 0.49–0.38 (m, 2H), 0.32–0.24 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.3, 164.7, 157.6, 150.0, 149.9, 145.9, 145.2, 139.7, 136.3, 136.1, 126.9, 126.4, 125.3, 119.6, 105.7, 105.3, 62.4, 57.5, 52.4, 46.4, 43.0, 29.2, 18.0, 16.6, 15.6, 4.0, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 583.1812 expected 583.1797.</div></div><div id="sec5_2_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (<i>S</i>)-2-(1-Cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopiperidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one (<b>64</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>), and 1-(6-bromopyridin-2-yl)piperidin-2-one (<b>47</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.62 (s, 1H), 8.10–8. 02 (m, 2H), 7.72 (t, <i>J</i> = 8.0 Hz, 1H), 7.31 (d, <i>J</i> = 7.9 Hz, 1H), 6.85 (d, <i>J</i> = 8.0 Hz, 1H), 4.71 (s, 2H), 4.11–4.02 (m, 2H), 3.69–3.58 (m, 4H), 2.48 (s, 3H), 2.00–1.92 (m, 2H), 1.90–1.81 (m, 2H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.12 (m, 1H), 0.64–0.54 (m, 1H), 0.48–0.37 (m, 2H), 0.31–0.23 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.1, 163.7, 157.6, 151.9, 150.1, 146.0, 145.3, 138.9, 137.7, 136.1, 126.5, 126.1, 119.5, 112.0, 107.0, 76.9, 52.0, 48.0, 46.0, 43.1, 33.3, 22.6, 20.4, 18.0, 16.9, 15.6, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 566.1915 expected 566.1896.</div></div><div id="sec5_2_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-(2-oxopiperidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>65</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>) and 1-(6-bromopyridin-2-yl)piperidin-2-one (<b>47</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 8.00 (d, <i>J</i> = 1.3 Hz, 1H), 7.92 (d, <i>J</i> = 1.5 Hz, 1H), 7.72 (t, <i>J</i> = 8.0 Hz, 1H), 7.57 (q, <i>J</i> = 5.2 Hz, 1H), 7.32–7.29 (m, 1H), 6.86 (d, <i>J</i> = 8.0 Hz, 1H), 4.76 (s, 2H), 4.09–4.04 (m, 2H), 3.69–3.62 (m, 1H), 2.52 (d, <i>J</i> = 5.3 Hz, 3H), 2.48 (s, 3H), 1.99–1.93 (m, 2H), 1.89–1.83 (m, 2H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.21–1.14 (m, 1H), 0.64–0.58 (m, 1H), 0.48–0.39 (m, 2H), 0.31–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 165.2, 158.1, 152.3, 150.5, 146.4, 145.8, 139.4, 136.8, 136.5, 127.1, 126.3, 125.6, 120.0, 112.5, 107.4, 52.8, 48.4, 46.9, 33.7, 29.6, 23.1, 20.8, 18.4, 17.2, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 581.1995 expected 581.2004.</div></div><div id="sec5_2_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>S</i>)-4-(6-((5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)morpholin-3-one (<b>66</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and 4-(6-bromopyridin-2-yl)morpholin-3-one (<b>48</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.64 (s, 1H), 8.07–8.03 (m, 2H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.60 (d, <i>J</i> = 7.9 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.71 (s, 2H), 4.29 (s, 2H), 4.19–4.15 (m, 2H), 4.09–4.05 (m, 2H), 3.64 (s, 3H), 3.6–3.63 (m, 1H), 2.47 (s, 3H), 1.31 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.12 (m, 1H), 0.63–0.57 (m, 1H), 0.46–0.38 (m, 2H), 0.30–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.0, 163.7, 157.4, 150.4, 150.1, 146.0, 145.3, 139.4, 137.7, 136.0, 126.5, 126.5, 126.1, 119.6, 110.4, 107.4, 67.9, 63.4, 52.0, 46.7, 46.0, 43.1, 18.0, 16.8, 15.6, 3.9, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 568.1710 expected 568.1688.</div></div><div id="sec5_2_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-(3-oxomorpholino)pyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>67</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>), and 4-(6-bromopyridin-2-yl)morpholin-3-one (<b>48</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.64 (s, 1H), 7.98 (d, <i>J</i> = 1.6 Hz, 1H), 7.91 (d, <i>J</i> = 1.6 Hz, 1H), 7.75 (t, <i>J</i> = 8.0 Hz, 1H), 7.63–7.54 (m, 2H), 6.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.80–4.70 (m, 2H), 4.29 (s, 2H), 4.21–4.14 (m, 2H), 4.09–4.04 (m, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 2.51 (d, <i>J</i> = 4.9 Hz, 3H), 2.46 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.12 (m, 1H), 0.64–0.56 (m, 1H), 0.47–0. 38 (m, 2H), 0.32–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.55, 165.5, 158.0, 150.9, 150.6, 146.4, 145.8, 139.9, 136.8, 136.5, 127.1, 126.3, 125.6, 120.0, 110.9, 108.0, 68.4, 63.9, 52.8, 47.2, 46.9, 29.6, 18.4, 17.2, 16.0, 4.4, 3.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 583.1825 expected 583.1797.</div></div><div id="sec5_2_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (<i>S</i>)-2-(1-Cyclopropylethyl)-6-(4-methyl-2-((6-(3-oxomorpholino)pyridin-2-yl)amino)thiazol-5-yl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide (<b>68</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-(oxetan-3-yl)-3-oxoisoindoline-4-sulfonamide (<b>59</b>, step 2) and 4-(6-bromopyridin-2-yl)morpholin-3-one (<b>48</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.64 (s, 1H), 8.56 (d, <i>J</i> = 6.3 Hz, 1H), 7.99 (d, <i>J</i> = 1.6 Hz, 1H), 7.89 (d, <i>J</i> = 1.6 Hz, 1H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.59 (d, <i>J</i> = 7.9 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.81–4.70 (m, 2H), 4.54 (dt, <i>J</i> = 11.1, 6.7 Hz, 2H), 4.48–4.41 (m, 1H), 4.37 (dt, <i>J</i> = 9.9, 6.3 Hz, 2H), 4.30 (s, 2H), 4.20–4.15 (m, 2H), 4.09–4.04 (m, 2H), 3.67 (dq, <i>J</i> = 9.4, 6.8 Hz, 1H), 2.46 (s, 3H), 1.34 (d, <i>J</i> = 6.8 Hz, 3H), 1.14–1.22 (m, 1H), 0. 64–0.58 (m, 1H), 0.47–0.40 (m, 2H), 0.32–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.0, 164.7, 157.5, 150.4, 150.1, 146.1, 145.5, 139.4, 137.4, 136.3, 126.0, 125.9, 124.8, 119.5, 110.5, 107.5, 76.9, 76.8, 67.9, 63.4, 52.5, 47.7, 46.7, 46.5, 17.9, 16.8, 14.5, 4.8, 2.7.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 625.1906 expected 625.1903.</div></div><div id="sec5_2_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>S</i>)-3-(6-((5-(2-(1-Cyclopropylethyl)-7-(methylsulfonyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)-1,3-oxazinan-2-one (<b>69</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-5-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-7-(methylsulfonyl)isoindolin-1-one (<b>16</b>) and 3-(6-bromopyridin-2-yl)-1,3-oxazinan-2-one (<b>49</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.59 (s, 1H), 8.06 (d, <i>J</i> = 1.6 Hz, 1H), 8.03 (d, <i>J</i> = 1.6 Hz, 1H), 7.72 (t, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.0 Hz, 1H), 6.84 (d, <i>J</i> = 8.0 Hz, 1H), 4.66–4.76 (m, 2H), 4.39 (t, <i>J</i> = 5.4 Hz, 2H), 4.12 (t, <i>J</i> = 6.2 Hz, 2H), 3.66–3.59 (m, 4H), 2.47 (s, 3H), 2.23–2.17 (m, 2H), 1.31 (d, <i>J</i> = 6.8 Hz, 3H), 1.19–1.11 (m, 1H), 0.63–0.56 (m, 1H), 0.47–0.37 (m, 2H), 0.31–0.24 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.5, 157.5, 152.5, 151.5, 149.9, 146.4, 145.3, 139.3, 137.7, 136.0, 126.4, 126.1, 119.5, 110.7, 106.7, 67.0, 51.1, 46.0, 45.9, 43.1, 21.9, 18.0, 16.8, 15.6, 3.9, 3.4. One C obscured—probably overlap of two peaks at 126.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 568.1713 expected 568.1688.</div></div><div id="sec5_2_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-(2-oxo-1,3-oxazinan-3-yl)pyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>70</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>) and 3-(6-bromopyridin-2-yl)-1,3-oxazinan-2-one (<b>49</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 8.00 (d, <i>J</i> = 1.6 Hz, 1H), 7.92 (d, <i>J</i> = 1.6 Hz, 1H), 7.73 (t, <i>J</i> = 8.0 Hz, 1H), 7.56 (q, <i>J</i> = 5.2 Hz, 1H), 7.37 (d, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 7.9 Hz, 1H), 4.80–4.68 (m, 2H), 4.39 (t, <i>J</i> = 5.4 Hz, 2H), 4.13 (t, <i>J</i> = 6.2 Hz, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 2.51 (d, <i>J</i> = 5.2 Hz, 3H), 2.47 (s, 3H), 2.22–2.15 (m, 2H), 1.32 (d, <i>J</i> = 6.9 Hz, 3H), 1.20–1.12 (m, 1H), 0.64–0.57 (m, 1H), 0.48–0.39 (m, 2H), 0.32–0.24 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.1, 157.6, 152.5, 151.5, 149.9, 145.9, 145.3, 139.6, 136.3, 136.0, 126.7, 125.9, 124.4, 120.8, 113.3, 107.7, 67.0, 52.8, 46.4, 44.6, 29.2, 21.9, 18.0, 16.7, 15.0, 4.6, 2.8.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> 583.1803 expected 583.1792.</div></div><div id="sec5_2_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-(2-oxopiperazin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>71</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>) and benzyl 4-(6-bromopyridin-2-yl)-3-oxopiperazine-1-carboxylate (<b>50</b>), following the method used for <b>52</b>, followed by deprotection of the carbamate: (BBr<sub>3</sub> (0.185 mL, 1.96 mmol) was added to (<i>S</i>)-benzyl 4-(6-((5-(2-(1-cyclopropylethyl)-7-(<i>N</i>-methylsulfamoyl)-1-oxoisoindolin-5-yl)-4-methylthiazol-2-yl)amino)pyridin-2-yl)-3-oxopiperazine-1-carboxylate (140 mg, 0.20 mmol) in DCM (10 mL) at 0 °C over 0.5 h. The resulting mixture was stirred at RT for 4 h. The reaction mixture was poured onto ice (20 mL), extracted with DCM (2 × 20 mL), and the aqueous layer was adjusted to pH = 9 with saturated Na<sub>2</sub>CO<sub>3</sub> and extracted with DCM (3 × 50 mL). The crude product was purified by preparative HPLC.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (s, 1H), 7.98 (d, <i>J</i> = 1.6 Hz, 1H), 7.91 (d, <i>J</i> = 1.6 Hz, 1H), 7.72 (t, <i>J</i> = 8.0 Hz, 1H), 7.60–7.54 (m, 1H), 7.48 (d, <i>J</i> = 7.9 Hz, 1H), 6.85 (d, <i>J</i> = 8.0 Hz, 1H), 4.80–4.71 (m, 2H), 4.06 (t, <i>J</i> = 5.5 Hz, 2H), 3.65 (dq, <i>J</i> = 9.1, 6.8 Hz, 1H), 3.48 (s, 2H), 3.10 (t, <i>J</i> = 5.5 Hz, 2H), 2.52 (d, <i>J</i> = 4.0 Hz, 3H), 2.46 (s, 3H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.13 (m, 1H), 0.64–0.57 (m, 1H), 0.49–0.39 (m, 2H), 0.31–0.25 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 164.7, 157.5, 150.9, 150.0, 145.9, 145.3, 139.1, 136.3, 136.1, 126.7, 125.9, 125.1, 119.5, 111.2, 107.1, 52.4, 51.2, 48.5, 46.4, 42.7, 29.2, 18.3, 16.8, 16.0, 4.7, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 582.1983 expected 582.1957.</div></div><div id="sec5_2_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>S</i>)-2-(1-Cyclopropylethyl)-<i>N</i>-methyl-6-(4-methyl-2-((6-(4-methyl-2-oxopiperazin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-3-oxoisoindoline-4-sulfonamide (<b>72</b>)</h4><div class="NLM_p">Prepared from (<i>S</i>)-6-(2-amino-4-methylthiazol-5-yl)-2-(1-cyclopropylethyl)-<i>N</i>-methyl-3-oxoisoindoline-4-sulfonamide (<b>17</b>),and 1-(6-bromopyridin-2-yl)-4-methylpiperazin-2-one (<b>51</b>), following the method used for <b>52</b>.</div><div class="NLM_p"><sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.58 (s, 1H), 8.00 (d, <i>J</i> = 1.7 Hz, 1H), 7.90 (d, <i>J</i> = 1.7 Hz, 1H), 7.75 (t, <i>J</i> = 8.0 Hz, 1H), 7.58 (br. q, <i>J</i> = 5.2 Hz, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 6.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.80–4.72 (m, 2H), 4.08 (dd, <i>J</i> = 6.7, 4.6 Hz, 2H), 3.65 (dq, <i>J</i> = 9.2, 6.8 Hz, 1H), 3.21 (s, 2H), 2.77–2.85 (m, 2H), 2.52 (d, <i>J</i> = 4.3 Hz, 3H), 2.46 (s, 3H), 2.29 (s, 3H), 1.33 (d, <i>J</i> = 6.8 Hz, 3H), 1.20–1.13 (m, 1H), 0.64–0.58 (m, 1H), 0.48–0.38 (m, 2H), 0.32–0.26 (m, 1H).</div><div class="NLM_p"><sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.9, 164.7, 157.5, 151.0, 150.1, 146.0, 145.3, 139.3, 136.3, 136.1, 126.8, 126.0, 125.2, 119.6, 110.8, 107.4, 59.8, 52.4, 51.3, 47.3, 46.4, 44.3, 29.2, 18.0, 16.7, 15.6, 4.0, 3.4.</div><div class="NLM_p last">ES+ (M + H)<sup>+</sup> observed 596.2106 expected 596.2114.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Biological Assays</h3><div class="NLM_p">All animal procedures were approved by the ethical committee in Gothenburg, Sweden and were carried out under the appropriate license.</div><div class="NLM_p last">Enzymatic inhibition assays for PI3K isoforms were run as previously described.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Cellular Assays</h3><div class="NLM_p">Inhibition of activity in JeKo-1 cells (PI3Kδ) was run as previously described.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Inhibition of p-Akt in RAW-264 cells was run as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Pharmacokinetic Studies</h3><div class="NLM_p last">Pharmacokinetic studies were carried out as described previously.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Rat Ovalbumin Challenge Study</h3><div class="NLM_p">All rat experiments were approved by the by the regional ethics committee in Gothenburg with approval number 94–2014 and the approved site number was 31–5373/11.</div><div class="NLM_p">Rats (male BN, Charles River Laboratories; male, 200–230 g; 8–10 per group) were sensitized by subcutaneous injection of a mixture of ovalbumin (100 μg) and aluminum hydroxide (100 mg) in saline (1 mL total volume) on days 1 and 8. On day 15 the animals were placed into a closed plexiglass box and were exposed to an aerosolized solution of 1% ovalbumin for 20 min. Compounds were administered by nebulization (compounds under investigation) or intratracheal instillation (budesonide positive control) on day 22. After a gap, normally 1 h, but of variable length for the time-course study, the animals were again exposed to aerosolized 1% ovalbumin. Rats were terminated either 2 h post challenge (for determination of phosphorylation of S6 ribosomal protein) or 48 h post challenge (for measurement of eosinophils and cytokines). Bronchioalveolar lavage (BAL) was collected using 4 mL PBS (without Ca2<sup>+</sup> or Mg2<sup>+</sup>) in a twice in, twice out manner. BAL fluid was centrifuged and the supernatant was divided into aliquots and stored at −70 °C until analysis. Eosinophil levels were determined using a Sysmex flow cytometer.</div><div class="NLM_p">Cytokine and mediator levels were determined by a MSD v-plex proinflammatory rat panel (Meso Scale Discovery), except for IL-17 which was determined using an ELISA with AbCam antibody 119536.</div><div class="NLM_p last">S6 ribosomal protein levels were determined by immunofluorescence of pS6RP+ lymphocytes which were measured using XPRabbit mAb (Alexa Fluor 488 Conjugate) #4803. Samples were processed by flow cytometry on a LSR Fortessa (BD Biosciences), and the lymphocyte population was selected based on FSC-A and SSC-A properties. Collected data were analyzed with FlowJo Software (TreeStar).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Human Peripheral Blood Studies</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Patients and Sample Collection</h4><div class="NLM_p last">Fresh venous blood samples were obtained from asthmatic blood donors in the West Sweden Asthma Study (WSAS).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The study was approved by the Regional Ethical Approval Committee in Gothenburg, Sweden, and all subjects had signed informed consents.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> PBMC T Cell Cytokine Responses</h4><div class="NLM_p last">Human PBMCs were isolated from six asthmatic donors classified as moderate to severe asthma. All asthmatic donors except one were treated with inhaled corticosteroids and β2 agonists. PBMCs were isolated by density gradient centrifugation using Polymorphoprep (Axis-Shield) and cultured in U-shaped 96-well plates at 200 000 cells/well in RPMI1640 media (Gibco) supplemented with 10% heat-inactivated FBS (hiFBS; Gibco) and penicillin-streptomycin (100 U/mL; Gibco). Cells were preincubated for 1 h with compounds in 3-fold serial dilutions (duplicates) at final concentrations of 1.84 μM to 0.13 pM at 37 °C, 5% CO<sub>2</sub> and incubated for 24 h with anti-CD2/CD3/CD28 T cell activation beads (100 000 beads/well; Miltenyi Biotec). Supernatants were collected by centrifugation and analyzed for cytokines by a V-PLEX custom IL-5 and IL-17A assay (Meso Scale Discovery).</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Eosinophil CD11b Assay</h3><div class="NLM_p">Primary human eosinophils were isolated from fresh venous blood samples from asthmatic donors classified moderate to severe asthma (<i>N</i> = 6–10 depending on compound). All asthmatic donors were treated with inhaled corticosteroids and β2 agonists.</div><div class="NLM_p">Granulocytes were isolated from whole blood by polymorphprep (Axis-Shield), seeded in U-shaped 96-well plates at 1 × 10<sup>5</sup> cells/well in Hank’s Balanced Salt solution media (HBSS, Gibco) with 0.1% bovine serum albumin (BSA, Sigma-Aldrich), and preincubated with inhibitors for 30 min at 37 °C, 5% CO<sub>2</sub> followed by stimulation with 3 nM eotaxin-3 (Peprotech) for 30 min at RT.</div><div class="NLM_p last">Stimulations were stopped by staining with APC-conjugated antihuman CD11b (Clone Vim12, Life technologies) and PE-conjugated antihuman CD16 (Clone 3G8, BD Biosciences) antibodies diluted in Streck cell preservative (Streck) for 30 min, in the dark at RT. Thereafter, residual red blood cells were lysed by addition of Optilyse B (Beckman Coulter), and samples were washed and resuspended in DPBS (Gibco), 2 mM EDTA (Invitrogen), 2% FBS (Gibco) prior to analysis on an Accuri C6 Cytometer (BD Biosciences). Data were analyzed with FlowJo Software (TreeStar, Ashland, OR). Eosinophils were gated by CD16-CD11b+ staining and SSC-A properties versus CD16+CD11b+ neutrophils, and median fluorescence intensity (MFI) values for CD11b were collected for each population.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-7"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00434" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00434?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00434</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details of the preliminary macrocyclization experiments and results; a ligand interaction diagram for the crystal structure of <b>58</b>; additional <i>in vivo</i> experiment results; off-target and kinase screening results, copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces for final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Table of molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf">jm1c00434_si_001.pdf (8.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_002.csv">jm1c00434_si_002.csv (4.24 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of PI3Kδ small molecule complexes have been deposited in the PDB under the following accession codes <b>7</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4">7oi4</a>); <b>12</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois">7ois</a>); <b>20</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij">7oij</a>); <b>58</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil">7oil</a>). Authors will release the atomic coordinates and experimental data upon article publication. PDB IDs have been provided in figure legends.</p><div class="testing" data-doi="10.1021/acs.jmedchem.1c00434" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew W. D. Perry</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-9799-0746" title="Orcid link">https://orcid.org/0000-0002-9799-0746</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#573a3623233f322079273225252e1736242325362d32393234367934383a"><span class="__cf_email__" data-cfemail="94f9f5e0e0fcf1e3bae4f1e6e6edd4f5e7e0e6f5eef1faf1f7f5baf7fbf9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Björhall</span> - <span class="hlFld-Affiliation affiliation">Bioscience
COPD/IPF, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Bold</span> - <span class="hlFld-Affiliation affiliation">DMPK,
Research and Early Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikael Brűlls</span> - <span class="hlFld-Affiliation affiliation">Early
Product Development & Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ulf Börjesson</span> - <span class="hlFld-Affiliation affiliation">Computational
Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Carlsson</span> - <span class="hlFld-Affiliation affiliation">Discovery
Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span>Present Address:
                        (J.C.) AstraZeneca Operations, Sweden Biomanufacturing Center (SBC), Gärtunavägen 14, Gärtuna, SE-15257 Södertälje, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Fang Amy Chang</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunhua Chen</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Eriksson</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Britt-Marie Fihn</span> - <span class="hlFld-Affiliation affiliation">DMPK,
Research and Early Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca Fransson</span> - <span class="hlFld-Affiliation affiliation">Advanced
Drug Delivery, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Fredlund</span> - <span class="hlFld-Affiliation affiliation">Discovery
Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2104-5617" title="Orcid link">https://orcid.org/0000-0002-2104-5617</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbin Ge</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haijuan Huang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kostas Karabelas</span> - <span class="hlFld-Affiliation affiliation">Projects,
Research and Early Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span>Present Address:
                        (K.K.) Bioglan AB, Borrgatan 31, SE-202 13 Malmö, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Lamm Bergström</span> - <span class="hlFld-Affiliation affiliation">DMPK,
Research and Early Development, Respiratory and Immunology (R&I),
BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Lever</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helena Lindmark</span> - <span class="hlFld-Affiliation affiliation">Discovery
Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mickael Mogemark</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonios Nikitidis</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna-Pia Palmgren</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nils Pemberton</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8875-7221" title="Orcid link">https://orcid.org/0000-0002-8875-7221</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Petersen</span> - <span class="hlFld-Affiliation affiliation">Structure
& Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mio Rodrigo Blomqvist</span> - <span class="hlFld-Affiliation affiliation">Bioscience
Cough and In Vivo, Research and Early Development, Respiratory and
Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reed W. Smith</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew J. Thomas</span> - <span class="hlFld-Affiliation affiliation">Bioscience
COPD/IPF, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span>Present Address:
                        (M.J.T.) Boehringer-Ingelheim Pharma, Birkendorf Strasse, Biberach 88397, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victoria Ullah</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Tyrchan</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6470-984X" title="Orcid link">https://orcid.org/0000-0002-6470-984X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tiiu Wennberg</span> - <span class="hlFld-Affiliation affiliation">Bioscience
COPD/IPF, Research and Early Development, Respiratory and Immunology
(R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annika Westin Eriksson</span> - <span class="hlFld-Affiliation affiliation">Clinical
Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhen Yang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2226-0869" title="Orcid link">https://orcid.org/0000-0003-2226-0869</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuchun Zhao</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Öster</span> - <span class="hlFld-Affiliation affiliation">Structure
& Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors were employees and/or shareholders of AstraZeneca or Pharmaron when this work was carried out. M.W.D.P., P.B., U.B., K.K:, M.M., A.N., J.P, N.P. and C.T. are inventors of patents assigned to AstraZeneca covering inhibitors of PI3Ks.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7893-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge Annika Borde for help with drawing plots of ovalbumin challenge results and our colleagues in the analytical and purification departments for their help with purification and analysis of the compounds described.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumin</p></td></tr><tr><td class="NLM_term">CCR2</td><td class="NLM_def"><p class="first last">CC chemokine receptor 2</p></td></tr><tr><td class="NLM_term">CCL2</td><td class="NLM_def"><p class="first last">CC chemokine ligand 2</p></td></tr><tr><td class="NLM_term">CCR5</td><td class="NLM_def"><p class="first last">CC chemokine receptor 5</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DPBS</td><td class="NLM_def"><p class="first last">Dulbecco’s phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balanced salt solution media</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">1-propanephosphonic anhydride</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilanges, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">PI3K Isoforms in Cell Signalling and Vesicle Trafficking</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1038/s41580-019-0129-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1038%2Fs41580-019-0129-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=31110302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFehtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=515-534&issue=9&author=B.+Bilangesauthor=Y.+Posorauthor=B.+Vanhaesebroeck&title=PI3K+Isoforms+in+Cell+Signalling+and+Vesicle+Trafficking&doi=10.1038%2Fs41580-019-0129-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K isoforms in cell signalling and vesicle trafficking</span></div><div class="casAuthors">Bilanges, Benoit; Posor, York; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">515-534</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  PI3Ks are a family of lipid kinases that phosphorylate intracellular inositol lipids to regulate signalling and intracellular vesicular traffic.  Mammals have eight isoforms of PI3K, divided into three classes.  The class I PI3Ks generate 3-phosphoinositide lipids, which directly activate signal transduction pathways.  In addn. to being frequently genetically activated in cancer, similar mutations in class I PI3Ks have now also been found in a human non-malignant overgrowth syndrome and a primary immune disorder that predisposes to lymphoma.  The class II and class III PI3Ks are regulators of membrane traffic along the endocytic route, in endosomal recycling and autophagy, with an often indirect effect on cell signalling.  Here, we summarize current knowledge of the different PI3K classes and isoforms, focusing on recently uncovered biol. functions and the mechanisms by which these kinases are activated.  Deeper insight into the PI3K isoforms will undoubtedly continue to contribute to a better understanding of fundamental cell biol. processes and, ultimately, of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92E4GNLUrSLVg90H21EOLACvtfcHk0ljhcGmSTWX1XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFehtrk%253D&md5=6f3e9dc5c8bee8204b1ee9c6c53acb8d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41580-019-0129-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-019-0129-z%26sid%3Dliteratum%253Aachs%26aulast%3DBilanges%26aufirst%3DB.%26aulast%3DPosor%26aufirst%3DY.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DPI3K%2520Isoforms%2520in%2520Cell%2520Signalling%2520and%2520Vesicle%2520Trafficking%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26issue%3D9%26spage%3D515%26epage%3D534%26doi%3D10.1038%2Fs41580-019-0129-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sogkas, G.</span>; <span class="NLM_string-name">Adriawan, I. R.</span>; <span class="NLM_string-name">Dubrowinskaja, N.</span>; <span class="NLM_string-name">Atschekzei, F.</span>; <span class="NLM_string-name">Schmidt, R. E.</span></span> <i>Homeostatic and Pathogenic Roles of PI3Kδ in the Human Immune System</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier Inc</span>., <span class="NLM_year">2020</span>. <span class="refDoi"> DOI: 10.1016/bs.ai.2020.02.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fbs.ai.2020.02.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Sogkas&author=I.+R.+Adriawan&author=N.+Dubrowinskaja&author=F.+Atschekzei&author=R.+E.+Schmidt&title=Homeostatic+and+Pathogenic+Roles+of+PI3K%CE%B4+in+the+Human+Immune+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fbs.ai.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252Fbs.ai.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DSogkas%26aufirst%3DG.%26btitle%3DHomeostatic%2520and%2520Pathogenic%2520Roles%2520of%2520PI3K%25CE%25B4%2520in%2520the%2520Human%2520Immune%2520System%26pub%3DElsevier%2520Inc%26date%3D2020%26doi%3D10.1016%2Fbs.ai.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piñeiro, R.</span></span> <span> </span><span class="NLM_article-title">Molecules in Medicine Mini-Review: Isoforms of PI3K in Biology and Disease</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&issue=1&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+Medicine+Mini-Review%3A+Isoforms+of+PI3K+in+Biology+and+Disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0ljBOfyWOXAtqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520Medicine%2520Mini-Review%253A%2520Isoforms%2520of%2520PI3K%2520in%2520Biology%2520and%2520Disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26issue%3D1%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span>PIK3CA
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000121879-PIK3CA" class="extLink">https://www.proteinatlas.org/ENSG00000121879-PIK3CA</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CA%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000121879-PIK3CA+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span>PIK3CB
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000051382-PIK3CB" class="extLink">https://www.proteinatlas.org/ENSG00000051382-PIK3CB</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CB%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000051382-PIK3CB+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagerberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallstrom, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindskog, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksvold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardinoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivertsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostedt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asplund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szigyarto, C. A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odeberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djureinovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hober, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edqvist, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwenk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamsten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Feilitzen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwahlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Heijne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponten, F.</span></span> <span> </span><span class="NLM_article-title">Tissue-Based Map of the Human Proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">6220</span>),  <span class="NLM_fpage">1260419</span>– <span class="NLM_lpage">1260419</span>, <span class="refDoi"> DOI: 10.1126/science.1260419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1126%2Fscience.1260419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=25613900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BC2MvptFakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=1260419-1260419&issue=6220&author=M.+Uhlenauthor=L.+Fagerbergauthor=B.+M.+Hallstromauthor=C.+Lindskogauthor=P.+Oksvoldauthor=A.+Mardinogluauthor=A.+Sivertssonauthor=C.+Kampfauthor=E.+Sjostedtauthor=A.+Asplundauthor=I.+Olssonauthor=K.+Edlundauthor=E.+Lundbergauthor=S.+Navaniauthor=C.+A.-K.+Szigyartoauthor=J.+Odebergauthor=D.+Djureinovicauthor=J.+O.+Takanenauthor=S.+Hoberauthor=T.+Almauthor=P.-H.+Edqvistauthor=H.+Berlingauthor=H.+Tegelauthor=J.+Mulderauthor=J.+Rockbergauthor=P.+Nilssonauthor=J.+M.+Schwenkauthor=M.+Hamstenauthor=K.+von+Feilitzenauthor=M.+Forsbergauthor=L.+Perssonauthor=F.+Johanssonauthor=M.+Zwahlenauthor=G.+von+Heijneauthor=J.+Nielsenauthor=F.+Ponten&title=Tissue-Based+Map+of+the+Human+Proteome&doi=10.1126%2Fscience.1260419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics. Tissue-based map of the human proteome</span></div><div class="casAuthors">Uhlen Mathias; Fagerberg Linn; Oksvold Per; Sivertsson ¡ÑÜAsa; Lundberg Emma; Odeberg Jacob; Alm Tove; Nilsson Peter; Schwenk Jochen M; von Feilitzen Kalle; Forsberg Mattias; Persson Lukas; Johansson Fredric; Zwahlen Martin; Hallstrom Bjorn M; Lindskog Cecilia; Kampf Caroline; Asplund Anna; Olsson IngMarie; Djureinovic Dijana; Edqvist Per-Henrik; Ponten Fredrik; Mardinoglu Adil; Sjostedt Evelina; Edlund Karolina; Navani Sanjay; Szigyarto Cristina Al-Khalili; Takanen Jenny Ottosson; Hober Sophia; Berling Holger; Tegel Hanna; Rockberg Johan; Hamsten Marica; Mulder Jan; von Heijne Gunnar; Nielsen Jens</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">1260419</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease.  Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level.  Our tissue-based analysis detected more than 90% of the putative protein-coding genes.  We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs.  All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT9YWouQZh5DEC-75aqa5AfW6udTcc2eYdZ6zhCl5Q5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvptFakug%253D%253D&md5=95510888806e5feb6b8024ee2a417d1c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260419%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DHallstrom%26aufirst%3DB.%2BM.%26aulast%3DLindskog%26aufirst%3DC.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DMardinoglu%26aufirst%3DA.%26aulast%3DSivertsson%26aufirst%3DA.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DSjostedt%26aufirst%3DE.%26aulast%3DAsplund%26aufirst%3DA.%26aulast%3DOlsson%26aufirst%3DI.%26aulast%3DEdlund%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DNavani%26aufirst%3DS.%26aulast%3DSzigyarto%26aufirst%3DC.%2BA.-K.%26aulast%3DOdeberg%26aufirst%3DJ.%26aulast%3DDjureinovic%26aufirst%3DD.%26aulast%3DTakanen%26aufirst%3DJ.%2BO.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DT.%26aulast%3DEdqvist%26aufirst%3DP.-H.%26aulast%3DBerling%26aufirst%3DH.%26aulast%3DTegel%26aufirst%3DH.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DRockberg%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DSchwenk%26aufirst%3DJ.%2BM.%26aulast%3DHamsten%26aufirst%3DM.%26aulast%3Dvon%2BFeilitzen%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DL.%26aulast%3DJohansson%26aufirst%3DF.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3Dvon%2BHeijne%26aufirst%3DG.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DTissue-Based%2520Map%2520of%2520the%2520Human%2520Proteome%26jtitle%3DScience%26date%3D2015%26volume%3D347%26issue%3D6220%26spage%3D1260419%26epage%3D1260419%26doi%3D10.1126%2Fscience.1260419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span>PIK3CG
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000105851-PIK3CG" class="extLink">https://www.proteinatlas.org/ENSG00000105851-PIK3CG</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CG%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000105851-PIK3CG+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>PIK3CD
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000171608-PIK3CD" class="extLink">https://www.proteinatlas.org/ENSG00000171608-PIK3CD</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CD%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000171608-PIK3CD+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&issue=20&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lgmB2a1ZokWVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valastro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span> <span> </span><span class="NLM_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4783</span>– <span class="NLM_lpage">4814</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4783-4814&issue=10&author=M.+W.+D.+Perryauthor=R.+Abdulaiauthor=M.+Mogemarkauthor=J.+Petersenauthor=M.+J.+Thomasauthor=B.+Valastroauthor=A.+Westin+Eriksson&title=Evolution+of+PI3K%CE%B3+and+%CE%B4+Inhibitors+for+Inflammatory+and+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.8b01298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span></div><div class="casAuthors">Perry, Matthew W. D.; Abdulai, Raolat; Mogemark, Mickael; Petersen, Jens; Thomas, Matthew J.; Valastro, Barbara; Westin Eriksson, Annika</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4783-4814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositol 3-kinases (PI3Ks) γ and δ are key enzymes in hematopoietic cells and have been seen as high-value targets for the treatment of diseases with inflammatory and immunomodulatory components since their discovery and the identification of their roles.  In this Perspective we review progress in the application of inhibitors of PI3Kγ and δ to inflammatory and immunol. conditions over the past 6 years.  We consider progress in the understanding of the roles of PI3Kγ and PI3Kδ in immunol. and inflammation, the experience from clin. trials where inhibitors have been tested, and what has been learned about the safety of their use.  The extensive medicinal chem. efforts to discover both isoform selective and dual PI3Kγδ inhibitors are analyzed and detailed.  Developments in understanding the structural chem. of the PI3K enzymes and the factors that govern isoform selectivity are discussed.  The effects obsd. with the known inhibitor compds. in animal models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tJy6u73_7bVg90H21EOLACvtfcHk0lgmB2a1ZokWVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O&md5=2b5cdec8135ee6ebd94624b9a675c889</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DAbdulai%26aufirst%3DR.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BJ.%26aulast%3DValastro%26aufirst%3DB.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26atitle%3DEvolution%2520of%2520PI3K%25CE%25B3%2520and%2520%25CE%25B4%2520Inhibitors%2520for%2520Inflammatory%2520and%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D10%26spage%3D4783%26epage%3D4814%26doi%3D10.1021%2Facs.jmedchem.8b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Southworth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">Anti-Inflammatory Potential of PI3K δ and JAK Inhibitors in Asthma Patients</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1186/s12931-016-0436-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1186%2Fs12931-016-0436-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=26739476" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1-12&author=T.+Southworthauthor=J.+Plumbauthor=V.+Guptaauthor=J.+Pearsonauthor=I.+Ramisauthor=M.+D.+Lehnerauthor=M.+Miralpeixauthor=D.+Singh&title=Anti-Inflammatory+Potential+of+PI3K+%CE%B4+and+JAK+Inhibitors+in+Asthma+Patients&doi=10.1186%2Fs12931-016-0436-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs12931-016-0436-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-016-0436-2%26sid%3Dliteratum%253Aachs%26aulast%3DSouthworth%26aufirst%3DT.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DPearson%26aufirst%3DJ.%26aulast%3DRamis%26aufirst%3DI.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DAnti-Inflammatory%2520Potential%2520of%2520PI3K%2520%25CE%25B4%2520and%2520JAK%2520Inhibitors%2520in%2520Asthma%2520Patients%26jtitle%3DRespir.%2520Res.%26date%3D2016%26volume%3D17%26spage%3D1%26epage%3D12%26doi%3D10.1186%2Fs12931-016-0436-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawicka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span> <span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase Gamma in Eosinophil Chemotaxis within Acute Pulmonary Inflammation</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2567.2008.02908.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1111%2Fj.1365-2567.2008.02908.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=18754810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2009&pages=413-422&issue=3&author=M.+Thomasauthor=M.+J.+Edwardsauthor=E.+Sawickaauthor=N.+Dugganauthor=E.+Hirschauthor=M.+P.+Wymannauthor=C.+Owenauthor=A.+Trifilieffauthor=C.+Walkerauthor=J.+Westwickauthor=P.+Finan&title=Essential+Role+of+Phosphoinositide+3-Kinase+Gamma+in+Eosinophil+Chemotaxis+within+Acute+Pulmonary+Inflammation&doi=10.1111%2Fj.1365-2567.2008.02908.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation</span></div><div class="casAuthors">Thomas, Matthew; Edwards, Matthew J.; Sawicka, Elzbieta; Duggan, Nicholas; Hirsch, Emilio; Wymann, Matthias P.; Owen, Charles; Trifilieff, Alexandre; Walker, Christoph; Westwick, John; Finan, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We and others have established an important role for phosphoinositide-3 kinase gamma (PI3Kγ) in the chemotactic responses of macrophages and neutrophils.  The involvement of this lipid kinase in allergic inflammatory responses is, however, yet to be fully detd.  Here we compare wild-type (WT) and PI3Kγ-/- (KO) mice within a model of ovalbumin (OVA)-specific pulmonary inflammation.  Upon OVA aerosol challenge, cell influx into the bronchoalveolar lavage (BAL) fluid consisted of neutrophils, macrophages and, more significantly, eosinophils - which are key effector cells in allergic inflammation.  Each population was reduced by up to 80% in KO mice, demonstrating a role for PI3Kγ in cell infiltration into the airways.  The mechanism of reduced eosinophilia was analyzed within both development and effector stages of the immune response.  Comparable levels of OVA-specific T-cell proliferation and Ig prodn. were established in both strains.  Furthermore, no significant differences between WT and KO chemokine prodn. were obsd.  Having identified the crit. point of PI3Kγ involvement, KO eosinophil chemotactic dysfunction was confirmed in vitro.  These data are the first to demonstrate the vital role of PI3Kγ in acute allergic inflammation.  The profound dependency of eosinophils on PI3Kγ for pulmonary influx identifies this lipid kinase as an attractive target for the pharmacol. intervention of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdLl0aeZ1dqLVg90H21EOLACvtfcHk0lhVqPBCA1S7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nurg%253D&md5=20de1f758aed11ee24e4cb23ed108fc7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2008.02908.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2008.02908.x%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DM.%2BJ.%26aulast%3DSawicka%26aufirst%3DE.%26aulast%3DDuggan%26aufirst%3DN.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DFinan%26aufirst%3DP.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520Gamma%2520in%2520Eosinophil%2520Chemotaxis%2520within%2520Acute%2520Pulmonary%2520Inflammation%26jtitle%3DImmunology%26date%3D2009%26volume%3D126%26issue%3D3%26spage%3D413%26epage%3D422%26doi%3D10.1111%2Fj.1365-2567.2008.02908.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">The Cytokines of Asthma</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2019.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fj.immuni.2019.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30995510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFGksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=975-991&issue=4&author=B.+N.+Lambrechtauthor=H.+Hammadauthor=J.+V.+Fahy&title=The+Cytokines+of+Asthma&doi=10.1016%2Fj.immuni.2019.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Cytokines of Asthma</span></div><div class="casAuthors">Lambrecht, Bart N.; Hammad, Hamida; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">975-991</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Asthma is a chronic inflammatory airway disease assocd. with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overprodn., bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis.  However, only half of asthma patients exhibit signs of an exacerbated Type 2 response.  "Type 2-low" asthma has different immune features: airway neutrophilia, obesity-related systemic inflammation, or in some cases, few signs of immune activation.  Here, we review the cytokine networks driving asthma, placing these in cellular context and incorporating insights from cytokine-targeting therapies in the clinic.  We discuss established and emerging paradigms in the context of the growing appreciation of disease heterogeneity and argue that the development of new and improved therapeutics will require understanding the diverse mechanisms underlying the spectrum of asthma pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwry0FZ9TwH7Vg90H21EOLACvtfcHk0lhVqPBCA1S7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFGksLk%253D&md5=766c51708e6bb5c02446956006b1d6df</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2019.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2019.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DLambrecht%26aufirst%3DB.%2BN.%26aulast%3DHammad%26aufirst%3DH.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520Cytokines%2520of%2520Asthma%26jtitle%3DImmunity%26date%3D2019%26volume%3D50%26issue%3D4%26spage%3D975%26epage%3D991%26doi%3D10.1016%2Fj.immuni.2019.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmalbach, T.</span>; <span class="NLM_string-name">Fuhr, R.</span>; <span class="NLM_string-name">Albayaty, M.</span>; <span class="NLM_string-name">Allen, K.</span>; <span class="NLM_string-name">Douglas, M.</span>; <span class="NLM_string-name">Dunbar, J.</span>; <span class="NLM_string-name">McLaughlin, J.</span>; <span class="NLM_string-name">Alexander, L.</span>; <span class="NLM_string-name">McKee, C.</span></span> <span> </span><span class="NLM_article-title">Duvelisib, a PI3K-δ,γ Inhibitor, in Subjects with Mild Asthma</span>. In  <i>European Respiratory Journal, 5.1 Airway Pharmacology and Treatment</i>; <span class="NLM_publisher-name">European Respiratory Society</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">46</span>, p  <span class="NLM_fpage">PA2122</span>. <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.PA2122</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1183%2F13993003.congress-2015.PA2122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=PA2122&author=T.+Schmalbach&author=R.+Fuhr&author=M.+Albayaty&author=K.+Allen&author=M.+Douglas&author=J.+Dunbar&author=J.+McLaughlin&author=L.+Alexander&author=C.+McKee&title=European+Respiratory+Journal%2C+5.1+Airway+Pharmacology+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.PA2122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.PA2122%26sid%3Dliteratum%253Aachs%26aulast%3DSchmalbach%26aufirst%3DT.%26atitle%3DDuvelisib%252C%2520a%2520PI3K-%25CE%25B4%252C%25CE%25B3%2520Inhibitor%252C%2520in%2520Subjects%2520with%2520Mild%2520Asthma%26btitle%3DEuropean%2520Respiratory%2520Journal%252C%25205.1%2520Airway%2520Pharmacology%2520and%2520Treatment%26pub%3DEuropean%2520Respiratory%2520Society%26date%3D2015%26volume%3D46%26spage%3DPA2122%26doi%3D10.1183%2F13993003.congress-2015.PA2122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikulenkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaidashev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA) - ACR Meeting Abstracts</span>. <i>Arthritis and Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">2138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=2138&issue=Suppl+10&author=R.+Leffauthor=S.+Kumarauthor=N.+Nikulenkovaauthor=I.+Kaidashevauthor=K.+Allenauthor=J.+Dunbarauthor=H.+Sternauthor=J.+Adamsauthor=M.+Weinblatt&title=Safety+and+Efficacy+Results+of+a+Phase+2%2C+Double-Blind%2C+Placebo-Controlled+Clinical+Study+of+Duvelisib+with+Background+Methotrexate+%28MTX%29+in+Adults+with+Moderate-to-Severe+Rheumatoid+Arthritis+%28RA%29+-+ACR+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeff%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DNikulenkova%26aufirst%3DN.%26aulast%3DKaidashev%26aufirst%3DI.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%26atitle%3DSafety%2520and%2520Efficacy%2520Results%2520of%2520a%2520Phase%25202%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Clinical%2520Study%2520of%2520Duvelisib%2520with%2520Background%2520Methotrexate%2520%2528MTX%2529%2520in%2520Adults%2520with%2520Moderate-to-Severe%2520Rheumatoid%2520Arthritis%2520%2528RA%2529%2520-%2520ACR%2520Meeting%2520Abstracts%26jtitle%3DArthritis%2520and%2520Rheumatology%26date%3D2015%26volume%3D67%26issue%3DSuppl%252010%26spage%3D2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khindri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajdner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig-Sengpiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.249516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1124%2Fjpet.118.249516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30217958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWgsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2018&pages=405-413&issue=3&author=S.+Khindriauthor=A.+Cahnauthor=M.+Beggauthor=M.+Montembaultauthor=C.+Leemereiseauthor=Y.+Cuiauthor=A.+Hoggauthor=H.+Wajdnerauthor=S.+Yangauthor=J.+Robertsonauthor=J.+N.+Hamblinauthor=A.+Ludwig-Sengpielauthor=O.+Kornmannauthor=E.+M.+Hessel&title=A+Multicentre%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Crossover+Study+To+Investigate+the+Efficacy%2C+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+Repeat+Doses+of+Inhaled+Nemiralisib+in+Adults+with+Persistent%2C+Uncontrolled+Asthma&doi=10.1124%2Fjpet.118.249516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma</span></div><div class="casAuthors">Khindri, Sanjeev; Cahn, Anthony; Begg, Malcolm; Montembault, Mickael; Leemereise, Claudia; Cui, Yi; Hogg, Annabel; Wajdner, Hannah; Yang, Shuying; Robertson, Jon; Hamblin, J. Nicole; Ludwig-Sengpiel, Andrea; Kornmann, Oliver; Hessel, Edith M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability, and pharmacokinetics of a PI3Kd inhibitor, nemiralisib (GSK2269557), in patients with persistent, uncontrolled asthma.  Spirometry demonstrated no discernible difference in trough forced expiratory vol. in 1 s (FEV1) from baseline (adjusted posterior median 7 mL; 95% credible interval -83, 102 mL) between nemiralisib and placebo treatment at day 28 (primary endpoint).  These results were supported by most secondary endpoints, including weighted mean FEV1 (0-4 h) and change in trough forced vital capacity at day 28.  Nemiralisib was generally well-tolerated, with few side effects except for post-inhalation cough (nemiralisib: 35%; placebo: 9%).  At day 14, sputum interleukin (IL)-5, IL-13, IL-6, and IL-8 levels were reduced by a median of 17%, 7%, 15%, and 8%, resp., when comparing nemiralisib with placebo [n = 15 (IL-5, IL-8) or 16 (IL-6, IL-13); posterior probability of a true ratio. >0%: 78%, 64%, 76%, and 63%, resp.].  These results suggest that nemiralisib inhibited PI3Kd locally; however, this did not translate into meaningful clin. improvement.  Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonized with bacteria and frequently exacerbate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYx837TIJvr7Vg90H21EOLACvtfcHk0lglHczBvaZ3Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWgsr%252FO&md5=fbad4b66d64f945225b2bdccfd88dd57</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.249516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.249516%26sid%3Dliteratum%253Aachs%26aulast%3DKhindri%26aufirst%3DS.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DHogg%26aufirst%3DA.%26aulast%3DWajdner%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DA%2520Multicentre%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Crossover%2520Study%2520To%2520Investigate%2520the%2520Efficacy%252C%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520Repeat%2520Doses%2520of%2520Inhaled%2520Nemiralisib%2520in%2520Adults%2520with%2520Persistent%252C%2520Uncontrolled%2520Asthma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D367%26issue%3D3%26spage%3D405%26epage%3D413%26doi%3D10.1124%2Fjpet.118.249516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayoun-Valiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeraus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E.</span></span> <span> </span><span class="NLM_article-title">Nemiralisib in Patients Experiencing an Acute Exacerbation of COPD: Design of a Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Phase IIb Study</span>. <i>American Journal of Respiratory and Critical Care Medicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">A4523</span>– <span class="NLM_lpage">A4523</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2019&pages=A4523-A4523&author=W.+Fahyauthor=F.+Homayoun-Valianiauthor=A.+Cahnauthor=J.+Robertsonauthor=A.+Templetonauthor=W.+Meerausauthor=R.+Wilsonauthor=M.+Lowingsauthor=M.+Marottiauthor=M.+Tabbererauthor=S.+Westauthor=E.+Hessel&title=Nemiralisib+in+Patients+Experiencing+an+Acute+Exacerbation+of+COPD%3A+Design+of+a+Double-Blind%2C+Randomized%2C+Placebo-Controlled%2C+Dose-Ranging+Phase+IIb+Study&doi=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523%26sid%3Dliteratum%253Aachs%26aulast%3DFahy%26aufirst%3DW.%26aulast%3DHomayoun-Valiani%26aufirst%3DF.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DTempleton%26aufirst%3DA.%26aulast%3DMeeraus%26aufirst%3DW.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DLowings%26aufirst%3DM.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DTabberer%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%26atitle%3DNemiralisib%2520in%2520Patients%2520Experiencing%2520an%2520Acute%2520Exacerbation%2520of%2520COPD%253A%2520Design%2520of%2520a%2520Double-Blind%252C%2520Randomized%252C%2520Placebo-Controlled%252C%2520Dose-Ranging%2520Phase%2520IIb%2520Study%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520and%2520Critical%2520Care%2520Medicine%26date%3D2019%26volume%3D199%26spage%3DA4523%26epage%3DA4523%26doi%3D10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>Safety,
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses
of Inhaled GSK2269557 in Patients With APDS/PASLI - Full Text View
- ClinicalTrials.gov; <a href="https://clinicaltrials.gov/ct2/show/NCT02593539" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02593539</a> (accessed Jun 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C%0APharmacokinetic+%28PK%29+and+Pharmacodynamic+%28PD%29+Study+of+Repeat+Doses%0Aof+Inhaled+GSK2269557+in+Patients+With+APDS%2FPASLI+-+Full+Text+View%0A-+ClinicalTrials.gov%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02593539+%28accessed+Jun+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poleski, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment - Expert Panel Opinion</span>. <i>Leukemia & Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8194</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8194&publication_year=2015&pages=1-20&author=S.+E.+Coutreauthor=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment+-+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%2520-%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeukemia%2520%2526%2520Lymphoma%26date%3D2015%26volume%3D8194%26spage%3D1%26epage%3D20%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span>; <span class="NLM_string-name">Narjes, F.</span>; <span class="NLM_string-name">Hemmerling, M.</span></span> <span> </span><span class="NLM_article-title">2018 Medicinal Chemistry Reviews</span>. In  <i>Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">171</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=155-171&author=P.+Sj%C3%B6&author=F.+Narjes&author=M.+Hemmerlingauthor=J.+J.+Bronson&title=Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3D2018%2520Medicinal%2520Chemistry%2520Reviews%26btitle%3DMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%26date%3D2018%26spage%3D155%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Triazole Aminopyrazines as a Highly Potent and Selective Series of PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fj.bmcl.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=28017532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCltr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=679-687&issue=3&author=I.+Terstiegeauthor=M.+Perryauthor=J.+Petersenauthor=C.+Tyrchanauthor=T.+Svenssonauthor=H.+Lindmarkauthor=L.+%C3%96ster&title=Discovery+of+Triazole+Aminopyrazines+as+a+Highly+Potent+and+Selective+Series+of+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors</span></div><div class="casAuthors">Terstiege, Ina; Perry, Matthew; Petersen, Jens; Tyrchan, Christian; Svensson, Tor; Lindmark, Helena; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of potent PI3Kδ inhibitors with >1000-fold selectivity against other class I PI3K isoforms is described.  Optimization of the substituents on a triazole aminopyrazine scaffold, emerging from an inhouse PI3Kα program, turned moderately selective PI3Kδ compds. into highly potent and selective PI3Kδ inhibitors.  These efforts resulted in a series of aminopyrazines with PI3Kδ IC50 ≤ 1 nM in the enzyme assay, some of the most selective PI3Kδ inhibitors published to date, with a cell potency in a JeKo-cell assay of 20-120 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq30_ESCcDWabVg90H21EOLACvtfcHk0ljcgiKxGtLf4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCltr3M&md5=a23e39caed37cd7f969dc4bba666ede5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Triazole%2520Aminopyrazines%2520as%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Series%2520of%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5057</span>– <span class="NLM_lpage">5071</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5057-5071&issue=12&author=M.+W.+D.+Perryauthor=K.+Bj%C3%B6rhallauthor=B.+Bonnauthor=J.+Carlssonauthor=Y.+Chenauthor=A.+Erikssonauthor=L.+Fredlundauthor=H.+Haoauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=H.+Lindmarkauthor=F.+Liuauthor=N.+Pembertonauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=R.+W.+Smithauthor=T.+Svenssonauthor=I.+Terstiegeauthor=C.+Tyrchanauthor=W.+Yangauthor=S.+Zhaoauthor=L.+%C3%96ster&title=Design+and+Synthesis+of+Soluble+and+Cell-Permeable+PI3K%CE%B4+Inhibitors+for+Long-Acting+Inhaled+Administration&doi=10.1021%2Facs.jmedchem.7b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span></div><div class="casAuthors">Perry, Matthew W. D.; Bjoerhall, Karin; Bonn, Britta; Carlsson, Johan; Chen, Yunhua; Eriksson, Anders; Fredlund, Linda; Hao, Hai'e; Holden, Neil S.; Karabelas, Kostas; Lindmark, Helena; Liu, Feifei; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist, Sandra; Smith, Reed W.; Svensson, Tor; Terstiege, Ina; Tyrchan, Christian; Yang, Wenzhen; Zhao, Shuchun; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system.  Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis.  In this work, identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation is described.  The initially identified compd. I had good potency and isoform selectivity but was not suitable for inhalation.  Addn. of basic substituents to a region of the mol. pointing to solvent was tolerated (enzyme inhibition pIC50 > 9), and by careful manipulation of the pKa and lipophilicity, the authors were able to discover compds. II (R = Me or i-Bu) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo9sRrhhb7Vg90H21EOLACvtfcHk0ljcgiKxGtLf4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D&md5=dafb9cfdf6c06e30c599dcceec85497a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00401%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DBj%25C3%25B6rhall%26aufirst%3DK.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEriksson%26aufirst%3DA.%26aulast%3DFredlund%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Soluble%2520and%2520Cell-Permeable%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Long-Acting%2520Inhaled%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Facs.jmedchem.7b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlbrandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo
Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatoidsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5435</span>– <span class="NLM_lpage">5441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00447</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00447" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5435-5441&issue=12&author=N.+Pembertonauthor=M.+Mogemarkauthor=S.+Arlbrandtauthor=P.+Boldauthor=R.+J.+Coxauthor=C.+Gardelliauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=J.+Karlssonauthor=S.+Leverauthor=X.+Liauthor=H.+Lindmarkauthor=M.+Norbergauthor=M.+W.+D.+Perryauthor=J.+Petersenauthor=S.+Rodrigo%0ABlomqvistauthor=M.+Thomasauthor=C.+Tyrchanauthor=A.+Westin+Erikssonauthor=P.+Zlatoidskyauthor=L.+%C3%96ster&title=Discovery+of+Highly+Isoform+Selective+Orally+Bioavailable+Phosphoinositide+3-Kinase+%28PI3K%29-%CE%B3+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span></div><div class="casAuthors">Pemberton, Nils; Mogemark, Mickael; Arlbrandt, Susanne; Bold, Peter; Cox, Rhona J.; Gardelli, Cristina; Holden, Neil S.; Karabelas, Kostas; Karlsson, Johan; Lever, Sarah; Li, Xueshan; Lindmark, Helena; Norberg, Monica; Perry, Matthew W. D.; Petersen, Jens; Rodrigo Blomqvist, Sandra; Thomas, Matthew; Tyrchan, Christian; Westin Eriksson, Annika; Zlatoidsky, Pavol; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5435-5441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors.  Starting from an HTS hit, potency and physicochem. properties could be improved to give compds. such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration.  Compd. 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3fbsxDWowrVg90H21EOLACvtfcHk0ljcgiKxGtLf4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO&md5=da8067ecb7fff28145f1c2bf82f0a7e7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00447%26sid%3Dliteratum%253Aachs%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DArlbrandt%26aufirst%3DS.%26aulast%3DBold%26aufirst%3DP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DGardelli%26aufirst%3DC.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DJ.%26aulast%3DLever%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DNorberg%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DZlatoidsky%26aufirst%3DP.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5435%26epage%3D5441%26doi%3D10.1021%2Facs.jmedchem.8b00447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunnarsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papavoine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span> <span> </span><span class="NLM_article-title">A Class of Highly Selective Inhibitors Bind to an Active State of PI3Kγ</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0215-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1038%2Fs41589-018-0215-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30718815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtF2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=348-357&issue=4&author=G.+Gangadharaauthor=G.+Dahlauthor=T.+Bohnackerauthor=R.+Raeauthor=J.+Gunnarssonauthor=S.+Blahoauthor=L.+%C3%96sterauthor=H.+Lindmarkauthor=K.+Karabelasauthor=N.+Pembertonauthor=C.+Tyrchanauthor=M.+Mogemarkauthor=M.+P.+Wymannauthor=R.+L.+Williamsauthor=M.+W.+D.+Perryauthor=T.+Papavoineauthor=J.+Petersen&title=A+Class+of+Highly+Selective+Inhibitors+Bind+to+an+Active+State+of+PI3K%CE%B3&doi=10.1038%2Fs41589-018-0215-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A class of highly selective inhibitors bind to an active state of PI3Kγ</span></div><div class="casAuthors">Gangadhara, Gangadhara; Dahl, Goeran; Bohnacker, Thomas; Rae, Rebecca; Gunnarsson, Jenny; Blaho, Stefan; Oester, Linda; Lindmark, Helena; Karabelas, Kostas; Pemberton, Nils; Tyrchan, Christian; Mogemark, Mickael; Wymann, Matthias P.; Williams, Roger L.; Perry, Matthew W. D.; Papavoine, Tineke; Petersen, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">348-357</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">We have discovered a class of PI3Kγ inhibitors exhibiting over 1000-fold selectivity over PI3Kα and PI3Kβ.  On the basis of X-ray crystallog., hydrogen-deuterium exchange-mass spectrometry and surface plasmon resonance expts. we propose that the cyclopropylethyl moiety displaces the DFG motif of the enzyme away from the adenosine tri-phosphate binding site, inducing a large conformational change in both the kinase- and helical domains of PI3Kγ.  Site directed mutagenesis explained how the conformational changes occur.  Our results suggest that these cyclopropylethyl substituted compds. selectively inhibit the active state of PI3Kγ, which is unique to these compds. and to the PI3Kγ isoform, explaining their excellent potency and unmatched isoform selectivity that were confirmed in cellular systems.  This is the first example of a Class I PI3K inhibitor achieving its selectivity by affecting the DFG motif in a manner that bears similarity to DFG in/out for type II protein kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcyKjzZy-40rVg90H21EOLACvtfcHk0lgb30-cCnbshA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtF2nsbo%253D&md5=a6b428b3964062820e045354134c3c21</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0215-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0215-0%26sid%3Dliteratum%253Aachs%26aulast%3DGangadhara%26aufirst%3DG.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DRae%26aufirst%3DR.%26aulast%3DGunnarsson%26aufirst%3DJ.%26aulast%3DBlaho%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPapavoine%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26atitle%3DA%2520Class%2520of%2520Highly%2520Selective%2520Inhibitors%2520Bind%2520to%2520an%2520Active%2520State%2520of%2520PI3K%25CE%25B3%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D4%26spage%3D348%26epage%3D357%26doi%3D10.1038%2Fs41589-018-0215-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&issue=11&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+Survey+of+the+Role+of+Noncovalent+Sulfur+Interactions+in+Drug+Design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0lgb30-cCnbshA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520Survey%2520of%2520the%2520Role%2520of%2520Noncovalent%2520Sulfur%2520Interactions%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route: Challenges and Approaches</span>. <i>Current Drug Metabolism</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&issue=4&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route%3A+Challenges+and+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lgb30-cCnbshA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route%253A%2520Challenges%2520and%2520Approaches%26jtitle%3DCurrent%2520Drug%2520Metabolism%26date%3D2012%26volume%3D13%26issue%3D4%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Waiver of In
Vivo Bioavailability and Bioequivalence Studies for Immediate-Release
Solid Oral Dosage Forms Based on a Biopharmaceutics Classification
System Guidance for Industry</span>; <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm" class="extLink">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm</a> (accessed Apr 21, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Waiver+of+In%0AVivo+Bioavailability+and+Bioequivalence+Studies+for+Immediate-Release%0ASolid+Oral+Dosage+Forms+Based+on+a+Biopharmaceutics+Classification%0ASystem+Guidance+for+Industry%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fdefault.htm+%28accessed+Apr+21%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWaiver%2520of%2520In%250AVivo%2520Bioavailability%2520and%2520Bioequivalence%2520Studies%2520for%2520Immediate-Release%250ASolid%2520Oral%2520Dosage%2520Forms%2520Based%2520on%2520a%2520Biopharmaceutics%2520Classification%250ASystem%2520Guidance%2520for%2520Industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, R.</span></span> <span> </span><span class="NLM_article-title">Lymphocytes Migrate from the Blood into the Bronchoalveolar Lavage and Lung Parenchyma in the Asthma Model of the Brown Norway Rat</span>. <i>American Journal of Respiratory and Critical Care Medicine</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.161.2.9812021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1164%2Fajrccm.161.2.9812021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10673200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2000&pages=558-566&author=M.+Schusterauthor=T.+Tschernigauthor=N.+Krugauthor=R.+Pabst&title=Lymphocytes+Migrate+from+the+Blood+into+the+Bronchoalveolar+Lavage+and+Lung+Parenchyma+in+the+Asthma+Model+of+the+Brown+Norway+Rat&doi=10.1164%2Fajrccm.161.2.9812021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat</span></div><div class="casAuthors">Schuster M; Tschernig T; Krug N; Pabst R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">558-66</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Lymphocyte migration from the blood into the lung has been suggested as being responsible for the increase of lymphocytes, in particular CD4 T cells, in the bronchoalveolar lavage (BAL) and bronchial mucosa in human asthma, but so far there has been no direct proof.  We studied lymphocyte immigration and lymphocyte subpopulations in three lung compartments in ovalbumin (OVA)-sensitized and -challenged brown Norway (BN) rats.  Increased numbers of CD4 and interleukin 2 (IL-2) receptor-positive T cells were found in the BAL and lung parenchyma in treated animals, but also increased numbers of CD8 T cells, B cells, and natural killer (NK) cells.  For direct proof of lymphocyte migration from the blood into the lung, leukocytes were labeled with a fluorescent dye, 5- (and 6-) carboxyfluorescein-diacetate-succinimidyl-ester (CFSE), and injected intravenously immediately prior to OVA aerosol challenge.  One day after challenge the number of CFSE(+), i.e., newly immigrated lymphocytes, was determined by flow cytometry gated on the lymphocyte cluster.  A 15 times (1.5 times) higher number of CFSE(+) lymphocytes was found in the BAL (the lung parenchyma) of treated animals in comparison with control rats.  In the BAL 51.8% of CFSE(+) cells were CD4-positive (parenchyma 72.7%) and 29.4% IL-2 receptor-positive (parenchyma 34.2%).  There was no difference whether the leukocytes for labeling and injection were obtained from untreated or from OVA-sensitized donor animals.  Our data show that lymphocyte immigration is at least in part responsible for the increase in lymphocyte numbers in the BAL and lung parenchyma in this animal asthma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3Cxch47IYMPxQvRxYU81tfW6udTcc2eajAsLOVoikdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otValuw%253D%253D&md5=4b123a2346d7892b07c70f424f14fdb9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.161.2.9812021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.161.2.9812021%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DPabst%26aufirst%3DR.%26atitle%3DLymphocytes%2520Migrate%2520from%2520the%2520Blood%2520into%2520the%2520Bronchoalveolar%2520Lavage%2520and%2520Lung%2520Parenchyma%2520in%2520the%2520Asthma%2520Model%2520of%2520the%2520Brown%2520Norway%2520Rat%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520and%2520Critical%2520Care%2520Medicine%26date%3D2000%26volume%3D161%26spage%3D558%26epage%3D566%26doi%3D10.1164%2Fajrccm.161.2.9812021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&issue=18&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+Novel+Indazoles+as+Highly+Potent+and+Selective+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0lhjCaqAl-y-Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520Novel%2520Indazoles%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäckström, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brülls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrén, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R. J. A.</span></span> <span> </span><span class="NLM_article-title">Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging</span>. <i>J. Aerosol Med. Pulm. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1089/jamp.2019.1536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1089%2Fjamp.2019.1536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=31364961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=43-53&issue=1&author=G.+R.+Hammauthor=E.+B%C3%A4ckstr%C3%B6mauthor=M.+Br%C3%BCllsauthor=A.+Nilssonauthor=N.+Strittmatterauthor=P.+E.+Andr%C3%A9nauthor=K.+Grimeauthor=M.+Frid%C3%A9nauthor=R.+J.+A.+Goodwin&title=Revealing+the+Regional+Localization+and+Differential+Lung+Retention+of+Inhaled+Compounds+by+Mass+Spectrometry+Imaging&doi=10.1089%2Fjamp.2019.1536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging</span></div><div class="casAuthors">Hamm, Gregory R.; Baeckstroem, Erica; Bruells, Mikael; Nilsson, Anna; Strittmatter, Nicole; Andren, Per E.; Grime, Ken; Friden, Markus; Goodwin, Richard J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Aerosol Medicine and Pulmonary Drug Delivery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">JAMPC4</span>;
        ISSN:<span class="NLM_cas:issn">1941-2711</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Background: For the treatment of respiratory disease, inhaled drug delivery aims to provide direct access to pharmacol. target sites while minimizing systemic exposure.  The aim of this study was to investigate the distribution and retention of different chemotypes typifying available inhaled drugs [slowly dissolving neutral fluticasone propionate (FP) and sol. bases salmeterol and salbutamol] using mass spectrometry imaging (MSI).  Methods: Salmeterol, salbutamol, and FP were simultaneously delivered by inhaled nebulization to rats.  In the same animals, salmeterol-d3, salbutamol-d3, and FP-d3 were delivered by i.v. (IV) injection.  Samples of lung tissue were obtained at 2- and 30-min postdosing, and high-resoln. MSI was used to study drug distribution and retention.  Results: IV delivery resulted in homogeneous lung distribution for all mols.  In comparison, while inhalation also gave rise to drug presence in the entire lung, there were regional chemotype-dependent areas of higher abundance.  At the 30-min time point, inhaled salmeterol and salbutamol were preferentially retained in bronchiolar tissue, whereas FP was retained in all regions of the lungs.  Conclusion: This study clearly demonstrates that inhaled small mol. chemotypes are differentially distributed in lung tissue after inhalation, and that high-resoln. MSI can be applied to study these retention patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpudsiJ1cuPdLVg90H21EOLACvtfcHk0lgVz-VvVmoQ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgt74%253D&md5=0ed5228556fc6a2d441f7844d5229960</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1089%2Fjamp.2019.1536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjamp.2019.1536%26sid%3Dliteratum%253Aachs%26aulast%3DHamm%26aufirst%3DG.%2BR.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DBr%25C3%25BClls%26aufirst%3DM.%26aulast%3DNilsson%26aufirst%3DA.%26aulast%3DStrittmatter%26aufirst%3DN.%26aulast%3DAndr%25C3%25A9n%26aufirst%3DP.%2BE.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DR.%2BJ.%2BA.%26atitle%3DRevealing%2520the%2520Regional%2520Localization%2520and%2520Differential%2520Lung%2520Retention%2520of%2520Inhaled%2520Compounds%2520by%2520Mass%2520Spectrometry%2520Imaging%26jtitle%3DJ.%2520Aerosol%2520Med.%2520Pulm.%2520Drug%2520Delivery%26date%3D2020%26volume%3D33%26issue%3D1%26spage%3D43%26epage%3D53%26doi%3D10.1089%2Fjamp.2019.1536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötvall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekerljung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönmark, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennergren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönmark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torén, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, B.</span></span> <span> </span><span class="NLM_article-title">West Sweden Asthma Study: Prevalence Trends over the Last 18 Years Argues No Recent Increase in Asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1186%2F1465-9921-10-94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=19821983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjslOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=94&issue=1&author=J.+L%C3%B6tvallauthor=L.+Ekerljungauthor=E.+P.+R%C3%B6nmarkauthor=G.+Wennergrenauthor=A.+Lind%C3%A9nauthor=E.+R%C3%B6nmarkauthor=K.+Tor%C3%A9nauthor=B.+Lundb%C3%A4ck&title=West+Sweden+Asthma+Study%3A+Prevalence+Trends+over+the+Last+18+Years+Argues+No+Recent+Increase+in+Asthma&doi=10.1186%2F1465-9921-10-94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma</span></div><div class="casAuthors">Lotvall Jan; Ekerljung Linda; Ronmark Erik P; Wennergren Goran; Linden Anders; Ronmark Eva; Toren Kjell; Lundback Bo</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Asthma prevalence has increased over the last fifty years, but the more recent changes have not been conclusively determined.  Studies in children indicate that a plateau in the prevalence of asthma may have been reached, but this has not yet been confirmed in adults.  Epidemiological studies have suggested that the prevalence of asthma in adults is approximately 7-10% in different parts of the western world.  We have now performed a large-scale epidemiological evaluation of the prevalence of asthma and respiratory symptoms in adults between the ages of 16-75 in West Sweden.  Thirty thousand randomly chosen individuals were sent a detailed questionnaire focusing on asthma and respiratory symptoms, as well possible risk factors.  Sixty-two percent of the contacted individuals responded to the questionnaire.  Asthma prevalence, defined as asthma diagnosed by a physician, was 8.3%.  Moreover, the prevalence of respiratory symptoms was lower compared to previous studies.  The most common respiratory symptom was any wheeze (16.6%) followed by sputum production (13.3%).  In comparison with studies performed 18 years ago, the prevalence of asthma has not increased, and the prevalence of most respiratory symptoms has decreased.  Therefore, our data argues that the continued increase in asthma prevalence that has been observed over the last half century is over.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6wTUah4VuAzdblLE_E9PWfW6udTcc2eb0YV7fVlyG47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjslOluw%253D%253D&md5=12211d35b30a5aff1a31be440618e8fc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-94%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tvall%26aufirst%3DJ.%26aulast%3DEkerljung%26aufirst%3DL.%26aulast%3DR%25C3%25B6nmark%26aufirst%3DE.%2BP.%26aulast%3DWennergren%26aufirst%3DG.%26aulast%3DLind%25C3%25A9n%26aufirst%3DA.%26aulast%3DR%25C3%25B6nmark%26aufirst%3DE.%26aulast%3DTor%25C3%25A9n%26aufirst%3DK.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DB.%26atitle%3DWest%2520Sweden%2520Asthma%2520Study%253A%2520Prevalence%2520Trends%2520over%2520the%2520Last%252018%2520Years%2520Argues%2520No%2520Recent%2520Increase%2520in%2520Asthma%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26issue%3D1%26spage%3D94%26doi%3D10.1186%2F1465-9921-10-94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed and investigational PI3Kδ and PI3Kδγ inhibitors referred to in the text.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PI3Kγ selective inhibitor <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Sulfonamides <b>5</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, PhCH<sub>2</sub>SH, NaO<i>t</i>-Am, DMF, 110 °C; ii, SO<sub>2</sub>Cl<sub>2</sub>, MeCN, AcOH, H<sub>2</sub>O, 0–5 °C; iii, R1R2NH, pyridine, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <i>N</i>-Heterocyclic Derivatives <b>18</b>–<b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, HCl, EtOH; ii, R4X, Pd(OAc)<sub>2</sub>, Xantphos, dioxane, 120 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Macrocycle Synthesis <i>via</i> Buchwald–Hartwig Amination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, diamine, CH<sub>2</sub>Cl<sub>2</sub>; ii, 4-acetamidobenzaldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH then aq CH<sub>2</sub>O; iii, HCl (3 M aq), EtOH; iv, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>N(Me)(CH<sub>2</sub>)<sub>2</sub>NHBOC, T3P, Et<sub>3</sub>N, EtOAc; v, HCl, dioxane, CH<sub>2</sub>Cl<sub>2</sub>; vi, <b>30</b>, BOCNHCH<sub>2</sub>CHO, NaBH<sub>3</sub>CN, AcOH, MeOH; vii, TFA, CH<sub>2</sub>Cl<sub>2</sub>; viii amine (<b>28</b>, <b>29</b>, <b>25</b>, <b>30</b>, <b>31</b>, <b>27</b>), Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; ix, HCl (3 M aq), EtOH; x, second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Amide Isosteres and Reversed Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>i, acetamidine hydrochloride, HATU, DIPEA, DMF; ii, MeNHNH<sub>2</sub>, AcOH, DMF, 80 °C; iii, ethyl 2-isocyanoacetate, Et<sub>3</sub>N, DMAP, THF; iv, NaBH<sub>4</sub>, EtOH, 0 °C; v, Ac<sub>2</sub>O, py, 120 °C; vi, second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C; vii, deprotection, if required; viii, ClCH<sub>2</sub>CH<sub>2</sub>NCO, toluene; ix, NaH, DMF, THF; x, Cl(CH<sub>2</sub>)<sub><i>n</i></sub>ZCOCl, pyridine; xi, Cs<sub>2</sub>CO<sub>2</sub>, DMF; xii second or third generation Xantphos precatalyst, Na<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Crystal structures of compounds <b>7</b> and <b>12</b> bound in PI3Kδ. (Top) <b>7</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4">7oi4</a>, 1.8 Å). (Bottom) <b>12</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois">7ois</a>, 2.3 Å) Note that for each compound hydrogen bonds can be seen from the acetylaminothiazole to the hinge Val828 and from the carbonyl of the isoindolinone to the terminal amino of Lys779.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Crystal structure of <b>20</b> in PI3Kδ. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> X-ray structure of compound <b>20</b> bound in mPI3Kδ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij">7oij</a>, 1.7 Å). Note how the amine at the terminus of the side chain ends up close to the sulfonamide on the isoindolinone suggesting the possibility for macrocyclization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of <b>58</b> bound to PI3Kδ. X-ray view of <b>58</b> bound in PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil">7oil</a>, 2.0 Å). The binding mode is essentially identical to earlier compounds. The lactam can be seen to make a water-mediated hydrogen bond to the terminal NH<sub>2</sub> of Asp836, which itself is in a network of hydrogen bonds with Thr833. Other residues shown are Trp760 and Met752 that form the other side of the pocket around the lactam and Lys779 that forms H-bonds with the carbonyl of the isoindolinone and the sulfone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A–D) Inhibition of eosinophil migration in response to an inhaled ovalbumin challenge. Rats (BN, male, 10 per group) were sensitized to ovalbumin by ip administration on two separate occasions, then challenged with aerosolized administration of ovalbumin and, after a week dosed with compound by nebulization before subsequent challenge with aerosolized ovalbumin. After 48 h the animals were terminated, the lungs lavaged, and the numbers of eosinophils in the BAL fluid were measured by flow cytometry. Budesonide (300 μg, dosed i.t.) was used as positive control. Individual animals are represented by points with the average effect shown in bars. Compound amounts represent the administered dose of compound.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Experiment showing duration of effect of nebulized <b>58</b> in rats. Compound <b>58</b> was dosed by nebulization (240 μg/kg administered dose) to male rats (BN, 8–10 per group) that had been sensitized to ovalbumin at varying intervals prior to ovalbumin challenge. 48 h after challenge, the animals were terminated, the lungs lavaged, and the numbers of eosinophils in the lung lavage fluid were measured by flow cytometry, and the results were compared to time-matched controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/medium/jm1c00434_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PI3K isoform specific inhibition of T cell cytokine release and eosinophil surface CD11b expression, using PBMC and purified granulocytes from severe asthma patients (GINA 3 and 4). Effects of PI3Kγ (Cpd <b>1</b>), PI3Kδ (Nemiralisib), or PI3Kγδ dual (Cpd <b>58</b>) selective inhibitors on (A) IL-5, (B) IL-17 release after anti-CD2/3/28 stimulation of PBMCs, and (C) CD11b surface expression on blood-derived eosinophils stimulated with eotaxin-3 measured by flow cytometry. The impact of treatment is visualized as %-inhibition. Error bars depicts SEM, asthmatic donors <i>N</i> = 6–10.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00434/20210616/images/large/jm1c00434_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00434&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bilanges, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">PI3K Isoforms in Cell Signalling and Vesicle Trafficking</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1038/s41580-019-0129-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1038%2Fs41580-019-0129-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=31110302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFehtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=515-534&issue=9&author=B.+Bilangesauthor=Y.+Posorauthor=B.+Vanhaesebroeck&title=PI3K+Isoforms+in+Cell+Signalling+and+Vesicle+Trafficking&doi=10.1038%2Fs41580-019-0129-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K isoforms in cell signalling and vesicle trafficking</span></div><div class="casAuthors">Bilanges, Benoit; Posor, York; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">515-534</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  PI3Ks are a family of lipid kinases that phosphorylate intracellular inositol lipids to regulate signalling and intracellular vesicular traffic.  Mammals have eight isoforms of PI3K, divided into three classes.  The class I PI3Ks generate 3-phosphoinositide lipids, which directly activate signal transduction pathways.  In addn. to being frequently genetically activated in cancer, similar mutations in class I PI3Ks have now also been found in a human non-malignant overgrowth syndrome and a primary immune disorder that predisposes to lymphoma.  The class II and class III PI3Ks are regulators of membrane traffic along the endocytic route, in endosomal recycling and autophagy, with an often indirect effect on cell signalling.  Here, we summarize current knowledge of the different PI3K classes and isoforms, focusing on recently uncovered biol. functions and the mechanisms by which these kinases are activated.  Deeper insight into the PI3K isoforms will undoubtedly continue to contribute to a better understanding of fundamental cell biol. processes and, ultimately, of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo92E4GNLUrSLVg90H21EOLACvtfcHk0lgH2Y8tQvnuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFehtrk%253D&md5=6f3e9dc5c8bee8204b1ee9c6c53acb8d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fs41580-019-0129-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-019-0129-z%26sid%3Dliteratum%253Aachs%26aulast%3DBilanges%26aufirst%3DB.%26aulast%3DPosor%26aufirst%3DY.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DPI3K%2520Isoforms%2520in%2520Cell%2520Signalling%2520and%2520Vesicle%2520Trafficking%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26issue%3D9%26spage%3D515%26epage%3D534%26doi%3D10.1038%2Fs41580-019-0129-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sogkas, G.</span>; <span class="NLM_string-name">Adriawan, I. R.</span>; <span class="NLM_string-name">Dubrowinskaja, N.</span>; <span class="NLM_string-name">Atschekzei, F.</span>; <span class="NLM_string-name">Schmidt, R. E.</span></span> <i>Homeostatic and Pathogenic Roles of PI3Kδ in the Human Immune System</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">Elsevier Inc</span>., <span class="NLM_year">2020</span>. <span class="refDoi"> DOI: 10.1016/bs.ai.2020.02.001</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fbs.ai.2020.02.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Sogkas&author=I.+R.+Adriawan&author=N.+Dubrowinskaja&author=F.+Atschekzei&author=R.+E.+Schmidt&title=Homeostatic+and+Pathogenic+Roles+of+PI3K%CE%B4+in+the+Human+Immune+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fbs.ai.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252Fbs.ai.2020.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DSogkas%26aufirst%3DG.%26btitle%3DHomeostatic%2520and%2520Pathogenic%2520Roles%2520of%2520PI3K%25CE%25B4%2520in%2520the%2520Human%2520Immune%2520System%26pub%3DElsevier%2520Inc%26date%3D2020%26doi%3D10.1016%2Fbs.ai.2020.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piñeiro, R.</span></span> <span> </span><span class="NLM_article-title">Molecules in Medicine Mini-Review: Isoforms of PI3K in Biology and Disease</span>. <i>J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&issue=1&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+Medicine+Mini-Review%3A+Isoforms+of+PI3K+in+Biology+and+Disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0lgH2Y8tQvnuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520Medicine%2520Mini-Review%253A%2520Isoforms%2520of%2520PI3K%2520in%2520Biology%2520and%2520Disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26issue%3D1%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span>PIK3CA
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000121879-PIK3CA" class="extLink">https://www.proteinatlas.org/ENSG00000121879-PIK3CA</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CA%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000121879-PIK3CA+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span>PIK3CB
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000051382-PIK3CB" class="extLink">https://www.proteinatlas.org/ENSG00000051382-PIK3CB</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CB%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000051382-PIK3CB+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagerberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallstrom, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindskog, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksvold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardinoglu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivertsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjostedt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asplund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szigyarto, C. A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odeberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djureinovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanen, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hober, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edqvist, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwenk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamsten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Feilitzen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forsberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwahlen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Heijne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponten, F.</span></span> <span> </span><span class="NLM_article-title">Tissue-Based Map of the Human Proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span> (<span class="NLM_issue">6220</span>),  <span class="NLM_fpage">1260419</span>– <span class="NLM_lpage">1260419</span>, <span class="refDoi"> DOI: 10.1126/science.1260419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1126%2Fscience.1260419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=25613900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BC2MvptFakug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=1260419-1260419&issue=6220&author=M.+Uhlenauthor=L.+Fagerbergauthor=B.+M.+Hallstromauthor=C.+Lindskogauthor=P.+Oksvoldauthor=A.+Mardinogluauthor=A.+Sivertssonauthor=C.+Kampfauthor=E.+Sjostedtauthor=A.+Asplundauthor=I.+Olssonauthor=K.+Edlundauthor=E.+Lundbergauthor=S.+Navaniauthor=C.+A.-K.+Szigyartoauthor=J.+Odebergauthor=D.+Djureinovicauthor=J.+O.+Takanenauthor=S.+Hoberauthor=T.+Almauthor=P.-H.+Edqvistauthor=H.+Berlingauthor=H.+Tegelauthor=J.+Mulderauthor=J.+Rockbergauthor=P.+Nilssonauthor=J.+M.+Schwenkauthor=M.+Hamstenauthor=K.+von+Feilitzenauthor=M.+Forsbergauthor=L.+Perssonauthor=F.+Johanssonauthor=M.+Zwahlenauthor=G.+von+Heijneauthor=J.+Nielsenauthor=F.+Ponten&title=Tissue-Based+Map+of+the+Human+Proteome&doi=10.1126%2Fscience.1260419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics. Tissue-based map of the human proteome</span></div><div class="casAuthors">Uhlen Mathias; Fagerberg Linn; Oksvold Per; Sivertsson ¡ÑÜAsa; Lundberg Emma; Odeberg Jacob; Alm Tove; Nilsson Peter; Schwenk Jochen M; von Feilitzen Kalle; Forsberg Mattias; Persson Lukas; Johansson Fredric; Zwahlen Martin; Hallstrom Bjorn M; Lindskog Cecilia; Kampf Caroline; Asplund Anna; Olsson IngMarie; Djureinovic Dijana; Edqvist Per-Henrik; Ponten Fredrik; Mardinoglu Adil; Sjostedt Evelina; Edlund Karolina; Navani Sanjay; Szigyarto Cristina Al-Khalili; Takanen Jenny Ottosson; Hober Sophia; Berling Holger; Tegel Hanna; Rockberg Johan; Hamsten Marica; Mulder Jan; von Heijne Gunnar; Nielsen Jens</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6220</span>),
    <span class="NLM_cas:pages">1260419</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease.  Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level.  Our tissue-based analysis detected more than 90% of the putative protein-coding genes.  We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs.  All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQT9YWouQZh5DEC-75aqa5AfW6udTcc2ebTaJerFw-Jarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvptFakug%253D%253D&md5=95510888806e5feb6b8024ee2a417d1c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.1260419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1260419%26sid%3Dliteratum%253Aachs%26aulast%3DUhlen%26aufirst%3DM.%26aulast%3DFagerberg%26aufirst%3DL.%26aulast%3DHallstrom%26aufirst%3DB.%2BM.%26aulast%3DLindskog%26aufirst%3DC.%26aulast%3DOksvold%26aufirst%3DP.%26aulast%3DMardinoglu%26aufirst%3DA.%26aulast%3DSivertsson%26aufirst%3DA.%26aulast%3DKampf%26aufirst%3DC.%26aulast%3DSjostedt%26aufirst%3DE.%26aulast%3DAsplund%26aufirst%3DA.%26aulast%3DOlsson%26aufirst%3DI.%26aulast%3DEdlund%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DE.%26aulast%3DNavani%26aufirst%3DS.%26aulast%3DSzigyarto%26aufirst%3DC.%2BA.-K.%26aulast%3DOdeberg%26aufirst%3DJ.%26aulast%3DDjureinovic%26aufirst%3DD.%26aulast%3DTakanen%26aufirst%3DJ.%2BO.%26aulast%3DHober%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DT.%26aulast%3DEdqvist%26aufirst%3DP.-H.%26aulast%3DBerling%26aufirst%3DH.%26aulast%3DTegel%26aufirst%3DH.%26aulast%3DMulder%26aufirst%3DJ.%26aulast%3DRockberg%26aufirst%3DJ.%26aulast%3DNilsson%26aufirst%3DP.%26aulast%3DSchwenk%26aufirst%3DJ.%2BM.%26aulast%3DHamsten%26aufirst%3DM.%26aulast%3Dvon%2BFeilitzen%26aufirst%3DK.%26aulast%3DForsberg%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DL.%26aulast%3DJohansson%26aufirst%3DF.%26aulast%3DZwahlen%26aufirst%3DM.%26aulast%3Dvon%2BHeijne%26aufirst%3DG.%26aulast%3DNielsen%26aufirst%3DJ.%26aulast%3DPonten%26aufirst%3DF.%26atitle%3DTissue-Based%2520Map%2520of%2520the%2520Human%2520Proteome%26jtitle%3DScience%26date%3D2015%26volume%3D347%26issue%3D6220%26spage%3D1260419%26epage%3D1260419%26doi%3D10.1126%2Fscience.1260419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span>PIK3CG
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000105851-PIK3CG" class="extLink">https://www.proteinatlas.org/ENSG00000105851-PIK3CG</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CG%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000105851-PIK3CG+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>PIK3CD
protein expression summary - The Human Protein Atlas; <a href="https://www.proteinatlas.org/ENSG00000171608-PIK3CD" class="extLink">https://www.proteinatlas.org/ENSG00000171608-PIK3CD</a> (accessed Nov 11, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=PIK3CD%0Aprotein+expression+summary+-+The+Human+Protein+Atlas%3B+https%3A%2F%2Fwww.proteinatlas.org%2FENSG00000171608-PIK3CD+%28accessed+Nov+11%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&issue=20&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0li2F0iwnlYb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D20%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valastro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span> <span> </span><span class="NLM_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4783</span>– <span class="NLM_lpage">4814</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4783-4814&issue=10&author=M.+W.+D.+Perryauthor=R.+Abdulaiauthor=M.+Mogemarkauthor=J.+Petersenauthor=M.+J.+Thomasauthor=B.+Valastroauthor=A.+Westin+Eriksson&title=Evolution+of+PI3K%CE%B3+and+%CE%B4+Inhibitors+for+Inflammatory+and+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.8b01298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span></div><div class="casAuthors">Perry, Matthew W. D.; Abdulai, Raolat; Mogemark, Mickael; Petersen, Jens; Thomas, Matthew J.; Valastro, Barbara; Westin Eriksson, Annika</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4783-4814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositol 3-kinases (PI3Ks) γ and δ are key enzymes in hematopoietic cells and have been seen as high-value targets for the treatment of diseases with inflammatory and immunomodulatory components since their discovery and the identification of their roles.  In this Perspective we review progress in the application of inhibitors of PI3Kγ and δ to inflammatory and immunol. conditions over the past 6 years.  We consider progress in the understanding of the roles of PI3Kγ and PI3Kδ in immunol. and inflammation, the experience from clin. trials where inhibitors have been tested, and what has been learned about the safety of their use.  The extensive medicinal chem. efforts to discover both isoform selective and dual PI3Kγδ inhibitors are analyzed and detailed.  Developments in understanding the structural chem. of the PI3K enzymes and the factors that govern isoform selectivity are discussed.  The effects obsd. with the known inhibitor compds. in animal models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tJy6u73_7bVg90H21EOLACvtfcHk0li2F0iwnlYb2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O&md5=2b5cdec8135ee6ebd94624b9a675c889</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DAbdulai%26aufirst%3DR.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BJ.%26aulast%3DValastro%26aufirst%3DB.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26atitle%3DEvolution%2520of%2520PI3K%25CE%25B3%2520and%2520%25CE%25B4%2520Inhibitors%2520for%2520Inflammatory%2520and%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D10%26spage%3D4783%26epage%3D4814%26doi%3D10.1021%2Facs.jmedchem.8b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Southworth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">Anti-Inflammatory Potential of PI3K δ and JAK Inhibitors in Asthma Patients</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1186/s12931-016-0436-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1186%2Fs12931-016-0436-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=26739476" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=1-12&author=T.+Southworthauthor=J.+Plumbauthor=V.+Guptaauthor=J.+Pearsonauthor=I.+Ramisauthor=M.+D.+Lehnerauthor=M.+Miralpeixauthor=D.+Singh&title=Anti-Inflammatory+Potential+of+PI3K+%CE%B4+and+JAK+Inhibitors+in+Asthma+Patients&doi=10.1186%2Fs12931-016-0436-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs12931-016-0436-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-016-0436-2%26sid%3Dliteratum%253Aachs%26aulast%3DSouthworth%26aufirst%3DT.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DPearson%26aufirst%3DJ.%26aulast%3DRamis%26aufirst%3DI.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DAnti-Inflammatory%2520Potential%2520of%2520PI3K%2520%25CE%25B4%2520and%2520JAK%2520Inhibitors%2520in%2520Asthma%2520Patients%26jtitle%3DRespir.%2520Res.%26date%3D2016%26volume%3D17%26spage%3D1%26epage%3D12%26doi%3D10.1186%2Fs12931-016-0436-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawicka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P.</span></span> <span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase Gamma in Eosinophil Chemotaxis within Acute Pulmonary Inflammation</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>126</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2567.2008.02908.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1111%2Fj.1365-2567.2008.02908.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=18754810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2nurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2009&pages=413-422&issue=3&author=M.+Thomasauthor=M.+J.+Edwardsauthor=E.+Sawickaauthor=N.+Dugganauthor=E.+Hirschauthor=M.+P.+Wymannauthor=C.+Owenauthor=A.+Trifilieffauthor=C.+Walkerauthor=J.+Westwickauthor=P.+Finan&title=Essential+Role+of+Phosphoinositide+3-Kinase+Gamma+in+Eosinophil+Chemotaxis+within+Acute+Pulmonary+Inflammation&doi=10.1111%2Fj.1365-2567.2008.02908.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Essential role of phosphoinositide 3-kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation</span></div><div class="casAuthors">Thomas, Matthew; Edwards, Matthew J.; Sawicka, Elzbieta; Duggan, Nicholas; Hirsch, Emilio; Wymann, Matthias P.; Owen, Charles; Trifilieff, Alexandre; Walker, Christoph; Westwick, John; Finan, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">We and others have established an important role for phosphoinositide-3 kinase gamma (PI3Kγ) in the chemotactic responses of macrophages and neutrophils.  The involvement of this lipid kinase in allergic inflammatory responses is, however, yet to be fully detd.  Here we compare wild-type (WT) and PI3Kγ-/- (KO) mice within a model of ovalbumin (OVA)-specific pulmonary inflammation.  Upon OVA aerosol challenge, cell influx into the bronchoalveolar lavage (BAL) fluid consisted of neutrophils, macrophages and, more significantly, eosinophils - which are key effector cells in allergic inflammation.  Each population was reduced by up to 80% in KO mice, demonstrating a role for PI3Kγ in cell infiltration into the airways.  The mechanism of reduced eosinophilia was analyzed within both development and effector stages of the immune response.  Comparable levels of OVA-specific T-cell proliferation and Ig prodn. were established in both strains.  Furthermore, no significant differences between WT and KO chemokine prodn. were obsd.  Having identified the crit. point of PI3Kγ involvement, KO eosinophil chemotactic dysfunction was confirmed in vitro.  These data are the first to demonstrate the vital role of PI3Kγ in acute allergic inflammation.  The profound dependency of eosinophils on PI3Kγ for pulmonary influx identifies this lipid kinase as an attractive target for the pharmacol. intervention of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdLl0aeZ1dqLVg90H21EOLACvtfcHk0lhItP-HjvsXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2nurg%253D&md5=20de1f758aed11ee24e4cb23ed108fc7</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2567.2008.02908.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2567.2008.02908.x%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DM.%2BJ.%26aulast%3DSawicka%26aufirst%3DE.%26aulast%3DDuggan%26aufirst%3DN.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DC.%26aulast%3DWestwick%26aufirst%3DJ.%26aulast%3DFinan%26aufirst%3DP.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520Gamma%2520in%2520Eosinophil%2520Chemotaxis%2520within%2520Acute%2520Pulmonary%2520Inflammation%26jtitle%3DImmunology%26date%3D2009%26volume%3D126%26issue%3D3%26spage%3D413%26epage%3D422%26doi%3D10.1111%2Fj.1365-2567.2008.02908.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">The Cytokines of Asthma</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">975</span>– <span class="NLM_lpage">991</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2019.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fj.immuni.2019.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30995510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFGksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=975-991&issue=4&author=B.+N.+Lambrechtauthor=H.+Hammadauthor=J.+V.+Fahy&title=The+Cytokines+of+Asthma&doi=10.1016%2Fj.immuni.2019.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Cytokines of Asthma</span></div><div class="casAuthors">Lambrecht, Bart N.; Hammad, Hamida; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">975-991</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Asthma is a chronic inflammatory airway disease assocd. with type 2 cytokines interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overprodn., bronchial hyperresponsiveness (BHR), and immunogloubulin E (IgE) synthesis.  However, only half of asthma patients exhibit signs of an exacerbated Type 2 response.  "Type 2-low" asthma has different immune features: airway neutrophilia, obesity-related systemic inflammation, or in some cases, few signs of immune activation.  Here, we review the cytokine networks driving asthma, placing these in cellular context and incorporating insights from cytokine-targeting therapies in the clinic.  We discuss established and emerging paradigms in the context of the growing appreciation of disease heterogeneity and argue that the development of new and improved therapeutics will require understanding the diverse mechanisms underlying the spectrum of asthma pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwry0FZ9TwH7Vg90H21EOLACvtfcHk0lhItP-HjvsXxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFGksLk%253D&md5=766c51708e6bb5c02446956006b1d6df</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2019.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2019.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DLambrecht%26aufirst%3DB.%2BN.%26aulast%3DHammad%26aufirst%3DH.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520Cytokines%2520of%2520Asthma%26jtitle%3DImmunity%26date%3D2019%26volume%3D50%26issue%3D4%26spage%3D975%26epage%3D991%26doi%3D10.1016%2Fj.immuni.2019.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmalbach, T.</span>; <span class="NLM_string-name">Fuhr, R.</span>; <span class="NLM_string-name">Albayaty, M.</span>; <span class="NLM_string-name">Allen, K.</span>; <span class="NLM_string-name">Douglas, M.</span>; <span class="NLM_string-name">Dunbar, J.</span>; <span class="NLM_string-name">McLaughlin, J.</span>; <span class="NLM_string-name">Alexander, L.</span>; <span class="NLM_string-name">McKee, C.</span></span> <span> </span><span class="NLM_article-title">Duvelisib, a PI3K-δ,γ Inhibitor, in Subjects with Mild Asthma</span>. In  <i>European Respiratory Journal, 5.1 Airway Pharmacology and Treatment</i>; <span class="NLM_publisher-name">European Respiratory Society</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">46</span>, p  <span class="NLM_fpage">PA2122</span>. <span class="refDoi"> DOI: 10.1183/13993003.congress-2015.PA2122</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1183%2F13993003.congress-2015.PA2122" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=PA2122&author=T.+Schmalbach&author=R.+Fuhr&author=M.+Albayaty&author=K.+Allen&author=M.+Douglas&author=J.+Dunbar&author=J.+McLaughlin&author=L.+Alexander&author=C.+McKee&title=European+Respiratory+Journal%2C+5.1+Airway+Pharmacology+and+Treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1183%2F13993003.congress-2015.PA2122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1183%252F13993003.congress-2015.PA2122%26sid%3Dliteratum%253Aachs%26aulast%3DSchmalbach%26aufirst%3DT.%26atitle%3DDuvelisib%252C%2520a%2520PI3K-%25CE%25B4%252C%25CE%25B3%2520Inhibitor%252C%2520in%2520Subjects%2520with%2520Mild%2520Asthma%26btitle%3DEuropean%2520Respiratory%2520Journal%252C%25205.1%2520Airway%2520Pharmacology%2520and%2520Treatment%26pub%3DEuropean%2520Respiratory%2520Society%26date%3D2015%26volume%3D46%26spage%3DPA2122%26doi%3D10.1183%2F13993003.congress-2015.PA2122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikulenkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaidashev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA) - ACR Meeting Abstracts</span>. <i>Arthritis and Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">Suppl 10</span>),  <span class="NLM_fpage">2138</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=2138&issue=Suppl+10&author=R.+Leffauthor=S.+Kumarauthor=N.+Nikulenkovaauthor=I.+Kaidashevauthor=K.+Allenauthor=J.+Dunbarauthor=H.+Sternauthor=J.+Adamsauthor=M.+Weinblatt&title=Safety+and+Efficacy+Results+of+a+Phase+2%2C+Double-Blind%2C+Placebo-Controlled+Clinical+Study+of+Duvelisib+with+Background+Methotrexate+%28MTX%29+in+Adults+with+Moderate-to-Severe+Rheumatoid+Arthritis+%28RA%29+-+ACR+Meeting+Abstracts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeff%26aufirst%3DR.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DNikulenkova%26aufirst%3DN.%26aulast%3DKaidashev%26aufirst%3DI.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DDunbar%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DH.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DWeinblatt%26aufirst%3DM.%26atitle%3DSafety%2520and%2520Efficacy%2520Results%2520of%2520a%2520Phase%25202%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Clinical%2520Study%2520of%2520Duvelisib%2520with%2520Background%2520Methotrexate%2520%2528MTX%2529%2520in%2520Adults%2520with%2520Moderate-to-Severe%2520Rheumatoid%2520Arthritis%2520%2528RA%2529%2520-%2520ACR%2520Meeting%2520Abstracts%26jtitle%3DArthritis%2520and%2520Rheumatology%26date%3D2015%26volume%3D67%26issue%3DSuppl%252010%26spage%3D2138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khindri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajdner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig-Sengpiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.249516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1124%2Fjpet.118.249516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30217958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWgsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2018&pages=405-413&issue=3&author=S.+Khindriauthor=A.+Cahnauthor=M.+Beggauthor=M.+Montembaultauthor=C.+Leemereiseauthor=Y.+Cuiauthor=A.+Hoggauthor=H.+Wajdnerauthor=S.+Yangauthor=J.+Robertsonauthor=J.+N.+Hamblinauthor=A.+Ludwig-Sengpielauthor=O.+Kornmannauthor=E.+M.+Hessel&title=A+Multicentre%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Crossover+Study+To+Investigate+the+Efficacy%2C+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+Repeat+Doses+of+Inhaled+Nemiralisib+in+Adults+with+Persistent%2C+Uncontrolled+Asthma&doi=10.1124%2Fjpet.118.249516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma</span></div><div class="casAuthors">Khindri, Sanjeev; Cahn, Anthony; Begg, Malcolm; Montembault, Mickael; Leemereise, Claudia; Cui, Yi; Hogg, Annabel; Wajdner, Hannah; Yang, Shuying; Robertson, Jon; Hamblin, J. Nicole; Ludwig-Sengpiel, Andrea; Kornmann, Oliver; Hessel, Edith M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability, and pharmacokinetics of a PI3Kd inhibitor, nemiralisib (GSK2269557), in patients with persistent, uncontrolled asthma.  Spirometry demonstrated no discernible difference in trough forced expiratory vol. in 1 s (FEV1) from baseline (adjusted posterior median 7 mL; 95% credible interval -83, 102 mL) between nemiralisib and placebo treatment at day 28 (primary endpoint).  These results were supported by most secondary endpoints, including weighted mean FEV1 (0-4 h) and change in trough forced vital capacity at day 28.  Nemiralisib was generally well-tolerated, with few side effects except for post-inhalation cough (nemiralisib: 35%; placebo: 9%).  At day 14, sputum interleukin (IL)-5, IL-13, IL-6, and IL-8 levels were reduced by a median of 17%, 7%, 15%, and 8%, resp., when comparing nemiralisib with placebo [n = 15 (IL-5, IL-8) or 16 (IL-6, IL-13); posterior probability of a true ratio. >0%: 78%, 64%, 76%, and 63%, resp.].  These results suggest that nemiralisib inhibited PI3Kd locally; however, this did not translate into meaningful clin. improvement.  Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonized with bacteria and frequently exacerbate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYx837TIJvr7Vg90H21EOLACvtfcHk0lgxdcJ620QhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWgsr%252FO&md5=fbad4b66d64f945225b2bdccfd88dd57</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.249516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.249516%26sid%3Dliteratum%253Aachs%26aulast%3DKhindri%26aufirst%3DS.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DHogg%26aufirst%3DA.%26aulast%3DWajdner%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DA%2520Multicentre%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Crossover%2520Study%2520To%2520Investigate%2520the%2520Efficacy%252C%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520Repeat%2520Doses%2520of%2520Inhaled%2520Nemiralisib%2520in%2520Adults%2520with%2520Persistent%252C%2520Uncontrolled%2520Asthma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D367%26issue%3D3%26spage%3D405%26epage%3D413%26doi%3D10.1124%2Fjpet.118.249516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homayoun-Valiani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeraus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowings, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E.</span></span> <span> </span><span class="NLM_article-title">Nemiralisib in Patients Experiencing an Acute Exacerbation of COPD: Design of a Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Phase IIb Study</span>. <i>American Journal of Respiratory and Critical Care Medicine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">A4523</span>– <span class="NLM_lpage">A4523</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2019&pages=A4523-A4523&author=W.+Fahyauthor=F.+Homayoun-Valianiauthor=A.+Cahnauthor=J.+Robertsonauthor=A.+Templetonauthor=W.+Meerausauthor=R.+Wilsonauthor=M.+Lowingsauthor=M.+Marottiauthor=M.+Tabbererauthor=S.+Westauthor=E.+Hessel&title=Nemiralisib+in+Patients+Experiencing+an+Acute+Exacerbation+of+COPD%3A+Design+of+a+Double-Blind%2C+Randomized%2C+Placebo-Controlled%2C+Dose-Ranging+Phase+IIb+Study&doi=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523%26sid%3Dliteratum%253Aachs%26aulast%3DFahy%26aufirst%3DW.%26aulast%3DHomayoun-Valiani%26aufirst%3DF.%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DTempleton%26aufirst%3DA.%26aulast%3DMeeraus%26aufirst%3DW.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DLowings%26aufirst%3DM.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DTabberer%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%26atitle%3DNemiralisib%2520in%2520Patients%2520Experiencing%2520an%2520Acute%2520Exacerbation%2520of%2520COPD%253A%2520Design%2520of%2520a%2520Double-Blind%252C%2520Randomized%252C%2520Placebo-Controlled%252C%2520Dose-Ranging%2520Phase%2520IIb%2520Study%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520and%2520Critical%2520Care%2520Medicine%26date%3D2019%26volume%3D199%26spage%3DA4523%26epage%3DA4523%26doi%3D10.1164%2Fajrccm-conference.2019.199.1_MeetingAbstracts.A4523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>Safety,
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses
of Inhaled GSK2269557 in Patients With APDS/PASLI - Full Text View
- ClinicalTrials.gov; <a href="https://clinicaltrials.gov/ct2/show/NCT02593539" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02593539</a> (accessed Jun 28, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Safety%2C%0APharmacokinetic+%28PK%29+and+Pharmacodynamic+%28PD%29+Study+of+Repeat+Doses%0Aof+Inhaled+GSK2269557+in+Patients+With+APDS%2FPASLI+-+Full+Text+View%0A-+ClinicalTrials.gov%3B+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02593539+%28accessed+Jun+28%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poleski, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenetz, A. D.</span></span> <span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment - Expert Panel Opinion</span>. <i>Leukemia & Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8194</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8194&publication_year=2015&pages=1-20&author=S.+E.+Coutreauthor=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment+-+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%2520-%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeukemia%2520%2526%2520Lymphoma%26date%3D2015%26volume%3D8194%26spage%3D1%26epage%3D20%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span>; <span class="NLM_string-name">Narjes, F.</span>; <span class="NLM_string-name">Hemmerling, M.</span></span> <span> </span><span class="NLM_article-title">2018 Medicinal Chemistry Reviews</span>. In  <i>Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">ACS</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">171</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=155-171&author=P.+Sj%C3%B6&author=F.+Narjes&author=M.+Hemmerlingauthor=J.+J.+Bronson&title=Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3D2018%2520Medicinal%2520Chemistry%2520Reviews%26btitle%3DMedicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DACS%26date%3D2018%26spage%3D155%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Triazole Aminopyrazines as a Highly Potent and Selective Series of PI3Kδ Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1016%2Fj.bmcl.2016.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=28017532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCltr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=679-687&issue=3&author=I.+Terstiegeauthor=M.+Perryauthor=J.+Petersenauthor=C.+Tyrchanauthor=T.+Svenssonauthor=H.+Lindmarkauthor=L.+%C3%96ster&title=Discovery+of+Triazole+Aminopyrazines+as+a+Highly+Potent+and+Selective+Series+of+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors</span></div><div class="casAuthors">Terstiege, Ina; Perry, Matthew; Petersen, Jens; Tyrchan, Christian; Svensson, Tor; Lindmark, Helena; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">679-687</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of potent PI3Kδ inhibitors with >1000-fold selectivity against other class I PI3K isoforms is described.  Optimization of the substituents on a triazole aminopyrazine scaffold, emerging from an inhouse PI3Kα program, turned moderately selective PI3Kδ compds. into highly potent and selective PI3Kδ inhibitors.  These efforts resulted in a series of aminopyrazines with PI3Kδ IC50 ≤ 1 nM in the enzyme assay, some of the most selective PI3Kδ inhibitors published to date, with a cell potency in a JeKo-cell assay of 20-120 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq30_ESCcDWabVg90H21EOLACvtfcHk0lhv0qEAOHon6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCltr3M&md5=a23e39caed37cd7f969dc4bba666ede5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Triazole%2520Aminopyrazines%2520as%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Series%2520of%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björhall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terstiege, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5057</span>– <span class="NLM_lpage">5071</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00401</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00401" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5057-5071&issue=12&author=M.+W.+D.+Perryauthor=K.+Bj%C3%B6rhallauthor=B.+Bonnauthor=J.+Carlssonauthor=Y.+Chenauthor=A.+Erikssonauthor=L.+Fredlundauthor=H.+Haoauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=H.+Lindmarkauthor=F.+Liuauthor=N.+Pembertonauthor=J.+Petersenauthor=S.+Rodrigo+Blomqvistauthor=R.+W.+Smithauthor=T.+Svenssonauthor=I.+Terstiegeauthor=C.+Tyrchanauthor=W.+Yangauthor=S.+Zhaoauthor=L.+%C3%96ster&title=Design+and+Synthesis+of+Soluble+and+Cell-Permeable+PI3K%CE%B4+Inhibitors+for+Long-Acting+Inhaled+Administration&doi=10.1021%2Facs.jmedchem.7b00401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span></div><div class="casAuthors">Perry, Matthew W. D.; Bjoerhall, Karin; Bonn, Britta; Carlsson, Johan; Chen, Yunhua; Eriksson, Anders; Fredlund, Linda; Hao, Hai'e; Holden, Neil S.; Karabelas, Kostas; Lindmark, Helena; Liu, Feifei; Pemberton, Nils; Petersen, Jens; Rodrigo Blomqvist, Sandra; Smith, Reed W.; Svensson, Tor; Terstiege, Ina; Tyrchan, Christian; Yang, Wenzhen; Zhao, Shuchun; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5057-5071</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system.  Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis.  In this work, identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation is described.  The initially identified compd. I had good potency and isoform selectivity but was not suitable for inhalation.  Addn. of basic substituents to a region of the mol. pointing to solvent was tolerated (enzyme inhibition pIC50 > 9), and by careful manipulation of the pKa and lipophilicity, the authors were able to discover compds. II (R = Me or i-Bu) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo9sRrhhb7Vg90H21EOLACvtfcHk0lhv0qEAOHon6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVGlu7w%253D&md5=dafb9cfdf6c06e30c599dcceec85497a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00401%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DBj%25C3%25B6rhall%26aufirst%3DK.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEriksson%26aufirst%3DA.%26aulast%3DFredlund%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DH.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BW.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Soluble%2520and%2520Cell-Permeable%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Long-Acting%2520Inhaled%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D5057%26epage%3D5071%26doi%3D10.1021%2Facs.jmedchem.7b00401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlbrandt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bold, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo
Blomqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatoidsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5435</span>– <span class="NLM_lpage">5441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00447</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00447" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5435-5441&issue=12&author=N.+Pembertonauthor=M.+Mogemarkauthor=S.+Arlbrandtauthor=P.+Boldauthor=R.+J.+Coxauthor=C.+Gardelliauthor=N.+S.+Holdenauthor=K.+Karabelasauthor=J.+Karlssonauthor=S.+Leverauthor=X.+Liauthor=H.+Lindmarkauthor=M.+Norbergauthor=M.+W.+D.+Perryauthor=J.+Petersenauthor=S.+Rodrigo%0ABlomqvistauthor=M.+Thomasauthor=C.+Tyrchanauthor=A.+Westin+Erikssonauthor=P.+Zlatoidskyauthor=L.+%C3%96ster&title=Discovery+of+Highly+Isoform+Selective+Orally+Bioavailable+Phosphoinositide+3-Kinase+%28PI3K%29-%CE%B3+Inhibitors&doi=10.1021%2Facs.jmedchem.8b00447"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors</span></div><div class="casAuthors">Pemberton, Nils; Mogemark, Mickael; Arlbrandt, Susanne; Bold, Peter; Cox, Rhona J.; Gardelli, Cristina; Holden, Neil S.; Karabelas, Kostas; Karlsson, Johan; Lever, Sarah; Li, Xueshan; Lindmark, Helena; Norberg, Monica; Perry, Matthew W. D.; Petersen, Jens; Rodrigo Blomqvist, Sandra; Thomas, Matthew; Tyrchan, Christian; Westin Eriksson, Annika; Zlatoidsky, Pavol; Oester, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5435-5441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we describe the discovery and optimization of a new chemotype of isoform selective PI3Kγ inhibitors.  Starting from an HTS hit, potency and physicochem. properties could be improved to give compds. such as 15, which is a potent and remarkably selective PI3Kγ inhibitor with ADME properties suitable for oral administration.  Compd. 15 was advanced into in vivo studies showing dose-dependent inhibition of LPS-induced airway neutrophilia in rats when administered orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3fbsxDWowrVg90H21EOLACvtfcHk0ljgsW8EXOXA8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsrvO&md5=da8067ecb7fff28145f1c2bf82f0a7e7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00447%26sid%3Dliteratum%253Aachs%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DArlbrandt%26aufirst%3DS.%26aulast%3DBold%26aufirst%3DP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DGardelli%26aufirst%3DC.%26aulast%3DHolden%26aufirst%3DN.%2BS.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DKarlsson%26aufirst%3DJ.%26aulast%3DLever%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DNorberg%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DRodrigo%2BBlomqvist%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DZlatoidsky%26aufirst%3DP.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Highly%2520Isoform%2520Selective%2520Orally%2520Bioavailable%2520Phosphoinositide%25203-Kinase%2520%2528PI3K%2529-%25CE%25B3%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D12%26spage%3D5435%26epage%3D5441%26doi%3D10.1021%2Facs.jmedchem.8b00447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunnarsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karabelas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemberton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papavoine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span> <span> </span><span class="NLM_article-title">A Class of Highly Selective Inhibitors Bind to an Active State of PI3Kγ</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">348</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0215-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1038%2Fs41589-018-0215-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=30718815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtF2nsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=348-357&issue=4&author=G.+Gangadharaauthor=G.+Dahlauthor=T.+Bohnackerauthor=R.+Raeauthor=J.+Gunnarssonauthor=S.+Blahoauthor=L.+%C3%96sterauthor=H.+Lindmarkauthor=K.+Karabelasauthor=N.+Pembertonauthor=C.+Tyrchanauthor=M.+Mogemarkauthor=M.+P.+Wymannauthor=R.+L.+Williamsauthor=M.+W.+D.+Perryauthor=T.+Papavoineauthor=J.+Petersen&title=A+Class+of+Highly+Selective+Inhibitors+Bind+to+an+Active+State+of+PI3K%CE%B3&doi=10.1038%2Fs41589-018-0215-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A class of highly selective inhibitors bind to an active state of PI3Kγ</span></div><div class="casAuthors">Gangadhara, Gangadhara; Dahl, Goeran; Bohnacker, Thomas; Rae, Rebecca; Gunnarsson, Jenny; Blaho, Stefan; Oester, Linda; Lindmark, Helena; Karabelas, Kostas; Pemberton, Nils; Tyrchan, Christian; Mogemark, Mickael; Wymann, Matthias P.; Williams, Roger L.; Perry, Matthew W. D.; Papavoine, Tineke; Petersen, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">348-357</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">We have discovered a class of PI3Kγ inhibitors exhibiting over 1000-fold selectivity over PI3Kα and PI3Kβ.  On the basis of X-ray crystallog., hydrogen-deuterium exchange-mass spectrometry and surface plasmon resonance expts. we propose that the cyclopropylethyl moiety displaces the DFG motif of the enzyme away from the adenosine tri-phosphate binding site, inducing a large conformational change in both the kinase- and helical domains of PI3Kγ.  Site directed mutagenesis explained how the conformational changes occur.  Our results suggest that these cyclopropylethyl substituted compds. selectively inhibit the active state of PI3Kγ, which is unique to these compds. and to the PI3Kγ isoform, explaining their excellent potency and unmatched isoform selectivity that were confirmed in cellular systems.  This is the first example of a Class I PI3K inhibitor achieving its selectivity by affecting the DFG motif in a manner that bears similarity to DFG in/out for type II protein kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcyKjzZy-40rVg90H21EOLACvtfcHk0ljgsW8EXOXA8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtF2nsbo%253D&md5=a6b428b3964062820e045354134c3c21</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0215-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0215-0%26sid%3Dliteratum%253Aachs%26aulast%3DGangadhara%26aufirst%3DG.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DRae%26aufirst%3DR.%26aulast%3DGunnarsson%26aufirst%3DJ.%26aulast%3DBlaho%26aufirst%3DS.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3DKarabelas%26aufirst%3DK.%26aulast%3DPemberton%26aufirst%3DN.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DPapavoine%26aufirst%3DT.%26aulast%3DPetersen%26aufirst%3DJ.%26atitle%3DA%2520Class%2520of%2520Highly%2520Selective%2520Inhibitors%2520Bind%2520to%2520an%2520Active%2520State%2520of%2520PI3K%25CE%25B3%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D4%26spage%3D348%26epage%3D357%26doi%3D10.1038%2Fs41589-018-0215-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beno, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4438</span>, <span class="refDoi"> DOI: 10.1021/jm501853m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501853m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4383-4438&issue=11&author=B.+R.+Benoauthor=K.+S.+Yeungauthor=M.+D.+Bartbergerauthor=L.+D.+Penningtonauthor=N.+A.+Meanwell&title=A+Survey+of+the+Role+of+Noncovalent+Sulfur+Interactions+in+Drug+Design&doi=10.1021%2Fjm501853m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design</span></div><div class="casAuthors">Beno, Brett R.; Yeung, Kap-Sun; Bartberger, Michael D.; Pennington, Lewis D.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4383-4438</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Electron deficient, bivalent sulfur atoms have two areas of pos. electrostatic potential, a consequence of the low-lying σ* orbitals of the C-S bond that are available for interaction with electron donors including oxygen and nitrogen atoms and, possibly, π-systems.  Intramol. interactions are by far the most common manifestation of this effect, which offers a means of modulating the conformational preferences of a mol.  Although a well-documented phenomenon, a priori applications in drug design are relatively sparse and this interaction, which is often isosteric with an intramol. hydrogen-bonding interaction, appears to be underappreciated by the medicinal chem. community.  In this Perspective, we discuss the theor. basis for sulfur σ* orbital interactions and illustrate their importance in the context of drug design and org. synthesis.  The role of sulfur interactions in protein structure and function is discussed and although relatively rare, intermol. interactions between ligand C-S σ* orbitals and proteins are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKXRsl4BQYrVg90H21EOLACvtfcHk0lgZvLXN2ppB1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjs1Giu7g%253D&md5=d12f53eb3271c161cfc833fb9f7c02b3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501853m%26sid%3Dliteratum%253Aachs%26aulast%3DBeno%26aufirst%3DB.%2BR.%26aulast%3DYeung%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DA%2520Survey%2520of%2520the%2520Role%2520of%2520Noncovalent%2520Sulfur%2520Interactions%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438%26doi%3D10.1021%2Fjm501853m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span> <span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route: Challenges and Approaches</span>. <i>Current Drug Metabolism</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&issue=4&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route%3A+Challenges+and+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lgZvLXN2ppB1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route%253A%2520Challenges%2520and%2520Approaches%26jtitle%3DCurrent%2520Drug%2520Metabolism%26date%3D2012%26volume%3D13%26issue%3D4%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Waiver of In
Vivo Bioavailability and Bioequivalence Studies for Immediate-Release
Solid Oral Dosage Forms Based on a Biopharmaceutics Classification
System Guidance for Industry</span>; <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm" class="extLink">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm</a> (accessed Apr 21, 2021).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA.+Waiver+of+In%0AVivo+Bioavailability+and+Bioequivalence+Studies+for+Immediate-Release%0ASolid+Oral+Dosage+Forms+Based+on+a+Biopharmaceutics+Classification%0ASystem+Guidance+for+Industry%3B+http%3A%2F%2Fwww.fda.gov%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fdefault.htm+%28accessed+Apr+21%2C+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWaiver%2520of%2520In%250AVivo%2520Bioavailability%2520and%2520Bioequivalence%2520Studies%2520for%2520Immediate-Release%250ASolid%2520Oral%2520Dosage%2520Forms%2520Based%2520on%2520a%2520Biopharmaceutics%2520Classification%250ASystem%2520Guidance%2520for%2520Industry" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, R.</span></span> <span> </span><span class="NLM_article-title">Lymphocytes Migrate from the Blood into the Bronchoalveolar Lavage and Lung Parenchyma in the Asthma Model of the Brown Norway Rat</span>. <i>American Journal of Respiratory and Critical Care Medicine</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.161.2.9812021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1164%2Fajrccm.161.2.9812021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10673200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BD3c7otValuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2000&pages=558-566&author=M.+Schusterauthor=T.+Tschernigauthor=N.+Krugauthor=R.+Pabst&title=Lymphocytes+Migrate+from+the+Blood+into+the+Bronchoalveolar+Lavage+and+Lung+Parenchyma+in+the+Asthma+Model+of+the+Brown+Norway+Rat&doi=10.1164%2Fajrccm.161.2.9812021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat</span></div><div class="casAuthors">Schuster M; Tschernig T; Krug N; Pabst R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2 Pt 1</span>),
    <span class="NLM_cas:pages">558-66</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Lymphocyte migration from the blood into the lung has been suggested as being responsible for the increase of lymphocytes, in particular CD4 T cells, in the bronchoalveolar lavage (BAL) and bronchial mucosa in human asthma, but so far there has been no direct proof.  We studied lymphocyte immigration and lymphocyte subpopulations in three lung compartments in ovalbumin (OVA)-sensitized and -challenged brown Norway (BN) rats.  Increased numbers of CD4 and interleukin 2 (IL-2) receptor-positive T cells were found in the BAL and lung parenchyma in treated animals, but also increased numbers of CD8 T cells, B cells, and natural killer (NK) cells.  For direct proof of lymphocyte migration from the blood into the lung, leukocytes were labeled with a fluorescent dye, 5- (and 6-) carboxyfluorescein-diacetate-succinimidyl-ester (CFSE), and injected intravenously immediately prior to OVA aerosol challenge.  One day after challenge the number of CFSE(+), i.e., newly immigrated lymphocytes, was determined by flow cytometry gated on the lymphocyte cluster.  A 15 times (1.5 times) higher number of CFSE(+) lymphocytes was found in the BAL (the lung parenchyma) of treated animals in comparison with control rats.  In the BAL 51.8% of CFSE(+) cells were CD4-positive (parenchyma 72.7%) and 29.4% IL-2 receptor-positive (parenchyma 34.2%).  There was no difference whether the leukocytes for labeling and injection were obtained from untreated or from OVA-sensitized donor animals.  Our data show that lymphocyte immigration is at least in part responsible for the increase in lymphocyte numbers in the BAL and lung parenchyma in this animal asthma model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3Cxch47IYMPxQvRxYU81tfW6udTcc2eZZaReQz1EaQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7otValuw%253D%253D&md5=4b123a2346d7892b07c70f424f14fdb9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.161.2.9812021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.161.2.9812021%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DM.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DPabst%26aufirst%3DR.%26atitle%3DLymphocytes%2520Migrate%2520from%2520the%2520Blood%2520into%2520the%2520Bronchoalveolar%2520Lavage%2520and%2520Lung%2520Parenchyma%2520in%2520the%2520Asthma%2520Model%2520of%2520the%2520Brown%2520Norway%2520Rat%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520and%2520Critical%2520Care%2520Medicine%26date%3D2000%26volume%3D161%26spage%3D558%26epage%3D566%26doi%3D10.1164%2Fajrccm.161.2.9812021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&issue=18&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+J.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+Novel+Indazoles+as+Highly+Potent+and+Selective+Inhibitors+of+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0lhDtsPygBcngA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520Novel%2520Indazoles%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D18%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäckström, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brülls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strittmatter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrén, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grime, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R. J. A.</span></span> <span> </span><span class="NLM_article-title">Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging</span>. <i>J. Aerosol Med. Pulm. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1089/jamp.2019.1536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1089%2Fjamp.2019.1536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=31364961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2020&pages=43-53&issue=1&author=G.+R.+Hammauthor=E.+B%C3%A4ckstr%C3%B6mauthor=M.+Br%C3%BCllsauthor=A.+Nilssonauthor=N.+Strittmatterauthor=P.+E.+Andr%C3%A9nauthor=K.+Grimeauthor=M.+Frid%C3%A9nauthor=R.+J.+A.+Goodwin&title=Revealing+the+Regional+Localization+and+Differential+Lung+Retention+of+Inhaled+Compounds+by+Mass+Spectrometry+Imaging&doi=10.1089%2Fjamp.2019.1536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging</span></div><div class="casAuthors">Hamm, Gregory R.; Baeckstroem, Erica; Bruells, Mikael; Nilsson, Anna; Strittmatter, Nicole; Andren, Per E.; Grime, Ken; Friden, Markus; Goodwin, Richard J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Aerosol Medicine and Pulmonary Drug Delivery</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">JAMPC4</span>;
        ISSN:<span class="NLM_cas:issn">1941-2711</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Background: For the treatment of respiratory disease, inhaled drug delivery aims to provide direct access to pharmacol. target sites while minimizing systemic exposure.  The aim of this study was to investigate the distribution and retention of different chemotypes typifying available inhaled drugs [slowly dissolving neutral fluticasone propionate (FP) and sol. bases salmeterol and salbutamol] using mass spectrometry imaging (MSI).  Methods: Salmeterol, salbutamol, and FP were simultaneously delivered by inhaled nebulization to rats.  In the same animals, salmeterol-d3, salbutamol-d3, and FP-d3 were delivered by i.v. (IV) injection.  Samples of lung tissue were obtained at 2- and 30-min postdosing, and high-resoln. MSI was used to study drug distribution and retention.  Results: IV delivery resulted in homogeneous lung distribution for all mols.  In comparison, while inhalation also gave rise to drug presence in the entire lung, there were regional chemotype-dependent areas of higher abundance.  At the 30-min time point, inhaled salmeterol and salbutamol were preferentially retained in bronchiolar tissue, whereas FP was retained in all regions of the lungs.  Conclusion: This study clearly demonstrates that inhaled small mol. chemotypes are differentially distributed in lung tissue after inhalation, and that high-resoln. MSI can be applied to study these retention patterns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpudsiJ1cuPdLVg90H21EOLACvtfcHk0lhDtsPygBcngA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOgt74%253D&md5=0ed5228556fc6a2d441f7844d5229960</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1089%2Fjamp.2019.1536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjamp.2019.1536%26sid%3Dliteratum%253Aachs%26aulast%3DHamm%26aufirst%3DG.%2BR.%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DBr%25C3%25BClls%26aufirst%3DM.%26aulast%3DNilsson%26aufirst%3DA.%26aulast%3DStrittmatter%26aufirst%3DN.%26aulast%3DAndr%25C3%25A9n%26aufirst%3DP.%2BE.%26aulast%3DGrime%26aufirst%3DK.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DR.%2BJ.%2BA.%26atitle%3DRevealing%2520the%2520Regional%2520Localization%2520and%2520Differential%2520Lung%2520Retention%2520of%2520Inhaled%2520Compounds%2520by%2520Mass%2520Spectrometry%2520Imaging%26jtitle%3DJ.%2520Aerosol%2520Med.%2520Pulm.%2520Drug%2520Delivery%26date%3D2020%26volume%3D33%26issue%3D1%26spage%3D43%26epage%3D53%26doi%3D10.1089%2Fjamp.2019.1536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötvall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekerljung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönmark, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennergren, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindén, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rönmark, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torén, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundbäck, B.</span></span> <span> </span><span class="NLM_article-title">West Sweden Asthma Study: Prevalence Trends over the Last 18 Years Argues No Recent Increase in Asthma</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">94</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=10.1186%2F1465-9921-10-94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=19821983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;key=1%3ACAS%3A280%3ADC%252BD1MjjslOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=94&issue=1&author=J.+L%C3%B6tvallauthor=L.+Ekerljungauthor=E.+P.+R%C3%B6nmarkauthor=G.+Wennergrenauthor=A.+Lind%C3%A9nauthor=E.+R%C3%B6nmarkauthor=K.+Tor%C3%A9nauthor=B.+Lundb%C3%A4ck&title=West+Sweden+Asthma+Study%3A+Prevalence+Trends+over+the+Last+18+Years+Argues+No+Recent+Increase+in+Asthma&doi=10.1186%2F1465-9921-10-94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma</span></div><div class="casAuthors">Lotvall Jan; Ekerljung Linda; Ronmark Erik P; Wennergren Goran; Linden Anders; Ronmark Eva; Toren Kjell; Lundback Bo</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Asthma prevalence has increased over the last fifty years, but the more recent changes have not been conclusively determined.  Studies in children indicate that a plateau in the prevalence of asthma may have been reached, but this has not yet been confirmed in adults.  Epidemiological studies have suggested that the prevalence of asthma in adults is approximately 7-10% in different parts of the western world.  We have now performed a large-scale epidemiological evaluation of the prevalence of asthma and respiratory symptoms in adults between the ages of 16-75 in West Sweden.  Thirty thousand randomly chosen individuals were sent a detailed questionnaire focusing on asthma and respiratory symptoms, as well possible risk factors.  Sixty-two percent of the contacted individuals responded to the questionnaire.  Asthma prevalence, defined as asthma diagnosed by a physician, was 8.3%.  Moreover, the prevalence of respiratory symptoms was lower compared to previous studies.  The most common respiratory symptom was any wheeze (16.6%) followed by sputum production (13.3%).  In comparison with studies performed 18 years ago, the prevalence of asthma has not increased, and the prevalence of most respiratory symptoms has decreased.  Therefore, our data argues that the continued increase in asthma prevalence that has been observed over the last half century is over.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6wTUah4VuAzdblLE_E9PWfW6udTcc2eauE-4HpoxUj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjjslOluw%253D%253D&md5=12211d35b30a5aff1a31be440618e8fc</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-94%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tvall%26aufirst%3DJ.%26aulast%3DEkerljung%26aufirst%3DL.%26aulast%3DR%25C3%25B6nmark%26aufirst%3DE.%2BP.%26aulast%3DWennergren%26aufirst%3DG.%26aulast%3DLind%25C3%25A9n%26aufirst%3DA.%26aulast%3DR%25C3%25B6nmark%26aufirst%3DE.%26aulast%3DTor%25C3%25A9n%26aufirst%3DK.%26aulast%3DLundb%25C3%25A4ck%26aufirst%3DB.%26atitle%3DWest%2520Sweden%2520Asthma%2520Study%253A%2520Prevalence%2520Trends%2520over%2520the%2520Last%252018%2520Years%2520Argues%2520No%2520Recent%2520Increase%2520in%2520Asthma%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26issue%3D1%26spage%3D94%26doi%3D10.1186%2F1465-9921-10-94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4','PDB','7oi4'); return false;">PDB: 7oi4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois','PDB','7ois'); return false;">PDB: 7ois</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij','PDB','7oij'); return false;">PDB: 7oij</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil','PDB','7oil'); return false;">PDB: 7oil</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-7"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i95"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00434">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_40048"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00434?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00434</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details of the preliminary macrocyclization experiments and results; a ligand interaction diagram for the crystal structure of <b>58</b>; additional <i>in vivo</i> experiment results; off-target and kinase screening results, copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra and HPLC traces for final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Table of molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_001.pdf">jm1c00434_si_001.pdf (8.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00434/suppl_file/jm1c00434_si_002.csv">jm1c00434_si_002.csv (4.24 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures of PI3Kδ small molecule complexes have been deposited in the PDB under the following accession codes <b>7</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oi4">7oi4</a>); <b>12</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7ois">7ois</a>); <b>20</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oij">7oij</a>); <b>58</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7oil">7oil</a>). Authors will release the atomic coordinates and experimental data upon article publication. PDB IDs have been provided in figure legends.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00434&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00434%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00434" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c1d7fa563dbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
